University of Wollongong

Research Online
University of Wollongong Thesis Collection

University of Wollongong Thesis Collections

2000

Analysis of plasminogen activator inhibitor type 2
(PAI-2) expression on the cell surface of monocytic
cell lines and human peripheral blood leukocytes
Michael Andrew Liew
University of Wollongong

Recommended Citation
Liew, Michael Andrew, Analysis of plasminogen activator inhibitor type 2 (PAI-2) expression on the cell surface of monocytic cell
lines and human peripheral blood leukocytes, Doctor of Philosophy thesis, Department of Biological Sciences, University of
Wollongong, 2000. http://ro.uow.edu.au/theses/1036

Research Online is the open access institutional repository for the
University of Wollongong. For further information contact the UOW
Library: research-pubs@uow.edu.au

ANALYSIS OF PLASMINOGEN
ACTIVATOR INHIBITOR TYPE 2 (PAI-2)
EXPRESSION ON THE CELL SURFACE OF
MONOCYTIC CELL LINES AND HUMAN
PERIPHERAL BLOOD LEUKOCYTES
A thesis submitted in fulfilment of the requirements for the
award of the degree

PhD
from

UNIVERSITY OF WOLLONGONG
by
MICHAEL ANDREW LIEW, B.Sc(Hons)

DEPARTMENT OF BIOLOGICAL SCIENCES
2000

STATEMENT OF ORIGINALITY
I, Michael Liew, declare that this thesis contains no material which has been accepted
for the award of any degree or diploma in any University, and to the best of my
knowledge contains no material which has been previously published or written by
another person except where due reference is made in the text of this thesis.

Michael Liew

i

ACKNOWLEDGEMENTS
Thank you to all past and present members of Lab 112 and the Department of

Biological Sciences at the University of Wollongong for their friendship and suppor
throughout my PhD. Thank you to Mark Baker for allowing me to work in his
laboratory. A very big thank you goes to both sides of my family for all their love
and support during my PhD. Without it, times would have been tough indeed.
Finally, thank you to my wife, Minh-Thu without whom I would have been missing a

very big part of my life. She is my best friend, soul mate and true love, whose fait
love and inspiration has helped me far more than she will ever know.

ii

ABSTRACT
Plasminogen activator inhibitor type 2 (PAI-2) is one of the inhibitors of the
plasminogen cascade, a powerful proteolytic cascade involved in many physiological
processes. The main aim of this thesis was to evaluate if PAI-2 could be detected on
the cell surface of monocytic cell lines and human peripheral blood leukocytes, which
could regulate the activity of cell surface urokinase type plasminogen activator (uPA).
By flow cytometry PAI-2 could only be detected very weakly on the surface of U937
cells. By ELISA and Western blotting, monomeric non-glycosylated PAI-2 was very
abundant in cytosol enriched preparations from U937, MM6 and HaCaT cells, and
present in lower amounts in plasma membrane enriched preparations. In addition,
Jurkat cells were observed not to express PAI-2 antigen or mRNA.

Since PAI-2 could not be detected on the surface of cells, the second aim of this thesis
was to determine if PAI-2 could localise to the extracellular matrix (ECM) surface by
transglutaminase activity in an in vitro fibrin clot model. By autoradiography it was
observed that three species of PAI-2 associated with a fibrin clot: monomeric PAI-2,
PAI-2 cross-linked to the fibrin and a high molecular weight PAI-2. Addition of

125

I-

uPA revealed that the only species of PAI-2 that was active in the fibrin clot, was the
monomer. Therefore, rather than inhibiting plasminogen activation as a cell surface
moiety, it seems more likely that PAI-2 inhibits plasminogen activation by localising
to the surface of the ECM.
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1. THE CELL SURFACE AND PERICELLULAR LOCALISATION
OF THE PLASMINOGEN ACTIVATION SYSTEM

1.1 THE PLASMINOGEN ACTIVATION CASCADE

The plasminogen activation cascade is an important pathway used in various
physiological and cellular functions. The activation of plasminogen into the active
protease plasmin has been demonstrated to be important in processes involving
extracellular matrix (ECM) remodelling. This occurs directly by plasmin cleaving
components of the ECM (eg. fibrin) or indirectly through the activation of other
proteases (eg. pro-collagenases). Such ECM remodelling is important in processes
including cell migration, angiogenesis, fibrinolysis, inflammation and pregnancy (Dano
et al, 1985; Saksela and Rifkin, 1988; Vassalli et al, 1991).

As with all tightly regulated processes, there are activators and inhibitors controlling
primary effector. In this case the primary effector is plasminogen, the activators are
urokinase type plasminogen activator (uPA) and tissue type plasminogen activator
(tPA), and the inhibitors are a2-antiplasmin, plasminogen activator inhibitor type 1
(PAI-1) and plasminogen activator inhibitor type 2 (PAI-2) (Fig. 1). The overall
purpose of this review is to examine evidence from the literature describing where
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plasminogen activation occurs with the emphasis on PAI-2. A n introduction to the
components of the system will be followed by examining plasminogen activation at

the cell surface and pericellularly at the surface of the ECM. Finally, the areas wil
discussed and a hypothetical model presented depicting where PAI-2 may localise.

1.1.1 Plasminogen/plasmin

Plasminogen is a zymogen of the active protease plasmin. The predominant site of

plasminogen synthesis is the liver (Raum et al., 1980), but other tissues and cells, l
microglia, have been reported to produce plasminogen (Valinsky and Reich, 1981;
Isseroff and Rifkin, 1983; Saksela and Vihko, 1986; Nakajima et al, 1992).
Plasminogen is an abundant molecule in extracellular fluids and is found in human
plasma at a concentration of 2u.M (Lijnen and Collen, 1982). Human plasminogen is
synthesised as a single chain glycoprotein 709 amino acids long with a molecular
weight of 92kDa (Wiman, 1973; Wiman, 1977; Sottrup-Jensen etal, 1978).

Plasminogen is a heterogeneous molecule and can be observed in several isoforms.
The native form of plasminogen is called Glu-plasminogen because there is a glutamic
acid at the amino terminus (Wallen and Wiman, 1975). Glu-plasminogen can be
converted to forms called Lys-plasminogen by cleavages at Arg67-Met68, Lys76-Lys77

2

and Lys 77 -Val 78 by plasmin (Wallen and Wiman, 1972; Collen and DeMaeyer, 1975;
Lijnen and Collen, 1982). The conversion of Glu-plasminogen to Lys-plasminogen

results in a large conformational change (Violand et al, 1978). The most notable resul
of the conformational change is that Lys-plasminogen is converted to plasmin much
faster than compared to Glu-plasminogen (Claeys and Vermylen, 1974). Lysplasminogen/a2-antiplasmin complexes could not be detected in the plasma of
patients with thromboembolic disease with an enzyme linked immunosorbent assay
(ELISA) using a Lys-plasminogen specific monoclonal antibody (Holvoet et al,
1985). This was interpreted as meaning that the in vivo conversion of Gluplasminogen to Lys-plasminogen may not occur or is extremely rapid. There are also
two different glycoforms of plasminogen, glycoform I and II depending upon if they
contain one or two carbohydrate side chains (Takada and Takada, 1988; Vassalli et al,
1991).

Plasmin is a serine protease formed from cleavage of the Arg560-Val561 bond in
plasminogen (Robbins et al, 1967) by the plasminogen activators. Plasmin has a
broad substrate specificity being able to cleave ECM components such as fibrin,
fibronectin (Liotta et al, 1981), laminin (Liotta et al, 1981) and thrombospondin
(Lawler and Slayter, 1981). Plasmin can also indirectly degrade ECM components by

the activation of latent pro-collagenases and other metalloproteases (Werb et al, 191
O'Grady et al, 1981; Tryggvason et al, 1987). In addition latent growth factors like

3

transforming growth factor (3 (TGF(3) found in the E C M can be activated by plasmin
cleavage (Lyons et al, 1988). The plasmin molecule has 2 polypeptide chains (A and
B) linked by a disulphide bond. The B chain is 25kDa and contains the active site,
which comprises the amino acids His602, Asp645 and Ser740 (Sottrup-Jensen et al,
1978). The A chain is 65kDa and contains 5 kringle domains.

The 5 kringle domains are triple loop structures which can bind to lysine (SottrupJensen et al, 1978) or lysine analogues such as £-amino caproic acid (EACA) (Markus
et al, 1978) or tranexamic acid (Markus et al, 1979). As a result of these kringles,
plasminogen/plasmin can bind to lysines available on the surface of cells or on the
surface of the ECM. One important aspect of plasmin being able to bind to a surface
is that once bound it is protected from inhibition by a2-antiplasmin (Plow et al,
1986; Gonias etal, 1989; Ellis etal, 1991).

1.1.2 uPA

For reviews on uPA see Pollanen et al. (1991), Duffy (1993) and Rijken (1995). uPA

is synthesised by a wide variety of cell types. It has been observed to be synthesis
by hepatocytes (Busso et al, 1994), lung adenocarcinoma cells (Stump et al, 1986b),
breast cancer cells (O'Grady et al, 1985), monocytes, granulocytes, lymphocytes
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(Carpen et al, 1986) and several other cell lines. u P A can be detected in human
plasma at a concentration of 3-5ng/ml (Binnema et al, 1986).

uPA is synthesised as a 411 amino acid long glycoprotein of 55kDa molecular weight
(Gunzler et al, 1982; Holmes et al, 1985). The calculated non-glycosylated
molecular weight is 46.4kDa (Mangel et al, 1991). There is one N-glycosylation site
at Asn302 and a fucosylation site at Thr13 (Kentzer et al, 1990; Buko et al, 1991).
The fucosylation site has been found to be involved in the mitogenic properties of
uPA (Rabbani etal, 1992). It is synthesised as a single chain pro-enzyme (sc-uPA),
that requires cleavage at the Lys158-Ile159 bond to become active twin chain uPA (tcuPA) (Kasai et al, 1985a). This generates a serine protease with 2 chains (A and B)
linked by a disulphide bond (Cys148 and Cys279) (Verde et al, 1984; Belin et al,
1985). The conversion into active tc-uPA can be catalysed by a variety of proteases.
These include: plasmin (Wun et al, 1982; Blasi et al, 1987), trypsin, plasma

kallikrein (Eaton et al, 1984; Ichinose et al, 1986), cathespin B, cathespin L (Schmit
etal, 1992), cathespin G (Drag and Petersen, 1994) bacterial thermolysin (Marcotte
and Henkin, 1993) and tryptase (Stack and Johnson, 1994).

The enzyme activity of tc-uPA has been shown to be 250 fold greater than sc-uPA
(Petersen et al. 1988). However, there is debate over whether sc-uPA is active
(reviewed by DeMunk and Rijken, 1990). A direct measure of sc-uPA activity is
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complicated because once any plasmin has been generated it will convert sc-uPA into
tc-uPA. The advent of molecular biological techniques has seemingly helped solve the
debate. A plasmin resistant sc-uPA mutant (Lys158—>Glu) in combination with an
active site mutant plasminogen (Ser740—>Ala) demonstrated that sc-uPA has low
activity (Lijnen et al, 1990).

Subunit A is 158 amino acids (24kDa) long and forms the amino terminal end of scuPA. This subunit contains 2 different domains. It contains a kringle structure
(Gunzler et al, 1982) and a growth factor domain (GFD) which is homologous to the
receptor-binding region of epidermal growth factor (EGF) and transforming growth
factor alpha (TGFoc) (Gunzler et al, 1982; Derynck et al, 1984; Komoriya et al,
1984). This subunit is also responsible for binding to it's specific receptor uPAR
because it was demonstrated that a peptide that covered the 16 amino acid residues of
the GFD region inhibited binding of uPA to uPAR (Apella et al, 1987). The B chain
is 253 amino acids (30kDa) long and contains the active site. The active site is
composed of the 3 amino acids His204, Asp255 and Ser356 (Strassburger et al, 1983;
Verde etal, 1984).

In addition to the cleavage site at Lys158-Ile159 there are other cleavage sites in the
molecule, that have been postulated to be involved in the regulation of uPA activity
(Ichinose et al, 1986a; Stump et al, 1986a; van Hinsbergh et al, 1987; Demunk and
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Rijken, 1990; Duffy, 1993). These are at:
Lys135-Lys136. Plasmin cleavage of active uPA generates a 33kDa molecule
that can not bind to it's receptor, but that is still active.
Arg156-Phe157. Thrombin cleavage of pro-uPA generates an inactive twin chain
molecule.
Glu143-Leu144. Cleavage of pro-uPA generates a 32kDa molecule.
Lys46-Ser47. Cleavage leads to a 40kDa molecule.

The function of cellular uPA is the activation of plasminogen at the surface of cells
has been demonstrated that the interaction between uPA and plasminogen is of high

affinity (Km=0.40-0.77 u_vf) and does not require the kringle structures (Lijnen et a
1985a). Earlier work suggested that plasminogen was the only natural substrate for
uPA because it was unable to cleave fibronectin, type IV and type V collagen and
laminin (Liotta et al, 1981). However, more recent work indicates that uPA can
cleave fibronectin directly (Quigley et al, 1987; Gold et al, 1989), uPAR (HoyerHansen et al., 1992) and the hepatocyte growth factor/scatter factor (Naldini et al,
1992). uPA proteolytic activity can also activate the latent form of membrane type 1
matrix metalloprotease (Kazes et al, 1998). A recombinant non-glycosylated form of
uPA produced in Escherichia coli (E. coli) was found to have a better catalytic
efficiency than the natural counterpart purified from conditioned cell culture media

(Lijnen et al, 1986a). An interesting parallel with plasminogen is that uPA in solution
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is inhibitable by a2-macroglobulin, while cell surface bound u P A is protected
(Stephens./ al, 1991).

1.1.3 tPA

tPA is a glycoprotein of 70kDa molecular weight (Pennica et al, 1983; Fisher et al,
1985) and like uPA is secreted as a single chain polypeptide (sc-tPA). The molecular
weight without the glycosylations is 59kDa and is 527 amino acids in length (Rijken,
1995). In vivo tPA is mainly synthesised by vascular endothelial cells and has a
plasma concentration of 5-1 Ong/ml and a plasma half-life of 5 minutes (Van Hinsbergh
et al, 1991; Lijnen and Collen, 1995; Rijken, 1995). tPA has also been found to be

synthesised by human breast cancer cells (O'Grady et al, 1985), mast cells (Sillaber e
al, 1999) mouse and rat oocytes (Huarte et al, 1985) and has been detected in

extracts from the following rat tissues: brain, lung, heart, liver, spleen, adrenal gl
skeletal muscle and the aorta (Padro et al, 1990).

The primary function of tPA is the activation of plasminogen at the surface of fibrin

clots to aid in their lysis and removal. tPA requires cleavage at Arg^-Ile276 to become
the active twin chain molecule (tc-tPA) like uPA. Using monoclonal antibodies, the
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active site was mapped to the A chain and a fibrin binding domain to the B chain
(Holvoet et al, 1986). The active site of tPA consists of three amino acids, His322,
Asp371 and Ser478 (Pennica et al, 1983). tPA has the same domains as uPA, but in

addition has an extra kringle and a 43 amino acid residue amino terminal finger domain.
The finger domain of tPA resides between residues 6-43, the growth factor domain
between residues 44-91, kringle 2 between residues 92-173 and kringle 1 between
residues 180-261 (Rijken, 1995). The finger domain is highly homologous to the
fibrin binding fingers found in fibronectin (Banyai et al, 1983; Petersen et al, 1983).
One of the primary features about tPA is that it is able to bind to fibrin. The fibrin
binding property of tPA is partly attributed to the finger domain, but is primarily
attributable to the second kringle as demonstrated using tPA deletion mutants (van
Zonneveld et al, 1986a; van Zonneveld et al., 1986b; Verheijen et al., 1986). tPA has

little activity in isolation and must bind to fibrin to acquire full activity (Hoylaert
al, 1982). It has been reported that the A chain of tPA is required for the stimulation
by fibrin (Rijken and Groeneveld, 1986).

tPA has N-linked and O-linked glycosylations, but the N-linked glycosylations do not
have any effect upon tPA activity (Rijken et al, 1985). The N-linked glycosylation
can vary in structure. For example recombinant tPA from Chinese Hamster Ovary
(CHO) cells and tPA from melanoma cells have mannose oligosaccharides on Asn117
and N-acetyllactosamine type oligosaccharides on Asn184 and Asn448 (Pohl et al,
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1987; Spellman

et al,

1989).

However, the

N-acetyllactosamine

type

oligosaccharides of melanoma tPA contain terminal intersecting N-acetylglucosamine
(GlcNAc) residues, while CHO tPA does not. An O-type glycosylation in tPA has
been reported by Harris et al, (1991), which was a fucose glycosidically linked to
Thr61.

In contrast to pro-uPA that has little to no activity, sc-tPA does possess activity.
Therefore, sc-tPA; has amidolytic activity, can activate plasminogen in the presence
of fibrin, can complex with plasminogen activator inhibitors and can be inactivated
with diisopropylfluorophosphate (DFP) (Bachmann and Kruithof, 1984; Dano et al,
1985; Hekman and Loskutoff, 1987). sc-tPA is also able to bind to fibrin (Higgins
and Vehar, 1987). In the absence of fibrin, the activity of tc-tPA is 3-6 times that
sc-tPA (Rijken, 1995).

1.1.4 a2-Antiplasmin

In the early 1970's a compound was identified in human plasma that reacted with
plasminogen anti-sera, was devoid of plasmin activity, not activatable by urokinase
and did not react with any of the anti-sera to known plasma protease inhibitors

(Mullertz, 1972; Mullertz, 1974). It was purified and proven to be different to other
previously identified protease inhibitors (Mullertz and Clemmensen, 1976). At
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around the same time there were two reports of a n e w inhibitor of plasmin activity.
One was observed in human serum and called a2-plasmin inhibitor (Aoki and von
Kaulla, 1971; Moroi and Aoki, 1976) and the other was called antiplasmin (Collen et
al, 1975). With the use of antisera it was finally established that the two inhibitors
were one in the same (Gallimore and Hedner, 1977; Mullertz and Clemmensen, 1976).
Hepatocytes are considered to be the main source of o^-antiplasmin (Hogstorp and
Saldeen, 1982; Saito et al, 1982; Fair and Plow, 1983), but the kidney has been
identified as another major source (Menoud et al, 1996).

otj-Antiplasmin is a glycoprotein with a molecular weight of 70.4kDa and is 452
amino acids in length (Wiman and Collen 1977, Lijnen et al, 1987). Under reducing
conditions the molecular weight of o^-antiplasmin is 67kDa. The carbohydrate
content of ct2-antiplasmin is approximately 13.7%. The reactive site of a2antiplasmin consists of the amino acids Arg364-Met365 (Holmes et al, 1987) and
contains 2 disulphide bridges at Cys64-Cys104 and Cys3I-Cys113 (Lijnen et al, 1987).
It has been observed that only upon reduction of all disulphide bridges does a2antiplasmin lose all of it's activity (Wiman et al, 1981). The concentration of a2antiplasmin in normal plasma is 7mg/ml or luM (Moroi and Aoki, 1976; Wiman and
Collen, 1977).

11

It has been reported that 3 0 % of the o^-antiplasmin circulating in normal human
plasma cannot be inactivated by excess plasmin (Mullertz and Clemmensen, 1976).
This has been demonstrated to be a form that is able to bind plasminogen while the
other form remains as an active plasmin inhibitor (Christensen and Clemmensen,
1978; Clemmensen, 1979; Wiman, 1980a). The half-life of a2-antiplasmin in plasma
has been examined (Collen and Wiman, 1979; Collen and Wiman, 1979a). The half-life
of iodinated a2-antiplasmin in the plasma of normal subjects was 2.64+0.32 days.

oc2-Antiplasmin has been observed to form 1:1 complexes with plasmin (Mullertz,
1974; Collen, 1976; Moroi and Aoki, 1976; Mullertz and Clemmensen, 1976; Wiman
and Collen, 1977) which also induces a conformational change in a2-antiplasmin
(Sorensen, 1981; Wiman et al, 1981). It is possible to inhibit the interaction of
plasmin with a2-antiplasmin using either the chromogenic substrate S-2251 or 6amino-hexanoic acid (Christensen and Clemmensen, 1978; Wiman and Collen, 1978).
This indicates that not only does the interaction involve the active site of plasmin,
that it is dependent upon one or more of the lysine binding kringles of plasmin.
Analysis of the plasmin/a2-antiplasmin complex by non-reducing SDS-PAGE
indicates the complex is 140kDa in size (Lijnen and Collen, 1985b). When the
complex is reduced, the complex dissociates into the intact A chain of plasmin
(60kDa) and a very stable complex between the plasmin B-chain and cc2-antiplasmin
12

(80kDa), provided that oc2-antiplasmin is in excess (Wiman and Collen, 1977; W i m a n
and Collen, 1979; Wiman and Collen, 1979a).

During complex formation a peptide of approximately 8kDa is released (Wiman and
Collen, 1979a). Sequence analysis revealed it as the carboxy terminal of oc2antiplasmin. In addition, the plasmin/a2-antiplasmin complex may be cleaved by

excess plasmin. Sites of cleavage are located on the B chain of plasmin and in bo
ends of a2-antiplasmin (Wiman and Collen, 1979a).

Interaction of oc2-antiplasmin with plasmin involves a fast reversible reaction f
by a slower irreversible reaction (Christensen and Clemmensen, 1977; Christensen
Clemmensen, 1978; Wiman and Collen, 1978). The rate constant for the reversible
reaction was found to be S.S+OJxlO^'V1 for plasmin I and LSiO^xlO^'V1 for
plasmin II. Plasmin I and plasmin II are different according to their affinities
lysine-Sepharose (Brockway and Castellino, 1972). For low molecular weight

plasmin, which has no kringles, the rate constant falls to 6.5±0.5xl05M"1s"1 (Wima

et al, 1978). Petersen and Clemmensen (1981) have also measured the kinetics of t

interaction between the non-plasminogen binding a2-antiplasmin, normal plasmin an

low molecular weight plasmin. Their results showed a simple irreversible reaction
constant of 3.9xl05M"1s"1.
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oc2-Antiplasmin is also able to bind to plasminogen (Moroi and Aoki, 1976; W i m a n
and Collen, 1977; Christensen and Clemmensen, 1978). Binding is mediated by the
high affinity kringle structures. It was demonstrated to be the first 3 kringles of
plasmin by examination of a fibrin competition assay (Thorsen, 1980; Thorsen,
1981). Fibrin binding by a plasminogen fragment containing those 3 kringles was
reduced by oc2-antiplasmin, while in contrast a low molecular weight plasmin and a
plasmin fragment that only contains kringle 4 were unaffected. The interaction
between oc2-antiplasmin and Lys-plasminogen is 10 times stronger than for Gluplasminogen (Wiman et al., 1979). This is because residues 1-76 of Glu-plasminogen
mask one of the kringles.

Other proteases can react with a2-antiplasmin in purified systems. It can react with
trypsin, chymotrypsin, uPA (Holmberg et al, 1980), kallikrein, factor Xa, thrombin
(Saito et al, 1979) and with tPA (Korninger and Collen, 1981). a2-Antiplasmin is
unable to inhibit purified granulocyte collagenase, elastase, chymotrypsin-like enzyme
(Ohlsson and Collen, 1977) and papain (Moroi and Aoki, 1977a). Another detailed
study revealed that a2-antiplasmin could also inhibit the clot promoting and pre-

kallikrein activating activity of Hageman factor fragments, the amidolytic kininogenase
and clot-promoting activities of plasma kallikrein, activated plasma thromboplastin
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antecedent (PTA, FactorXIa) and thrombin (Saito et al, 1979). In contrast, a 2 antiplasmin in normal plasma does not inhibit thrombin or chymotrypsin (Edy and

Collen, 1977). This demonstrates that like other protease inhibitors found in plasma,
cc2-antiplasmin has broad in vitro inhibitory activity but very specific activity at
physiological level (Lijnen and Collen, 1985b).

1.1.5 PAI-2

For reviews see Belin (1993), Dear and Medcalf (1995) and Kruithof et al. (1995).
PAI-2 was first isolated by Kawano et al, (1970) from human placental tissue and
later from cells of a monocyte/macrophage lineage (Golder and Stephens, 1983;
Vassalli et al, 1984; Chapman and Stone, 1985; Saksela et al, 1985; Kruithof et al,
1986b). PAI-2 has subsequently been detected in several other cell types. Fibroblast
like cells from fetal lung (Michel and Quertermous, 1989; Kumar et al, 1992; Wick et
al, 1994), foreskin (Kumar et al, 1992; Pytel et al, 1990), human synovial explants
(Hamilton etal, 1992; Hamilton etal, 1993a) and bone marrow stroma (Hannocks et
al, 1992) have all been found to express PAI-2. Endothelial cells stimulated with
inflammatory stimuli (Scarpati and Sadler, 1989; Laug etal, 1989; Wojta et al, 1993),

human omental and pleural mesothelial cells (Van Hinsbergh et al, 1990; Idell et al,
1992), microglia (Akiyama et al, 1993), human cumulus and granulosa-luteal cells
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(Piquette et al, 1993) and human corneal epithelium (Williams et al, 1999) also
express PAI-2. A mixture of glycosylated and non-glycosylated PAI-2 may be
detected in whole saliva and human gingival crevicular fluid (Kinnby et al, 1991;
Kinnby et al., 1993). The levels detected are relatively high, at concentrations of 28mg/l. PAI-2 has also been detected in seminal plasma (Zheng et al, 1994).

PAI-2 has been observed in skin. In normal epidermis PAI-2 is primarily detected in
the granular layers, but diffusely located in the lower and basal areas (Hibino et al,
1988; Chen, C. etal, 1993; Gissler et al, 1993; Lyons-Giordano etal, 1994; Spiers et
al, 1994). In an organotypic coculture system, PAI-2 messenger ribonucleic acid
(mRNA) was detected strongest suprabasally but weakly basally (Chen, C. et al,
1993). In addition, PAI-2 has been identified in the cornified envelopes of
keratinocytes (Jensen, P.J. etal, 1995; Robinson etal, 1997). It has been postulated
that PAI-2 may be a differentiation marker in the epidermis because PAI-2 is elevated

in keratinocytes induced to differentiate using calcium, as well as in differentiating

cells of murine hair, nail and stratified squamous epithelia (Lavker et al, 1998; Riss
al, 1998; Wang and Jensen, 1998). PAI-2 also appears to have a role in the

protection of normal epithelium from blistering. In skin diseases where blistering doe
occur, uPA and tPA levels were found to be elevated (Baird et al, 1990; Morioka et
al, 1987; Jensen, P.J. et al, 1988). Schaefer etal, (1996a) observed that PAI-2 and

uPA co-localized intracellularly and along the cell border in keratinocytes surroundin
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the blister cavity, and Bechtel et al, (1998) found strong expression of PAI-2 in
keratinocytes that re-epithelialised a lesion.

1.1.5.1 PAI-2 and pregnancy

Plasma levels of PAI-2 antigen are below detection in non-pregnant women (Lecander
& Astedt, 1989). However during pregnancy, PAI-2 antigen levels in the plasma of
pregnant women increases and peaks during term (Lecander and Astedt, 1986; Nilsson
etal, 1986; Kruithof et al, 1987a; Lecander and Astedt, 1987; Wright et al, 1988;
Koh et al, 1992; Halligan et al, 1994; Astedt et al, 1998). The levels of PAI-2 have
also been observed to remain elevated several days post-partum (Lecander and
Astedt, 1987). Both 47kDa and 60kDa PAI-2 can be detected in plasma from
pregnant women, but it is mainly 60kDa PAI-2 that is detected (Kruithof et al,
1987a; Lecander and Astedt, 1987).
PAI-2 protein and mRNA can be detected in placental villous syncytiotrophoblast
(Astedt etal, 1986; Feinberg et al, 1989; Fazleabas et al, 1991). PAI-2 in amniotic

fluid increases from 70ng/ml in the first trimester to 170ng/ml in the third trimeste
(Estelles et al, 1990). PAI-2 activity in fetal plasma was found to be very low
(Reverdiau-Moalic et al, 1991). The PAI-2 activity in fetal plasma (2.0U/ml) were
lower than in control plasma (9.2U/ml) and plasma from pregnant women (30.7U/ml).

PAI-2 concentrations in decidual and placental tissue at gestational week 8-12 are 50
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times higher than those found in term pregnancy plasma (Jonasson et al, 1989).

In pre-eclampsia or intra-uterine growth retardation the levels of PAI-2 protein and
mRNA are decreased (De Boer et al, 1988; Gilabert et al, 1990; Estelles et al, 1991;
Reith era/., 1993; Koh _/„•/., 1993;Halliganetal, 1994; Gilabert etal, 1994; Estelles
etal., 1994; Lindoff and Astedt, 1994; Granchaetal, 1996; Schjetleinef al, 1997). In
patients with intra-uterine growth retardation without pre-eclampsia PAI-2 levels
were found to be low, and PAI-1 levels were normal. In patients with pre-eclampsia
without intra-uterine growth retardation PAI-2 levels were normal and PAI-1 levels
were elevated. It has been suggested that reduced PAI-2 levels may be a marker for
decreased placental function and intra-uterine growth retardation (Reith et al, 1993;

Gilabert et al, 1994; Estelles et al, 1989). The ratio of PAI-1 :PAI-2 antigen levels i
the plasma has also been used to better discriminate between a normal pregnancy,
given a value of 0.6 and pre-eclampsia with values around 2.5 (Reith et al, 1993).

1.1.5.2 PAI-2 biochemistry

PAI-2 is a member of the serine protease inhibitor (SERPIN) superfamily. PAI-2 is a
415 amino acid long protein that occurs mainly as a non-glycosylated 47kDa
(Kruithof et al, 1986b; Collen et al, 1986a) and a glycosylated 60kDa form
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(Wohlwend et al, 1987a; Genton etal, 1987; Medcalf etal, 1988). The 47kDa form
is primarily found intracellularly and the 60kDa form is secreted. PAI-2 has 3 Nglycosylation sites at Asn75, Asn115 and Asn339 (Ye et al, 1988), and 3 potential
transglutamination sites at Gin83, Gin84 and Gin86 (Jensen, P.H. et al, 1989; Jensen,
P.H. etal, 1993; Jensen, P.H. etal, 1994a). The reactive centre (P! and P^) of PAI2 is at amino acid position Arg380-Thr381 (Kiso et al, 1988). To inactivate the target
protease, the carboxyl group of the ?i amino acid forms an ester bond with the
hydroxy 1 group of the active site serine of the protease (Egelund et al, 1998). Only
very recently has the crystal structure of PAI-2 been solved (Harrop et al, 1999).

PAI-2 forms SDS stable complexes with tc-uPA and tc-tPA in a 1:1 ratio. The rate
constant for the interaction between PAI-2 and tc-uPA is lO^'V1 and for tc-tPA
2_105M-1s_1 (Kruithofe/ al, 1986b; Thorsen et al, 1988; Mikuse/a/., 1993). uPA is
the more likely target of PAI-2 based on the rate constants, and the observation that
PAI-2 is unable to inhibit fibrin bound tPA (Leung et al, 1987). A 4kDa fragment of

PAI-2 is cleaved off after complexing with uPA or tPA (Sanzo et al, 1987; Kiso et al,
1988).

PAI-2 is unusual from other SERPENS, as it possesses no signal peptide for secretion.
As a result PAI-2 is targeted intracellularly and extracellularly by a process known
facultative translocation (Belin et al, 1989). The process has been investigated
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further in vitro using murine PAI-2 and it was found that the signal sequence bound
the signal recognition particle (SRP) with moderate efficiency, and only a fraction of
the polypeptide chains were translocated to the Golgi apparatus for secretion (Belin
etal, 1996). PAI-2 also has been found to occur as polymers, which are dependent
upon a loop sheet mechanism (Mikus et al, 1993; Mikus and Ny, 1996).

Besides inhibiting uPA extracellularly, the precise role for this predominantly

intracellular protease inhibitor has still not been clearly elucidated. The most likely

role would be an interaction with an as yet unidentified intracellular protease, as has
been postulated in normal epidermal keratinocytes (Risse et al, 2000). The
unidentified protease could be involved in a variety of functions. There has been a lot
of research into its possible role in preventing apoptosis (Kumar and Baglioni, 1991;
Dickinson et al, 1995; Dickinson et al, 1998; Jensen, P.H. et al, 1999). There has
also been reports of the possibility of PAI-2 conferring protection against viral or
bacterial infection (Semeraro et al, 1996; Antalis et al, 1998; Costelloe et al, 1999;
Kinnby etal, 1999; Shafren et al, 1999). However, it has proven ineffective against
the plasminogen activation found on the surface of the spirochete, Borrelia
burgdorferi, that causes Lyme disease (Perides et al, 1996). In keratinocytes it has
also been proposed that PAI-2 may be a marker of differentiation and proliferation,
particularly in keratinocytes (Lavker et al, 1998; Risse et al, 1998; Wang and Jensen,
1998; Hibino etal, 1999; Williams etal, 1999). Finally, the PAI-2 may only have a
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role in the protection against proteolytic activity once released from a necrotic or
lysed cell.

1.1.5.3 Regulation of PAI-2 expression

PAI-2 expression can be regulated by various factors that either act at a
transcriptional level or affects mRNA stability. The most widely implemented

factors which can up-regulate PAI-2 expression are lipopolysaccharide (LPS), phorbo

myristate acetate (PMA), tumor necrosis factor alpha (TNF-oc) and interleukin-1 (IL
1). LPS has been shown to increase expression of PAI-2 in monocyte/macrophagelike cells (Schwartz and Bradshaw, 1992; Chapman and Stone, 1985a; Schwartz et al,
1989; Schlichting et al, 1993). PMA has been shown to increase PAI-2 in
monocytes, macrophages and myelomonocytic cell lines (Kruithof et al, 1986b;

Genton et al, 1987; Wohlwend et al, 1987a; Wohlwend et al, 1987b; Schleuning et al,
1987; Alving et al, 1988; Arndt et al, 1989; Oliver et al, 1989; Antalis and
Dickinson, 1992; Dickinson et al, 1993; Niiya et al, 1994). PMA can also induce
PAI-2 expression in HT-1080 fibrosarcoma cells (Medcalf, 1992; Bergonzelli et al,
1992), SK-MEL-109 melanoma cells (Johnson and Baglioni, 1990) and in human
umbilical vein endothelial cells (HUVEC) (Scarpati and Sadler, 1989).

TNF-oc enhances expression of PAI-2 in monocyte-like cells (Medcalf 1992; Gyetko
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etal, 1992), fibroblast-like cells (Medcalf et al, 1988; Pytel et al, 1990; K u m a r and
Baglioni, 1991), human endothelial cells (Scarpati and Sadler, 1989; Schleef et al,
1988; Zoellner et al, 1993), human omental and pleural mesothelial cells (Van
Hinsbergh et al, 1990; Well et al, 1992) and melanoma cells (Pytel et al, 1990;
Johnson and Baglioni, 1990; Smith et al, 1994). IL-1 induces expression of PAI-2 in
monocytes (Gyetko etal, 1993), human bone marrow stromal cells (Hannocks et al,

1992), human endothelial cells (Zoellner et al, 1993), human fibroblasts (Hamilton et
al, 1992; Michel and Quertermous, 1989; Hamilton etal, 1993a) and granulosa luteal
cells (Piquette et al, 1994).

There are several other factors that have been identified that can induce the expre
of PAI-2. They include the cytokines and growth factors interleukin-2 (IL-2)
(Gyetko etal, 1993), interferon-gamma (IFN-y) (Gyetko et al, 1992), macrophage
colony stimulating factor (M-CSF) (Wohlwend et al, 1987b) and granulocytemacrophage colony stimulating factor (GM-CSF) (Hamilton et al, 1993b). Epidermal
growth factor (EGF) has also been used to induce PAI-2 in A431 epidermoid
carcinoma cells (George et al, 1990) and human granulosa luteal cells (Piquette et
1993).

Cyclic adenosine monophosphate (cAMP) can induce the expression of PAI-2, but
can have opposite effects depending upon the cell type. cAMP stimulates PAI-2
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production in monocyte/macrophage-like cells (Wohlwend et al, 1987b; Niiya et al,

1994; Medcalf, 1992; Hayashi etal, 1992), but inhibits the PMA stimulated PAI-2
production in HT-1080 fibrosarcoma cells (Bergonzelli et al, 1992) and TNF-a

stimulated PAI-2 production in SK-MEL-109 melanoma cells (Johnson and Baglioni
1990). Other factors found to stimulate or potentiate PMA stimulation of PAI-2

production are okadaic acid (Medcalf, 1992), retinoic acid (Alving et al, 1988;

Schuster etal, 1993; Tapiovaara etal, 1994), calcitriol (Kole et al, 1991), Deng

virus (Krishnamurti etal, 1989) and the fibrin degradation product D-dimer (R
etal, 1994).

1.1.6 PAI-1

PAI-1 was originally described as being synthesised by endothelial cells (Los

and Edgington, 1977) and was later purified from bovine endothelial cell cult

Mourik et al, 1984). It has subsequently been found to be synthesised by a wide
variety of cell types. By Northern blot PAI-1 could be detected in the liver,

placenta, weakly in the myocardium, but undetectable in the skeletal muscle an

(Lucore etal, 1988). By immunocytochemistry, PAI-1 was detected in noradrenalin

producing cells of the adrenal medulla (Eriksen et al, 1989), and Philips et a
reported that the placenta, in addition to PAI-2 has a high content of PAI-1.
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Monocytes/macrophages are also n o w known to synthesise PAI-1 as well as PAI-2
(Castellote et al, 1990). Other cell types that synthesise PAI-1 are fibroblasts
(Hamilton, et al. 1992; Hamilton, et al. 1993a), vascular smooth muscle cells,
hepatocytes (Busso et al, 1994), hepatoma cells, mammary cells, melanoma cells,
fibrosarcoma cells and platelets (Pollanen et al, 1991).

PAI-1 antigen levels in human plasma is variable but is approximately 20ng/ml
(Kruithof et al, 1987b). It has been shown to increase with age and varies diurnally
(Sprengers and Kluft, 1987; Thorsen and Philips, 1987; Kruithof, 1988a). An
increase in PAI-1 levels in plasma can be seen in certain diseases. It has been
observed in patients with septicaemia (Colucci et al, 1985; Emeiss and Kooistra,
1986) and meningococcal disease (Engebretsen et al, 1986).

PAI-1 is a single chain glycoprotein 379 amino acids long and 46-54kDa in molecular
weight (Erickson et al, 1984; Andreasen et al, 1986). The calculated molecular
weight of the protein alone is 42kDa. From the amino acid sequence, PAI-1 has 3
potential glycosylation sites (Asn209, Asn265 and Asn329) but no cysteine residues
(Loskutoff et al, 1987; Klinger et al, 1987). The active site of PAI-1 is located at
amino acid positions Arg346-Met347 as identified by amino acid sequencing of
plasminogen activator processed PAI-1 (Andreasen et al, 1986c; Sanzo et al, 1987)
and by sequence alignment with other SERPINs (Ny et al, 1986). PAI-1 has an
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amino terminal signal peptide 21-23 amino acids long that is cleaved off the mature
protein (Andreasen et al, 1986c; Ginnsburg etal, 1986; Ny et al, 1986; Pannekoek et
al, 1986; Wun and Kretzmer, 1987).

PAI-1 is able to inhibit tc-tPA and tc-uPA (Erickson et al, 1984, Colucci et al, 198
but not pro-uPA (Andreasen et al, 1986b). The rate constants for PAI-1 and tc-tPA
and tc-uPA are the same, 2_107M"1s"1 (Kruithof, 1988b). This makes PAI-1 an

efficient inhibitor of both active twin chain plasminogen activators. PAI-1 reacts w
sc-tPA slower than compared with tc-tPA (5.5x1 O^'V1) (Thorsen et al, 1988) and

PAI-1 is better able to inhibit free tPA compared to fibrin bound tPA (Kruithof et a
1984). The complexes formed by PAI-1, are SDS-stable, equimolar and involve the

active site of the protease (Philips et al, 1984; Erickson et al, 1985; Colucci et a
1986b; Kruithof et al, 1986a; Coleman et al, 1986; Sprengers e/a/., 1986). Like PAI2, PAI-1 from HT1080 fibrosarcoma cells, after complexing with uPA or tPA releases
a 4kDa fragment resulting in an inactive PAI-1 molecule (Nielsen et al, 1986). Apart
from the active site, PAI-1 can react with a secondary site on uPA and tPA. On uPA
it is residues 179-184 (Arg-His-Arg-Gly-Gly-Ser) (Adams et al, 1991) and in tPA it
is residues 296-302 (Lys-His-Arg-Arg-Ser-Pro-Gly) (Madison et al, 1990; Li, X et
al, 1992). The site on PAI-1 that interacts with those sites are Glu350, Glu351 and
Asp355 (P4, P5 and P9) (Madison et al, 1990b).
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PAI-1 is a relatively unstable inhibitor and is rapidly converted into a latent or
inactive form at 37°C (Mimuro et al, 1987; Levin and Santell, 1987; Reilly et al,
1990). This latent form of PAI-1 can be re-activated in vitro by protein denaturants
(Hekman and Loskutoff, 1985), some negatively charged phospholipids (Lambers et
al, 1987; Vaughan et al, 1990) and heat (Katagiri et al, 1988). PAI-1 has also been

observed as a non-inhibitory substrate, because it is inactivated by cleavage at the Pr
Pi' bond (Declerckera/., 1992).

1.2 PLASMINOGEN ACTIVATION AND THE CELL SURFACE

There is wide evidence that the plasminogen activation system is localised specifically
at the cell surface (PoTlanen etal, 1991; Vassalli et al, 1991; Vassalli et al, 1992).
Since all components of the plasminogen activation cascade do not have membrane

spanning domains, specific receptors are required for localisation to the cell surface.
This would provide a means for plasminogen activation at the cell surface to enable
cellular migration through the ECM. As will be seen, the interactions between the
components of the plasminogen activation system and the receptors can be
heterogeneous and range from low to high affinity.

1.2.1 T h e u P A receptor (uPAR)

O f the cell surface receptors to be described, the u P A / u P A R interaction is the most
specific. For reviews of uPAR structure and function refer to Moller (1993) or
Behrendt etal, (1995). uPARhasbeen found to be expressed by several normal and

malignant cell types. These include various tumor cell lines (Nielsen et al, 1988)

human foreskin fibroblasts, (Bajpai and Baker, 1985), human breast cancers (Needha
et al, 1987), human endothelial cells (Barnathan, et al. 1990a; Barnathan et al,

1990b), human monocytes (Vassalli etal, 1985; Nykjaer et al, 1990), human alveolar

macrophages (Chapman et al, 1990), human monocyte-like cell lines (Cubellis et al,
1986), human granulocytes and human activated T-lymphocytes (Nykjasr et al,
1994). More uPAR has been detected on the surface of breast cancer cell lines
compared to normal mammary cells (Li, Y et al, 1999).

One of the earliest observations of the possibility of uPA having a membrane rece
was using Rous Sarcoma virus (RSV) transformed chorio-embryonic fibroblast (CEF)

cells (Quigley et al, 1980). Plasminogen activator activity was found to bind with

high affinity to membranes isolated from these cells by subfractionation. uPAR wa
first purified and cloned in 1990 (Behrendt et al, 1990; Roldan et al, 1990). The
copy deoxyribonucleic acid (cDNA) of uPAR encodes for a 313 amino acid residue

protein excluding the signal sequence (Roldan et al, 1990). When analysing uPAR by
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S D S - P A G E the apparent molecular weight of u P A R varies from 50-65kDa.

This

heterogeneity is due to N-linked glycosylations because when deglycosylated the
molecular weight is 35kDa. There are 5 potential N-glycosylation sites at: Asn52,
Asn162, Asn172, Asn200, and Asn233 (Behrendt et al, 1990). Of those 5, only Asn52
was found to be functional in uPAR purified from U937 cells (Behrendt etal, 1991).

uPAR serves to localise uPA activity to the surface of cells. The ligands uPAR is abl
to bind are sc-uPA and tc-uPA. The conversion of sc-uPA to active tc-uPA was
found to be enhanced when bound to uPAR (Ellis et al, 1989). Reported values of
the Kd of binding of uPA to uPAR vary from 55-1000pM (Vassalli et al, 1985;

Estreicher etal, 1989; Stoppelli et al, 1985; Nielsen et al, 1988; Picone et al, 1989
Jensen, P.H. et al, 1991; Nykjasr et al, 1990). The half-life of the uPA/uPAR

complex ranges from 2-6h at 37°C (Stopelli et al, 1985; Picone et al, 1989; Nykjasr e
al, 1990; Estreicher et al, 1990). Kinetic studies suggest that uPAR is occupied by
secreted uPA that binds back to the receptor. If cells that have uPA bound to uPAR
are treated with a mild acid, the uPA is released. If the cells are then placed into
neutral pH environment, the receptors are re-occupied by newly secreted uPA
(Stoppelli et al, 1986; Bajpai and Baker, 1985).

uPAR has 3 domains, the first domain starting from the NH2-terminal part of the
protein. The ligand binding region of uPAR resides in the first domain. This was
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demonstrated by Behrendt et al, (1991) by digesting purified u P A R

with

chymotrypsin under mild conditions. The digest yielded a 16kDa fragment and a
heterogeneously glycosylated 35-50kDa fragment. Only the 16kDa fragment could be

cross-linked to radiolabeled ligand and amino acid sequencing revealed it was domai
1. uPAR is anchored to the plasma membrane by a glycosylphosphatidylinositol
(GPI) anchor (Ploug et al, 1991). The attachment site is contained in the sequence
Ser^-Gly^-Ala284 (Moller et al, 1992).

It has been observed that there is a form of uPAR cleaved between domains 1 and 2
on the surface of cultured cells leading to the release of the uPA binding region
(Hoyer-Hansen et al, 1992). It was demonstrated to be caused by uPA activity,
because adding an anti-catalytic monoclonal antibody against uPA to the culture
medium inhibited the formation of cleaved uPAR. The reaction has been
demonstrated to be more efficient if the uPA is cell surface bound on uPAR (HoyerHansen et al, 1997a). This does seem to indicate an in vivo regulatory step as
postulated by Hoyer-Hansen et al, (1997b).

It has been demonstrated that cell surface uPAR is polarised to the leading edge du

cell migration. Estreicher et al, (1990) observed that uPAR could be observed on the
leading edge of migrating monocytes and Okada et al, (1995) observed the same
phenomena in cultured human vascular smooth muscle cells using a wound assay.
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Wounding

of the culture lead to polarization of u P A R

as observed

by

immunofluorescence microscopy. In human breast carcinomas, 5 times more u P A R
was located at the periphery of the tumor compared to benign breast lesions (Del
Vecchioera/., 1993).

1.2.2 Cell surface uPA

Pollanen et al, (1987) detected uPA antigen at the leading edge of cells and in area
cell-cell contacts. At these locations the u P A co-localises with intracellular vinculin, a
marker of focal contacts (Pollanen et al, 1988).

The u P A detected by immuno-

electron microscopy was predominantly found at sites where the cells made contact
with the growth substratum (Pollanen et al, 1988). These results mean that u P A is
an important component in focal contacts (Pollanen et al, 1989), which are the sites
of closest contact between the ventral cell surface and the growth substratum
(Abercrombieera/., 1971; Chen, W . etal, 1982). Focal contacts are also frequently
observed close to the forward edge of migrating cells.

uPAR is vital in localising uPA to the cell surface. Hebert and Baker (1988)
demonstrated that u P A associated with cell surface u P A R , inhibited binding of u P A
to the focal contacts of HT-1080 cells using a synthetic 16 amino acid peptide that
matched part of the u P A R binding region in uPA.

u P A and u P A R have been
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demonstrated to co-localise using double immunofluorescence staining in H U V E C
cells (Ueshima et al, 1999). Several groups have proposed that the receptor bound
uPA may enable detachment of the cell from the ECM during phases of migration,

mitosis, invasion and tissue remodelling (Dano et al., 1985; Goldfarb and Liotta, 1986;
Sakselaand Rijken, 1988). To detach from the ECM, uPA may be able to exert it's

effect directly, like the plasminogen activator from transformed chick fibroblasts tha

was able to cleave fibronectin (Quigley et al, 1987). The other alternative is that uPA
can activate plasminogen on or near the cell surface to degrade the ECM. This is a
possibility because at the cell surface, uPA interacting with uPAR stimulated
plasminogen binding (Plow et al, 1986), and the activation of cell surface plasmin
(Ellis etal, 1989). The activation of plasmin was due to increased conversion of scuPA to tc-uPA (Ellis et al, 1989) and was limited to surface bound reactants because
in the presence of a2-antiplasmin activation still proceeded.

Other studies have also observed the importance of the uPA/uPAR interaction.
uPAR binding was found to be important because secretion of mouse uPA, which can
not bind to human uPAR (Apella etal, 1987; Huarte et al, 1987) did not enhance
invasion in a chorioallantoic membrane invasion model (Ossowski, 1988). The role of
tPA was also examined but tPA secretion did not enhance invasion like secreted uPA.
Invasion of amnion tissue by IFN-y stimulated monocytes was dependent on receptor
bound uPA (Kirchheimer and Remold, 1989b). Schlechte et al, (1989) using colon
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carcinoma cells found a strong correlation of receptor bound u P A with laniinin
degradation but a poor correlation existed between soluble uPA and laminin
degradation. Finally, receptor bound uPA was observed to aid the infiltration by
granulocytes into a fibrin matrix (Herijgers et al, 1995).

Receptor bound active uPA can bind either PAI-1 (Cubellis et al, 1989; Ellis et al,
1990) or PAI-2 (Estreicher etal, 1990; Ellis et al, 1990), and uPAR can also bind
pre-formed uPA/PAI-1 or uPA/PAI-2 complexes (Blasi et al, 1990). Studies have
examined the internalization of uPA/PAI-1 and uPA/PAI-2 complexes using
radiolabelled ligands (Estreicher et al, 1990; Cubellis et al, 1990),
immunofluorescence (Olson et al, 1992) and electron microscopy autoradiography
(Jensen, P.H. et al, 1991). It was observed that these complexes are internalized
when cells are incubated at 37°C. This is in stark contrast to uPA alone which is
either not internalized at all or only to a low degree (Olson et al, 1992). The
internalization was demonstrated to be uPAR dependent because it could be inhibited
by incubation with the amino terminal fragment of uPA (ATF) or a monoclonal
antibody directed against the binding domain of uPAR (Olson et al, 1992).

Finally, it has recently been proposed that uPA may associate with the surface of
cells independent of uPAR (Longstaff et al, 1999). The mechanism envisaged is that
there are other uPA receptors available that are low affinity but high capacity.
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1.2.3 Cell surface plasminogen

The plasminogen receptor found on the surface of cells is a diverse group of proteins.
Unlike uPA there is no single high affinity plasminogen receptor. Miles and Plow

(1985) were the first to report plasminogen binding sites on platelets as well as o

cells that express uPAR (Plow et al, 1986). There are receptors which bind differen
forms of plasminogen with equal affinity (Miles and Plow, 1988; Plow and Miles,
1990) and other receptors which have been reported to bind different forms of

plasminogen with a higher affinity (Bauer et al, 1984; Burtin and Fondaneche, 1988;
Gonzalez-Gronow et al, 1989; Murata etal, 1991).

Numerous cell types have been found to bind plasminogen. The cells of the immune
system; neutrophils, monocytes, B and T lymphocytes bind plasminogen (Miles and

Plow, 1987; Silverstein et al, 1988). Other cells that bind plasminogen are activa

platelets (Miles and Plow, 1985; Hajjar et al, 1986; Adelman et al, 1988; Hajjar an

Nachman, 1988), endothelial cells (Hajjar et al, 1986; Miles et al, 1988; Dudani an
Ganz, 1996), neurones (Nakajima et al, 1993) and microglial cells (Nakajima et al,
1993). Many cancer cell lines used in tissue culture have been observed to bind
plasminogen. These include the monocyte-like cell line U937 (Lu et al, 1988;
Gonzalez-Gronow etal, 1991a; Miles et al, 1991), the colonic carcinoma cell line

SW1116 (Burtin and Fondaneche, 1988; Correc etal, 1992), the fibrosarcoma cell line
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HT-1080 (Pollanen, 1989; Stephens et al, 1989) and the breast cancer cell line M D A MB-231 (Ranson et al, 1998). In addition, plasminogen has been observed by
immunofluorescence bound to breast and colorectal adenocarcinomas and their
metastases (Burtin et al, 1987).

As there are numerous cell types that bind plasminogen, there are numerous examples
of plasminogen/plasmin binding proteins (Table 1). The number of receptors varies
between cell types and they are of relatively low affinity. However, due to the high
concentration of plasma plasminogen it means that the receptors should be fully
occupied (Adelman et al, 1988; Miles et al, 1988).

The binding of plasminogen/plasmin to candidate cell surface receptors appears to be
mediated by the lysine binding kringle structures. The bmding of plasminogen to
endothelial cells and subsequent plasmin activation can be inhibited (Miles et al,
1989a; Hajjar et al, 1989; Gonzales-Gronow etal, 1989; Edelberg etal, 1989) using
lipoprotein A which contains 37 repeats of kringle 4 found in plasminogen (McLean
et al, 1987). The binding of plasminogen to the cell surface therefore can also be
inhibited by lysine analogs, as has been shown by the inhibition of plasminogen
binding to HT-1080 cells using tranexamic acid (Stephens et al, 1989).

Specifically, it is believed that kringle 1 of plasrriinogen is important in cellular
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Plasminogen/plasmin binding protein

Reference

Actin

Dudani and Ganz, (1996)

Annexin U

Hajjar et al, (1994)

a-Enolase

Miles et al, (1991)
Redlitzetal, (1995)
Andronicos et al, (1997)

Fibrin

Cederholm-Williams, (1977)
W i m a n and Wallen, (1977)

Fibrinogen bound to the glycoprotein Hb- Miles and Plow, (1985)
Ula complex
Adelman et al, (1988)
Hajjar et al, (1986)
Hajjar and Nachman, (1988)
Fibronectin

Salonen et al, (1985)

Histidinerichglycoprotein

Lijnen et al, (1980)

Laminin

Salonen etal, (1984)

Tetranectin

Christensen
(1989)

Thrombospondin

Silversteinefa/., (1985)

and

Walz _/#/., (1987)
DePoliefa/., (1989)

Table 1. Examples of plasminogen/plasmin binding proteins.

Clemmensen,

(Miles et al, 1988).

This is because kringle 1 containing fragments inhibit

plasminogen binding to cells, kringle 1 containing fragments bind directly to cells and

the concentration of lysine or lysine analogs required to inhibit plasminogen binding is
consistent with kringle 1 occupancy. Kringle 5 is also believed to mediate
plasminogen binding, but it is cell type specific (Redlitz and Plow, 1995).

The kringles of plasminogen recognise carboxyl-terminal lysines, making proteins with
such determinants potential cell surface plasminogen receptors. Good examples
which have been identified on the surface of cells are oc-enolase (Miles et al, 1991;
Redlitz et al, 1995) and annexin II (Hajjar et al, 1994). Glutaraldehyde-6phosphatase has also been isolated from the cell surface of bacteria (Lottenberg et al,
1992). This is not the sole determinant of binding though. For example, amphoterin
(Parkkinen and Rauvala, 1991) and a plasminogen binding protein of the group A
streptococcal isolate M53 (Berge and Sjobring, 1993) bind plasminogen independent
of a carboxyl-terminal lysine. There are also non-protein plasminogen binding sites
such as gangliosides (Miles et al, 1989b). A puzzle that remains to be solved is how
some of the plasminogen receptors like a-enolase, which is an intracellular enzyme,
could bind plasminogen in vivo. A possibility is that when a cell becomes damaged or
non-viable, intracellular plasminogen binding proteins are then accessible. Enhanced
plasminogen binding has been observed in non-viable U937 cells and breast cancer cell
lines (O'Mullane and Baker, 1998; Ranson et al, 1998).
35

1.2.4 T h e cell surface plasminogen activation amplification cycle

A cell that has the capacity to bind uPA and plasminogen has the ability to localise

tremendous proteolytic activity. This is because cell surface plasmin and tc-uPA are
able to activate sc-uPA and plasminogen respectively, generating an amplification
loop. Moller (1993) makes a very good point that the activation of the bound sc-uPA
is dependent on the bound plasmin and that activation of the bound plasminogen is
dependent upon the bound active uPA.

A study of uPA associated with U937 cells via uPAR found that the activation of
plasminogen was favored compared to solution phase uPA (Ellis et al, 1991). The
Km of solution phase uPA mediated plasminogen activation was 25[xM versus
0.67|iM for the cell-associated reaction. This is well below the physiological
plasminogen concentration of 2uM indicating that the kinetics of plasminogen

activation are favored by the reactants being bound to a surface. A similar dependanc
upon a surface has been demonstrated using streptokinase and tPA (Miles and Plow,
1985; Deguchi et al, 1985; Hajjar et al, 1986; Strieker et al, 1986). These
observations indicate the importance of a cell surface plasminogen activator

component in plasmin generation. In addition plasmin activity is increased at the ce
surface (Gonzalez-Gronow et al, 1991; Duval-Jobe and Parmely, 1994).
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If plasminogen is added to cells with endogenous u P A it is possible to generate
plasmin.

The plasmin formed was reported to be not from plasmin in the

plasminogen preparation, or from plasmin formed in the media, as the plasmin formed
in the media does not bind back to the cells (Stephens et al, 1989). The plasmin
generation was dependent on u P A as pre-incubation of cells with an inhibitory
monoclonal antibody to u P A inhibited plasmin generation. PAI-2 also prevented
plasmin generation, and inhibition of tPA had no effect. A comparable decrease in
plasmin generation could be seen if D F P inactivated u P A was used to occupy u P A R .

In a cyclical process, it is also possible to activate sc-uPA into active tc-uPA on the
surface of cells. Stephens et al, (1989) was also able to demonstrate that almost all of
the u P A on the surface of HT-1080 cells was sc-uPA and that after incubation with
plasminogen the u P A became tc-uPA. The amount of sc-uPA also increased if the
plasminogen was incubated in the presence of aprotinin or an inhibitory antibody to
plasmin.

1.2.5 Cell surface tPA

Receptors for tPA binding have recently been reviewed by Redlitz and Plow (1995).
tPA has been observed to bind to the cell surface of endothelial cells with high and
low affinity (Hajjar et al, 1987). The high affinity binding was due to cell surface
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PAI-1 (see next section 1.2.6.1), but the low affinity binding was due to a t P A
receptor. A candidate cell surface receptor of 40kDa was purified from cultured
endothelial cells and placental tissue which could bind tPA in a kringle dependent
manner (Hajjar and Hamel, 1990; Hajjar, 1991). tPA bound to immobilised purified
receptor activated 6.4 times more plasminogen into plasmin than an equivalent
amount of t-PA in the fluid phase. The protein turned out to be annexin II and the
binding site has been localised to the carboxy terminal lysine residues on the pll

subunit (Hajjar et al, 1994; Hajjar et al, 1998; Kassam et al, 1998). Since annexin II

is also capable of bmding plasminogen simultaneously, this provides an exquisite site
for plasminogen activation.

Dudani and Ganz (1996) demonstrated that one of the binding proteins responsible

could be cell surface actin. Using anti-actin antibodies tPA binding to the cell surf
could be inhibited by 46%. Other tPA receptors that have been identified on
endothelial cells are tubulin (Beebe et al, 1990) and a 20kDa protein (Fukao et al,
1992). Like plasminogen binding, tPA binding is mediated by the kringle structures.
The binding of tPA to the cell surface of endothelial cells could be inhibited by 7080% using lysine (Dudani and Ganz, 1996).

Other cell types have been studied for their ability to bind tPA. tPA has been
observed to bind to platelets (Vaughan et al, 1989), neutrophils and monocytes
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(Felez et al, 1991). O n monocytes tPA shares binding sites with plasminogen (Felez
etal, 1993), meaning they possess tremendous plasminogen activating capabilities at
their cell surface. Granule cells from the cerebellum (Verrall and Seeds, 1989) and
h u m a n sympathetic neurones (Pittman et al, 1989) are also able to bind tPA.

The

best candidate in neuronal cells for the tPA binding protein is amphoterin, a protein
which binds plasminogen and is associated with developing neurites. It is believed
that tPA can aid in neurite outgrowth, from observations that neurite outgrowth was
inhibited by amphoterin antibodies (Merenmies et al, 1991).

1.2.6 Plasminogen activator inhibitors

Since plasminogen activators have been detected on the cell surface, it would be
intuitive that plasminogen activator inhibitors might also possess a secreted or cell
surface topology.

It is feasible that the plasminogen activator inhibitors can be

observed at the cell surface by inhibiting cell surface u P A or tPA. Cell surface u P A
can be inhibited by soluble PAI-1 or PAI-2 (Ellis et al, 1990). The rate constant for
inhibition using PAI-1 against cell surface bound u P A was 4.5_10 6 M~ 1 s"1 and against
soluble u P A 7.9_10 6 M _1 s"1. The rate constant for inhibition using PAI-2 against cell
surface bound u P A was 3.3_105M"1 s"1 and against soluble u P A 5.3_10 5 M _1 s"1. The
inhibition of u P A bound to u P A R was a little better compared to free uPA. Detection
of uPA/PAI complexes is difficult because of the rapid turnover of u P A R / u P A / P A I
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complex. But, the interaction can be seen indirectly, by the inhibition of cell surface
u P A activity.

1.2.6.1 PAI-1

Stephens et al, (1989) observed that even though there is an increase in tc-uPA
protein on the cell surface, there is a decrease in total u P A activity on the cell surface.
They demonstrated that it was a result of pericellular PAI-1 because a monoclonal
antibody that inhibits PAI-1 activity could prevent the decrease in cell surface u P A
activity.

Active PAI-1 has been observed associated with other cell surfaces. PAI-1 made by
endothelial cells can associate with the cell surface (Sakata et al, 1988) or with the
matrix underneath the cells (Schleef et al, 1990) and can bind tPA. The binding sites
for radiolabeled tPA on H U V E C cells were found to be of high and low affinity
(Barnathan et al, 1988). The high affinity binding sites were observed to be via PAI1 and found to be enhanced or stabilised by the use of heparin (Cheng et al, 1992;
Rosenfeld et al, 1992). Researchers have also found active PAI-1 on the surface of
other cells that could bind tPA. PAI-1 has been demonstrated to be associated with
the plasma and outer acrosomal membranes of spermatozoa (Smokovitis et al, 1992).
PAI-1 on explant cultures of h u m a n vascular smooth muscle cells has been found to
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bind tPA because binding was inhibitable using PAI-1 monoclonal antibodies
(Grobmyer et al, 1993).

1.2.6.2 PAI-2

PAI-2 can potentially be seen as a cell surface component by inhibiting cell surface
uPA. PAI-2 was found to inhibit cell surface u P A on human monocytes (Kirchheimer
and Remold, 1989a; Ellis et al, 1990). There is a similar effect for PAI-2 in HT-1080
cells (Stephens et al, 1989). In R D rhabdomyosarcoma cells, cell surface plasmin
activity was inhibited with PAI-2, tranexamic acid and with an anti-catalytic
monoclonal antibody to human u P A (Pollanen etal, 1990). Reinartz et al, (1996)
was able to observe PAI-2 on the cell surface of H a C a T cells by flow cytometry and
reported it was complexed with u P A as detected by ELISA.

The inhibitory effect of PAI-2 on cell surface uPA was found to be strongly
dependent on cell surface bound plasminogen in R D rhabdomyosarcoma cell cultures
(Pollanen et al, 1990).

M o r e specifically recombinant PAI-2 could be detected

associating with

at focal contacts on

uPA

the

ventral

surface

of

RD

rhabdomyosarcoma cells in the presence of plasminogen. Without plasminogen, there
was no PAI-2 detectable associating with the cells. The PAI-2 also did not react
significantly with u P A w h e n plasminogen was prevented from binding using
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tranexamic acid. This indicates the need for active u P A activated by plasmin to bind
PAI-2.

Apart from being seen as a complex, active PAI-2 has been identified associated wi

membranes. Jensen, P.H. et al, (1989) found PAI-2 associated with isolated placent
microvillous membranes. The PAI-2 detected in those membrane preparations

migrated as a large complex under SDS-PAGE conditions, suggesting that it was cros
linked to other proteins within the membrane preparation. In skin, PAI-2 has been

detected associated with the periphery of cells located in the suprabasal granular
layer of normal human epidermis (Lyons-Giordano et al, 1994). Baker et al, (1993)
originally observed that PAI-2 was on the cell surface of U937 cells by flow
cytometry, and suggested that the PAI-2 found on the surface was active using a
monoclonal antibody which distinguished formation of uPA/PAI-2 complexes from

active PAI-2. In contrast a recent study observed no cell surface PAI-2 on HeLa ce
induced to undergo apoptosis (Dickinson et al, 1998).

The annexins may be potential PAI-2 binding proteins. PAI-2 can bind to the

annexins I, II, IV and V (Jensen, P.H. et al, 1996) and U937 cells have been shown
express annexin I (Morand et al, 1995; Harricane et al, 1996) while monocytes

express annexin I and III (Morand et al, 1995; Harricane et al, 1996; Le Cabec and
Maridonneau Parini, 1994). Annexin I was also found in association with
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phagosomes in differentiated U 9 3 7 cells (Harricane et al, 1996).

In activated

monocytes annexin III was found to translocate to the plasma membrane or
phagosomes (Le Cabec and Maridonneau Parini, 1994). It has also been observed that
a form of annexin IV exists, that spans the membrane of the human colon cancer cell
line HT-29 (Satoh et al, 1996). Thus, it is possible that other annexins are also

translocated to the cell surface, providing a PAI-2 binding site. In the case of annexi

II it would provide a nice means of inhibiting plasminogen activation at the surface o
endothelial cells, by preventing the binding of tPA and plasminogen and providing a
source of inhibitory activity.

1.3 PERICELLULAR ECM BINDING BY COMPONENTS OF THE
PLASMINOGEN ACTIVATION CASCADE

This is a very important aspect of plasminogen activation because in order for the
plasminogen activation cascade to degrade the ECM, there must be an initial
interaction between them to increase the efficiency of either the degradation or
protection of the ECM.

1.3.1 Plasminogen

Fibrin is the most important E C M component that binds plasminogen. It has been

observed that after plasminogen binds to fibrin that this leads to better activatio
plasmin by tPA (Hoylaerts et al, 1982; Dunn et al, 1984; Zamarron et al, 1984a).

The binding has been found to be enhanced following the polymerisation of fibrin and
requires kringles 1-4 of plasminogen (Suenson et al, 1990). Using electron
microscopy plasminogen was observed to bind to the end-to-end junctions between 2
fibrin molecules (Weisel et al, 1994). This interaction of plasminogen with fibrin
probably is via a mechanism very similar to the interaction of plasminogen with the

cell surface. It has also been observed that the catalytic efficiency of the activat
plasminogen by uPA is increased 10-fold by the presence of CNBr digested fragments
of fibrinogen (Lijnen et al, 1984a). The fibrinogen is believed to be leading to a
conformational change in Glu-plasminogen making it more susceptible to activation
similar to the change seen in the conversion from Glu-plasminogen to Lysplasminogen.
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1.3.2 Plasminogen activators

1.3.2.1 uPA

uPA does interact with some components of the ECM. It was initially reported that
native sc-uPA does have an affinity for fibrin that is lost when the molecule is
converted into tc-uPA (Kasai et al, 1985b; Kasai et al, 1985c). Other researchers
also have reported sc-uPA preparations with a low affinity for fibrin (Stump et al,
1986b; Lijnen et al, 1986b). The affinity has been reported to increase in the
presence of zinc ions (Husain, 1993). More recently, it has been found that the
intrinsic activity of sc-uPA can be promoted by the fibrin fragment E2 (Liu and
Gurewich, 1991; Liu and Gurewich, 1992) and partially degraded fibrin (Fleury et al,
1993).

A model has been proposed by Pannel et al, (1988) where fibrin is degraded initially
by fibrin bound plasminogen which has been activated by tPA. Then as the surface of
the clot is removed, carboxy-terminal lysine residues become exposed. Finally, more
plasminogen can bind becoming a good substrate for sc-uPA which enhances the fibrin
degradation. The degradation of fibrin by recombinant sc-uPA and tc-uPA has been
studied (Lijnen et al, 1989). It was found that the activity of tc-uPA toward fibrin
was 2-3 fold higher than sc-uPA and 2-3 orders of magnitude higher than a plasmin
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resistant sc-uPA.

It has also been investigated whether there is any synergism

between uPA and tPA in fibrin degradation (Collen et al, 1986). It was found that in
the presence of combinations of tc-tPA and sc-uPA, tc-tPA and tc-uPA or sc-uPA
and tc-uPA that there was no synergism for thrombolysis.

There is another interesting facet to the presence of sc-uPA during fibrin clot
formation and degradation. It has been observed that sc-uPA can be inactivated by
thrombin at Arg156-Phe157 (Ichinose et al, 1986a; van Hinsbergh et al, 1987).
Subsequently, it has been reported in a rabbit jugular venous thrombosis model that
this uPA is only half as potent as sc-uPA (Abercrombie et al, 1990). Liu and
Gurewich (1993) observed that thrombin cleaved uPA is active in the presence of the

fibrin fragment E2. Therefore, during the formation of a fibrin clot the thrombin can
inactivate any sc-uPA protecting the clot from degradation. But, assuming that the
"inactive" uPA can bind to the fibrin, it can still possibly act as a reservoir of
plasminogen activation when the clot starts to be degraded.

Edelberg et al, (1991a) observed that the glycosaminoglycans (GAGs); heparin,
heparan sulphate and chondroitin sulphate are able to enhance the activation of
plasminogen by uPA. The effect was not due to an increase in affinity of uPA for
plasminogen, so it appears it is an effect on the rate of reaction. It was initially
observed that heparin was also able to stimulate the activity of cell surface uPA on
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R D rhabdomyosarcoma cells (Stephens et al, 1991b).

It was subsequently

discovered that the kringle domain in the ATF of uPA is able to interact with heparin
(Stephens et al, 1992a) In addition the ATF of uPA was also found to bind to the E4
domain of laminin, and the rod or amino-terminal regions of nidogen (Stephens et al,
1992b).

1.3.2.2 tPA

The principle member of the ECM that tPA is able to interact with is fibrin. In the
presence of fibrin tPA mediated plasminogen activation is greatly enhanced, while in
contrast the effect by fibrinogen is smaller (Hoylaerts et al, 1982; Rinby, 1982). It
also dependent upon fibrin polymerisation (Suenson and Petersen, 1986). The sites
involved in this enhancement of the tPA mediated plasminogen activation are Actl48160 and y312-324 (Nieuwenhuizen et al, 1983; Schielen et al, 1991; Schielen et al,
1991a; Yonekawae/.a/., 1992; Schielen et al, 1993; Nieuwenhuizen, 1994). It is not
an absolute requirement though because a similar enhancement can be observed using
fibrinogen treated by freeze drying, urea, ethylenediaminetetraacetic acid (EDTA),
alkaline pH treatment or heat denaturation (Haddeland et al, 1995; Haddeland et al,
1996) as well as by peptides that are homologous to Aocl48-160 (Schielen et al,
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1991; Schielen et al, 1991a) and

certain C N B r fragments of fibrinogen

(Nieuwenhuizen et al, 1983a; Graihle etal, 1994).

The binding of tPA to fibrin is mediated simultaneously by its finger and kringle 2

domains (Horrevoets et al, 1994). Following the polymerisation of fibrin, the binding

of tPA was found to be enhanced and altered (Higgins and Vehar, 1987; de Vries et al
1989). It has been postulated that the altered binding arises due to the generation
carboxy-terminal lysines which are generated by plasmin cleavage of the Aot chain
(Lijnen and Collen, 1995). During clot lysis sc-tPA is converted into tc-tPA at the
clot surface (Rijken et al, 1982).

In addition to tPA being able to bind to fibrin, it is also able to bind to
thrombospondin and fibronectin (Silverstein and Nachman, 1987; Salonen et al,
1985). Heparin sulphate and heparan sulphate are able to modulate tPA activity
(Edelberg and Pizzo, 1990). In the presence of these two GAG molecules the rate of

activation of plasminogen to plasmin was increased 25-fold and 3.5-fold respectively
The effect of heparin has subsequently been found to be dependent upon the ionic

strength of the environment and the presence of divalent cations (Young et al, 1992)
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1.3.3 u P A R

u P A R was observed by Wei et al, (1994) to bind vitronectin.

Epithelial cells

expressing recombinant membrane bound uPAR in the absence of uPA were strongly
adherent to vitronectin compared to cells expressing soluble uPAR. The interaction
reported was of high affinity (Kd<30nM). More recently it was observed that uPAR
on the plasma membrane of human breast cancer cells could form a ternary complex
with the ATF of uPA and vitronectin (Carriero et al, 1997). This was confirmed
when Chang et al, (1998) observed that uPA or the ATF of uPA enhanced the
adhesion of human vascular smooth muscle cells uPAR to vitronectin but not to
lanxuiin, collagen I, or collagen IV. The adhesion of uPAR to vitronectin is also

enhanced by pertussis toxin (Wong, et al, 1996) and zinc ions (Chavakis et al, 1999)

It has also been demonstrated that PAI-1 competes with uPAR for the binding site on
vitronectin (Deng etal, 1996; Stahl and Mueller, 1997; Waltz et al, 1997; Loskutoff
et al, 1999). PAI-1 was able to detach U937 cells from a vitronectin substrate, and

uPA was able to reverse the dissociation. Stahl and Mueller (1997) found that uPA o
the ATF of uPA enhances the adhesion of uPAR to vitronectin but in the absence of
bivalent cations uPA/uPAR only promoted cell attachment. The effect of uPA on
uPAR mediated cell adhesion is believed to be due to a strong increase in the cell-

surface expression of the integrin 03 and a moderate increase of the integrin av (R
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et al, 1999).

Therefore, the addition of PAI-1 or u P A can regulate the u P A R

mediated cell adhesion to vitronectin to affect cell migration.

The region of vitronectin that binds to uPAR is in the region of amino acids 364-380
which is near a plasmin cleavage site at amino acid 361 (Waltz et al, 1997). Limited
cleavage of vitronectin by plasmin can abolish cellular binding and adhesion. Peptides
synthesised in this region of vitronectin were able to inhibit the binding of u P A R to
intact vitronectin.

But it has also been observed using real-time biomolecular

interaction analysis that intact u P A R was required to bind vitronectin, because
domain 1 of u P A R and recombinant domains 2 and 3 of soluble u P A R did not bind
vitronectin (Hoyer-Hansen et al, 1997b). In a metastatic melanoma cell line, u P A R
expression was linked to the expression of another vitronectin receptor, the integrin
ocvp3 (Nip etal, 1995). Vitronectin has also been proposed to enhance plasminogen
activation by forming complexes with soluble u P A R and u P A at the cell surface or at
the E C M (Chavakis et al, 1998).

1.3.4 a2-Antiplasmin

oc2-Antiplasmin can interact with fibrin. The binding of plasminogen to fibrin has
been reported to be inhibitable by a2-antiplasmin (Moroi and Aoki, 1977b; Aoki and
Sakata, 1980). There is a conflicting report where there was no effect on plasminogen
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binding to fibrin in the presence of normal or a2-antiplasmin depleted plasma
(Rakoczi et al, 1978). An important stage in the stabilisation of fibrin clots is the
cross-linking of fibrin monomers together by the plasma fransglutaminase, factor
Xllla. A n important finding, w a s that a2-antiplasmin can be cross-linked tofibrinor
fibrinogen in the presence of factor Xllla and calcium ions (Sakata and Aoki, 1980;
Ichinose and Aoki, 1982). The cross-linked a2-antiplasmin could protect the fibrin
clot from plasmin mediated lysis (Sakata and Aoki, 1980).

It was later found that the NH2-terminal 12-residue peptide of o^-antiplasmin (Npeptide) could also be cross-linked to fibrin (Kimura et al, 1985). The incorporation
of the N-peptide w a s found to enhance the fibrinolysis of clots by inhibiting crosslinking of intact a2-antiplasmin to the fibrin. The residues involved were identified as
Gin2 of 02-antiplasmin and Lys303 of the a-chain of fibrinogen (Kimura and Aoki,
1986). The cross-linking of a2-antiplasmin has also been reported to be reversible
(Mimuro et al, 1986). It was found that removal of free a2-antiplasmin from around
a normal fibrin clot lead to release of a2-antiplasmin from the fibrin. This could be
decreased by increasing concentrations of a2-antiplasmin in the surrounding milieu.
The release could also be accelerated by increasing concentrations of factor Xllla or
by the N-peptide. Platelets can also promote the cross-linking of a2-antiplasmin to
fibrin (Hevessey et al, 1996).
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1.3.5 Plasminogen activator inhibitors

1.3.5.1 PAI-1

The evidence in the literature so far makes it clear that PAI-1 can be associated w
the ECM. Work carried out by Pollanen et al, (1987) demonstrates that PAI-1 could
be detected on the growth substratum under cells removed by saponin and this
distribution was very different to the distribution of uPA on cells at the focal
contacts.

PAI-1 can bind to vitronectin either in plasma or in the ECM (Declerck et al, 1988;
Wiman et al, 1988; Lawrence et al, 1989; Mimuro and Loskutoff, 1989; Salonen et
al, 1989; Wvmetal, 1989). PAI-1 does not interact with fibronectin (Salonen etal,
1989). The distribution of PAI-1 in the extracellular space is almost the same as
vitronectin (Barnes et al, 1983; Hayman etal, 1983;Neyfakhe/a/., 1983). The PAI-

1/vitronectin interaction decreases the rate of conversion of PAI-1 into the inact
form. This was demonstrated using recombinant PAI-1 and vitronectin (Reilly et al,

1992). In the presence of vitronectin the half-life of the recombinant PAI-1 molecul
was doubled at 24°C and 37°C. Binding of vitronectin also protects PAI-1 from
oxidative damage (Mousa et al, 1993).

The vitronectin binding site is located in the 50kDa part of PAI-1 after cleavage by
uPA (Salonen et al, 1989). In human plasma, PAI-1 circulates as a complex with a
multimeric formofvitronectin(Declercke/a/., 1988). The vitronectin was still active
when complexed with PAI-1 because it was still able to promote cell adhesion and
spreading (Salonen et al, 1989). In addition the cellular receptor for vitronectin
distributes at focal contacts (Singer et al, 1988), potentially meaning that the PAI-1 is
a primary component promoting cell attachment at focal contacts (Pollanen et al,
1991). More recently, the binding of PAI-1 has been found to interfere with the
adhesion of platelets and megakaryoblastic cells to vitronectin, so it has been
\ proposed that PAI-1 may also regulate cellular differentiation (Wohn et al, 1999).

Podor et al, (1997) observed that
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I-vitronectin can bind to purified fibrin clots, and

that because PAI-1 can bind to vitronectin this allows a larger amount of PAI-1 to
bind to the fibrin compared to PAI-1 in isolation. Vitronectin binding to PAI-1
stabilises PAI-1 activity over 24hrs. In vitro, PAI-1 was able to bind to the ECM
synthesised by Hep G2 cells via vitronectin found in the bovine serum the cells were
cultured in (Owensby et al, 1991). It was also observed that the PAI-1 and
vitronectin associated only following secretion using pulse chase experiments.

In addition to vitronectin being able to bind to PAI-1, vitronectin is able to modulate
the affinity of PAI-1 for tPA. It has been observed that vitronectin, fibrinogen and
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heparin were able to enhance the rate of inhibition of tPA by PAI-1 (Edelberg et al,
1991b; Keijer et al, 1991). There is also a change in specificity because the PAI-

1/vitronectin complex is an efficient inhibitor of thrombin (Ehrlich et al, 1990). PA

1 can also bind heparin which also leads to an efficient inhibitor of thrombin (Keij
al, 1991). In contrast though, heparin does not stabilise PAI-1 activity.

PAI-1 is also able to bind to fibrin. PAI-1 has been detected associated with fibrin
and platelet material in human thrombus (Robbie et al, 1996). Vitronectin was also
found to localise with the PAI-1 in the clot. PAI-1 bound in vitro to fibrin clots
(Wagner et al, 1989) has been found to remain active. It was observed that upon
interaction with uPA the complex was released into the surrounding medium, but
complexes with tPA remained bound to the fibrin by the finger and kringle 2 domain
of tPA. In addition, PAI-1 can directly bind fibrin via either a low number of high
affinity binding sites or a high number of low affinity binding sites (Reilly and
Hutzelmann, 1992). The PAI-1 was also found to have a protective effect. In

contrast, other studies have found that fibrin bound PAI-1 is not as good an inhibito
(Chmielewska etal, 1988; Masson and Angeles-Cano, 1988).

1.3.5.2 PAI-2

PAI-2 unlike PAI-1 does not appear to bind to vitronectin, as determined by no
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binding being seen w h e n PAI-2 was incubated with vitronectin coated plates (Mikus
et al, 1993). But, in contrast Radtke et al, (1990) observed that PAI-2 was bound to
vitronectin in vivo from cellular placental extracts.

It is feasible that PAI-2 may be able to bind to certain components of the ECM due to
the PAI-2 being cross-linked by transglutaminase activity (Jensen, P.H. et al, 1993).
In the study by Jensen, P.H. et al, (1989) the cross-linked PAI-2 in trophoblast
membranes could be attached to the ECM surrounding it, as opposed to integral
plasma membrane components. Plasma membrane proteins may not be the target for
PAI-2 because Dickinson et al, (1998) observed no PAI-2 cross-linked to the plasma
membrane of HeLa cells. PAI-2 has also been cross-linked in vitro to basement
membrane proteins (Matrigel) and to fibronectin (Jensen, P.H. et al, 1989).
Fibronectin can also be cross-linked to fibrin (Tamaki and Aoki, 1981), so this may
provide a site for PAI-2 to bind to in the ECM. Under the correct conditions
monocytic cells, which are a major source of PAI-2, may be able to cross-link PAI-2
to the ECM. U937 cells and monocytes are known to express tissue transglutaminase
(Defacque et al, 1995; Mehta et al, 1985) and the U937 cells were reported to
express factor Xllla on their cell surface (Kradin et al, 1987).

PAI-2 is known to be cross-linked to other structures. Jensen, P.H. et al, (1993)
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were able to cross-link PAI-2 to fibronectin. In keratinocytes PAI-2 was observed to

be a part of the cornified envelope (Jensen, P.J. et al, 1995), a very stable structu
found just under the plasma membrane of keratinocytes that is stabilised by
transglutaminase activity. In addition, peptides corresponding to PAI-2 have been
obtained from CNBr digests of cornified envelopes (Robinson et al, 1997). In a
study by Ritchie et al, (1999) it was observed that PAI-2 could be cross-linked to

fibrin. Their results indicate that the PAI-2 is active in the clot and only protects
against uPA mediated but not tPA mediated lysis. If the PAI-2 is cross-linked to the
ECM and remains active this could provide another mechanism to protect the ECM
from proteolysis.

1.4 CONCLUDING REMARKS

From the evidence in the literature, plasminogen and it's activators can localise to
surface of cells and pericellularly on the surface of the ECM. Plasminogen and tPA

can bind to a variety of low affinity receptors on the cell surface, while uPA locali
to the cell surface by the high affinity receptor uPAR. Plasminogen, tPA and uPA are
able to bind to components on the surface of the ECM, in particular fibrin. As a
result, there are three possible ways in which a2-antiplasmin, PAI-1 or PAI-2 can
inhibit the activation of plasminogen. See Figure 2 for a schematic representation
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Figure 2. Hypothetical model of h o w PAI-2 m a y inhibit plasminogen
activation, a) Cell surface-ECM model. The interaction between components
of the E C M is modified from Darnell et al, 1990. b) Fibrin matrix-pericellular
model. 1 = Inhibition by PAI-2 in solution (Kirchheimer and Remold, 1989a;
Ellis et al, 1990). 2 = Inhibition by PAI-2 observed at the cell surface (Baker
et al, 1993). 3 = Inhibition by PAI-2 cross-linked to the surface of the E C M
or fibrin matrix (Jensen, P.H. et al, 1993; Ritchie and Booth, 1997).

using PAI-2 as an example.

Thefirstis that inhibition is facilitated by inhibitors found in solution. For example,
in an inflammatory site monocytes/macrophages would release PAI-2, endothelial
cells would release PAI-1 and a2-antiplasmin is already present in the plasma. This

would lead to relatively high local concentrations of inhibitors. But, this is relative
inefficient as the inhibitor depends on diffusion and may diffuse away as it is not
anchored there by a specific interaction. In addition, if tPA, uPA or plasminogen are
able to bind to a surface prior to being inhibited in solution, they become protected
from inhibition.

The second possibility is that the inhibitors are placed on the cell surface with the
activators providing a site for efficient inhibition. PAI-1 has been observed on the
surface of cells, and does actively bind tPA (Sakata et al, 1988; Cheng et al, 1992;
Smokovitis et al, 1992; Grobmyer et al, 1993). Active PAI-2 has been observed on
the surface of U937 cells (Baker et al, 1993), and could also be cross-linked to
elements on the cell surface (Jensen, P.H. etal, 1989). This could serve to localise

the inhibitors on the cell surface, providing a source of inhibitory activity against t
plasminogen activators. Cell surface inhibitors could serve to down-regulate cell
surface plasminogen activation, or to provide regulation of plasminogen activation
from soluble activators or those found on the ECM.
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The final possibility is that the inhibitors could be anchored to the E C M to protect
from plasmin mediated proteolysis. It has been established that o^-anuplasmin is
cross-linked to fibrin by plasma transglutaminase (Sakata and Aoki, 1980) and PAI-1
binds to either vitronectin or fibrin (Wun et al, 1989; Wagner et al, 1989). PAI-2
may be cross-linked to fibrin or fibronectin (Ritchie etal, 1997; Jensen, P.H. et al,
1993). All of the inhibitors remain active after being bound to the ECM. Therefore,
this would serve to protect the ECM against plasmin mediated proteolysis from both
soluble or cell surface bound tPA, uPA and plasminogen. The inhibitors could protect
the ECM in two ways. Firstly, by providing an active inhibitor at the ECM surface.

Secondly, in particular for the cross-linked inhibitors, surface lysines that the krin
of plasminogen or tPA would normally bind to would be used by the inhibitor. Since
the inhibitors do interact more with the ECM than the cell surface, the ECM does
appear to be a reservoir of functional inhibitors (Knudsen et al, 1987; Mimuro et al,
1987; Laiho et al, 1987; Levin and Santell, 1987; Knudsen andNachman, 1988).

The localisation of PAI-2 has not been well studied. The evidence for the cell surfac
expression of PAI-2 requires confirmation, and the possibility of PAI-2 localisation
the ECM needs addressing. Therefore, the primary aim of this thesis was to confirm
whether PAI-2 can be found on the cell surface of human CD3+ lymphocytes or other
PAI-2 expressing cell lines. The second aim was to determine whether the Jurkat cell
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line expressed PAI-2 m R N A . Thefinalaim was to determine if PAI-2 could localise
to the ECM by using an in vitro fibrin clot model.
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2.

EXAMINATION

OF

PAI-2

EXPRESSION

BY

LYMPHOCYTES FROM HUMAN PERIPHERAL BLOOD AND
MONOCYTIC CELL LINES
2.1 INTRODUCTION

Leukocytes are an actively migrating population of cells known to utilise the
plasminogen activation cascade. All leukocytes are capable of binding plasminogen
(Miles and Plow, 1987; Miles et al, 1988; Silverstein et al, 1988). Monocytes and
granulocytes have been shown to express both uPA and uPAR (Vassalli et al, 1985;

Nykjasr et al, 1990; Jardi et al, 1996) on their cell surface. T-lymphocytes express
uPAR following activation by IL-2 (Nykjasr et al, 1994), stimulation by PMA (Jardi

et al, 1996) or co-clustering of the antigen receptor complex and (31 or p2 integrin
(Bianchi et al, 1996). Gundersen et al, (1997) observed that stimulated Tlymphocytes secrete uPA. It is also known that monocytes express PAI-1 and PAI-2
(Castellote et al, 1990). However, it has not been clearly defined whether
lymphocytes express or bind PAI-2.

Billstrom et al, (1996) demonstrated by in situ hybridisation that lymphocytes from
human peripheral blood do not express PAI-2 mRNA. In contrast in the Tlymphoblastic cell lines; CEM, HUT102, HSB-2, 8402 and Jurkat, PAI-2 was

detected in cell homogenates by ELISA (Reiter et al, 1997). In addition, cell surface
PAI-2 on U937 cells has been observed by employing flow cytometry and two
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different monoclonal antibodies (Baker et al, 1993). PAI-2 has also been observed on
the cell surface of human leukocytes from peripheral blood, in particular C D 3 +
lymphocytes (McPhun, unpublished observation).

Based on the observation by McPhun, the aim of this chapter was to confirm tha
C D 3 + lymphocytes were positive for cell surface PAI-2. Upon confirmation of cell
surface PAI-2 expression, the next aim was to investigate the possible role(s) of cell
surface PAI-2. The final aim of this chapter was to examine PAI-2 expressing cell
lines for the expression of cell surface PAI-2.

2.2 METHODS

2.2.1 Reagents

The hybridomas OKT3 (anti-human CD3), OKT8 (anti-human CD8) and OKT11
(anti-human C D 2 ) were the kind gift of Virginia McPhun, Division of Molecular
Medicine, John Curtin School of Medical Research, Canberra, A C T , Australia. The
hybridoma DNP-9 (Immunoglobulin Gl (IgGl) isotype control) was a kind gift from
Dr. Mark Wilson, University of Wollongong, Wollongong, N S W , Australia. The
monoclonal antibodies directed against human u P A (#394) and human PAI-2 (#3750)
were from America Diagnostica Incorporated, Greenwich, CT, U S A .

The IgG2a

isotype control (Gl55-78) was from Pharmingen, San Diego, C A , U S A and was
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directed against trinitrophenol (TNP).

Fluorescein isothiocyanate (FITC) labelled

affinity isolated F(ab)*2 fragments of anti-mouse immunoglobulin and a phycoerythrin
(PE) labelled IgGl isotype control were obtained from Silenus, Hawthorn, VIC,
Australia. PE labelled anti-human CD4 monoclonal antibody (13B8.2-PE) was from
Immunotech, A Coulter Company, Marseille, France. Recombinant human PAI-2
expressed in either E. coli or Saccharomyces cerevisiae (S. cerevisiae) were obtained
from Biotech Australia, Sydney, NSW, Australia. Avidin labelled with PE (avidinPE) was from Pierce, Rockford, IL, USA. Ammonium sulphate (NH4SO4), sodium
azide (NaNs), dimethylsulfoxide (DMSO), saponin, propidium iodide (PI), ophenyldiamine (OPD) and Concanavalin A (ConA) were obtained from Sigma
Chemical Co., St Louis, MO, USA. Avidin-peroxidase (avidin-POD), sheep antimouse IgG conjugated to POD, protein G and biotin-n-hydroxysuccinimidyl ester
(biotin-NHS) were obtained from Calbiochem-Novabiochem Pty., Alexandria, NSW,
Australia. The DC protein assay kit was from Bio-Rad Laboratories, North Ryde,
NSW, Australia.

2.2.2 Celllines

The U937, HaCaT and MM6 cell lines were chosen for their ability to express PAI-2
(Kruithof, et al 1986b; Reinartz et al, 1996; Liew et al, 2000 In press). The Jurkat
cell line was also chosen because it has recently been reported to synthesise PAI-2
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(Reiter et al, 1997). The THP-1 cell line was used in these experiments as a negative
control for expression of PAI-2 because sub-clones have been found to express a
truncated form of PAI-2 mRNA (Gross and Sitrin 1990). The K562 cell line was also
chosen as a negative control for the expression of PAI-2. The Jurkat cell line was

kind gift of Dr. Charles Harvey, St Vincent's Hospital. The human keratinocyte cel
line, HaCaT, was the kind gift of Professor Norbert E. Fusenig, DKFZ. The MM6

cell line was the kind gift of Dr. H.W.L. Ziegler-Heitbrock, University of Munich.

2.2.2.1 Cell culture

All cell lines were incubated in a humidified incubator at 37°C in 5% (v/v) C02. T
hybridoma cell lines OKT3, OKT8 and OKT11 were grown in RPMI+10% (v/v) FCS
and the DNP-9 in DMEM+10% (v/v) FCS. The human cell lines K562, THP-1,
U937, MM6 and Jurkat were cultured in RPMI+10% (v/v) FCS. In addition the MM6

cells (Ziegler-Heitbrock, et al 1988) were cultured under lipopolysaccharide (LPS)

free conditions by baking all glassware overnight at 150°C, as well as autoclaving
glassware and glass distilled water before preparation of media. HaCaT cells were
cultured in DMEM+10% (v/v) FCS (Boukamp, et al. 1988).
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2.2.3 Purification of IgG from hybridoma supernatants

Hybridomas were routinely cultured for 3-4 days before media was changed and cells
harvested. NaN3 was added to the harvested supernatant, at a final concentration of
0.02% (w/v) and stored at 4°C until used. An equal volume of saturated NH4SO4 was
added to the supernatant to give a final concentration of 50% (w/v) NH4SO4, to
precipitate secreted IgG. The saturated NH4SO4 was added slowly drop-wise with
constant stirring, and then stirred continuously for at least 6hrs at 4°C. The
precipitate was then pelleted at 3000g for 30min at 4°C. The pellet was resuspended
in 1/10th of the original volume in phosphate buffered saline (PBS) and dialysed
against another 3 changes of PBS over 24hr. The concentrated antibody was then
filtered through a 0.22um filter before further purification on a protein G Fast
Performance Liquid Chromatography (FPLC) column.

Prior to the purification procedure, the protein G column was equilibrated with 20mM
sodium phosphate buffer, pH7.0 at a flow rate of 0.5ml/min until a steady baseline
was achieved on the chart recorder. The concentrated antibody was then loaded on at
a flow rate of 0.2ml/min. See Appendix A for FPLC settings. Once all of the
unbound protein was washed away, bound antibody was eluted using lOOmM glycine,
pH2.3 at a flow rate of 0.5ml/min. 1ml fractions were collected into tubes containing
lOOul of 1M Tris, pH9.0. To examine the purity of the preparations, the fractions
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were separated using non-reducing 7.5% S D S - P A G E .

The fractions containing

antibody were pooled and dialysed against 3 changes of PBS over 24hr. The
concentration of the antibody was determined using the DC protein assay kit with
BSA as the standard. Antibodies were either stored at 4°C without BSA or

concentrated using centrifugal concentrators and stored at a concentration of 1 mg/
with BSA added to a final concentration of lOmg/ml at -70°C.

2.2.4 Biotinylation of #3750, OKT8 and G155-78

Prior to biotinylation of Gl 55-78, it was dialysed versus 3 changes of PBS over 24
Biotinylations of #3750, OKT8 and Gl55-78 were carried out by adding 20ug of
biotin-NHS dissolved in lul of DMSO to lOOug of antibody dissolved in lOOul of
PBS. The reaction was allowed to proceed overnight at 4°C with constant shaking.
Unincorporated biotin-NHS was removed either by passing through a G-25 Sepharose
column or by dialysis versus 3 changes of PBS over 24hr at 4°C.

The fractions or dialysed antibody were assayed by DC protein assay and
biotinylations were confirmed by Western blotting methods. This involved
electrophoresis of the antibody on a non-reducing 12% SDS-PAGE and transfer to a
nitrocellulose membrane. The membrane was blocked with PBS containing 0.05%
(v/v) Tween20 and 5% (w/v) skim milk powder for 2hr at room temperature with
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shaking. The biotinylated antibodies were detected using a 1/1000 dilution of avidinPOD in PBS containing 0.05% (v/v) Tween20 + 0.1% (w/v) BSA for 2hr at room
temperature with shaking. The membrane was then washed using 4 x lOmin washes
with PBS+0.05% Tween 20 (PBS-T) and 2 x 5min washes in PBS. The membrane
was incubated in PBS containing 17% (v/v) methanol, 0.05% (v/v) H202 and 2mg/ml
4-chloro-l-napthol for approximately 15min in the dark to allow the color
development of any protein bands.

In addition, to confirm that biotinylated #3750 was still active, the antibody was u
in a Western blot using PAI-2 as antigen. 5 fig of PAI-2 was resolved on a 12% nonreducing SDS-PAGE followed by transfer and blocking as described above. PAI-2

was detected using 5[j,g/ml of biotinylated #3750 diluted in blocking buffer for 2h
room temperature with shaking. The membrane was washed 4 times for lOmin with
PBS-T and the bound antibody detected using the avidin-POD, washes and substrate
as described above.

2.2.5

Single color staining of peripheral blood leukocytes (PBL)

Blood was obtained by venipuncture from human volunteers (University of
Wollongong ethics approval number HE96/04). Blood was placed in a 50ml centrifuge
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tube containing 8 5 m M tri-sodium citrate, 6 5 m M citric acid, H O m M dextrose as anticoagulant (1.6ml/10ml blood). Erythrocytes were lysed in 168mM NH4CI, lOmM
KHCO3 and 110|aiM EDTA, pH7.3 (16ml/ml of blood) for 5min at room temperature
and the PBL pelleted with centrifugation at 200g for 5min at 4°C. The PBL were
washed once with cold PBS and resuspended in a small volume of cold PBS+0.1%

(w/v) BSA and cell viability estimated using the trypan blue exclusion method. Cel
were then resuspended at a concentration of 5xl06cells/ml and were transferred to
well vee-bottom plates (5xl05cells/well) and stained.

In order to confirm that lymphocytes could be positively identified, PBL were stai
with the purified antibodies; OKT11, OKT3, biotinylated OKT8 and 13B8.2-PE.
Cells were also stained with biotinylated #3750 to determine if PAI-2 could be
detected on the cell surface of lymphocytes. As controls, PBL were stained with
DNP-9, Gl55-78, biotinylated Gl 55-78 and PE labelled IgGl isotype control.

PBL were stained in 50ul of primary antibody diluted in PBS+0.1% (w/v) BSA for
30min at 4°C. Cells were washed 3 times by resuspending in 200ul of cold
PBS+0.1% (w/v) BSA followed by centrifugation at 200g for 2min at 4°C. Bound
antibodies were then detected using 50ul of FITC labelled anti-mouse IgG
immunoglobulin and biotinylated antibodies were detected using avidin-PE diluted
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1/50 in P B S + 0 . 1 % (w/v) B S A for 30min at 4°C. Cells were then washed again as
before and fixed using 1% (w/v) paraformaldehyde in PBS, pH7.4 for at least lOmin at
4°C. The fixed cells were stored at 4°C in the dark and either analysed straight away
or the following day. Prior to fixation a sample of the PBL were stained with
propidium iodide to ascertain their viability. In general the PBL stained were >90%
viable after the staining procedure as determined by their ability to exclude PI.
Samples were acquired on a FACSort (Becton Dickinson). For cytometer settings see
Appendix B. 50,000 events were acquired at a high flow rate. The 3 groups of PBL;
lymphocytes, monocytes and granulocytes were identified by their different sizes and
granularities on a forward versus side scatter dot plot.

2.2.6 Dual color staining of PBL for cell surface CD3 and PAI-2 (Protocol I)

The cells from human peripheral blood were prepared and stained with primary
antibody as described above with the exception that staining was for 60min at 4°C
and not 30min (Fig. 1). Following the incubation with the FITC labelled anti-mouse
IgG the cells were washed and stained with another primary antibody for 30min at
4°C. The binding of this primary antibody was detected using a PE labelled antimouse IgG. Cells were then analysed as described above.
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2.2.7

Dual color staining of P B L for cell surface C D 3 and PAI-2 (Protocol II)

Results from the previous protocol (Protocol I) gave rise to false positive staining of
antigen (refer to Result section 3.3.4), so therefore had to be modified. This second
protocol was similar to the one in section 3.2.6 with the following 2 modifications
(Fig. 1).

a) The second primary antibody (#3750) was biotinylated and detected using
avidin labelled with PE. This step was included to avoid the use of the PE labelled
secondary antibody which could still bind to any bound OKT3 on the CD3+
lymphocytes.

b) Following the FITC labelled anti-mouse IgG incubation a 30min incubation in
PBS+0.1% (w/v) BSA+1% (v/v) heat inactivated mouse serum at 4°C was included.
The purpose of this step was to block any unreacted antigen binding sites on the
FITC labelled anti-mouse immunoglobulin to prevent the biotinylated primary
antibody from binding.

To validate the assay, it had to be confirmed that the second primary antibody
utilised in the assay was not binding to the secondary antibody already bound and
correct instrument settings were used to compensate for the spectral overlap between
fluorescein and phycoerythrin. It is established that CD4 antigen and CD8 antigen
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expression on T-lymphocytes are mutually exclusive in normal human blood.
Therefore specific antibodies were used to discriminate between CD4+ and CD8+ Tlymphocytes in PBL. The assay was set up using 13B8.2-PE as the first primary
antibody and biotinylated OKT8 as the second primary antibody. See Appendix C for
FACSort settings.

2.2.8 Stimulation of CD3+ positive cells

Cells were stimulated under the same conditions as the dual color labelling protoco
ie. PBS, 4°C, for 60min to determine if using different stimuli would lead to the
appearance of cell surface PAI-2. The reagents used to stimulate the CD3+ cells
were, lOug/ml OKT3 alone, lOug/ml OKT3 plus a 1/50 dilution of peroxidase
conjugated sheep anti-mouse IgG, lOug/ml OKT3 plus 50|ag/ml protein G or
500ug/ml ConA. These were then followed by staining of the PBL with the
biotinylated IgG2a isotype control or #3750 and detection with PE labelled avidin.

2.2.9 ELISA mimic

In order to mimic what was potentially being seen at a cellular level, an ELISA
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protocol was developed.

All of the following incubations were carried out in a

humidified container. Polystyrene 96 well microtitre trays were coated with 10u.g/ml
OKT3 in 35mM NaHC03, 14mM Na2C03; pH9.5 (coating buffer) overnight at 4°C.
The plates were then washed 3 times with 200ul/well PBS-T followed by 3 washes in
distilled water. The plates were then blocked using 200ul/well PBS containing 1%
(w/v) skim milk powder and 0.05% (v/v) Tween 20 (PBS-SMT) for 2h at room
temperature. The plates were then washed as before. The plate was then probed
with FITC labelled affinity isolated F(ab)'2 fragments of anti-mouse immunoglobulin
in serial doubling dilutions from 1/100 to 1/800 in PBS-SMT for 2hr at room
temperature. This was followed by washing and another blocking step using 1% (v/v)
heat inactivated mouse serum diluted in PBS-SMT overnight at 4°C. Plates were then
washed and probed using 5ug/ml biotinylated IgG2a isotype control or biotinylated
#3750 for 2hr at room temperature. After washing bound antibody was detected
using avidin-POD diluted 1/1000 in PBS+0.1% (w/v) BSA+0.05% (v/v) Tween20 for
2hr at room temperature. After washing, 150ul 0.2M Na2HP04, pH5.0 with citric
acid containing 400ug/ml OPD and 0.012% (v/v) H202 (substrate) was added to each
well and the absorbance determined at 490nm on a Bio-Rad plate reader (Model
3550).
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2.2.10 Flow cytometry of cell surface antigens on viable cell lines

Cell lines were harvested 2-3 days following a change of media and cell viability
estimated using the trypan blue exclusion method. HaCaT cells were harvested with
PBS+0.05% (w/v) EDTA for 20min at 37°C followed by l-2min in trypsin-EDTA at
37°C. The trypsin was then neutralised by adding RPMI + 10% (v/v) FCS. The
media was removed by pelleting the cells at 200g for 5min at 4°C. Cells were
resuspended at a concentration of 107cells/ml in PBS+0.1% (w/v) BSA and IO6 cells

were stained in 50ul of either DNP-9, Gl 55-78, #394 or #3750 at a concentration of
20fig/ml for 30min at 4°C. Bound primary antibody was detected using 50ul of a
1/50 dilution of FITC labelled affinity isolated F(ab)'2 fragments of anti-mouse
immunoglobulin for 30min at 4°C. After washing, cells were resuspended in 200ul of
PBS+0.1%) (w/v) BSA. Prior to analysis on a FACSort (Becton Dickinson) cells were
stained with PI (5|ig/ml) for 5min to allow discrimination of viable cells from

apoptotic or dead cells. Viable cells were defined as those cells which excluded s

and exhibited no PI fluorescence. A total of 20,000 events were acquired. These flo
cytometry experiments were carried out three times. Human PBL were stained in the
same way except 5xl05cells were stained and 50,000 events were acquired.
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2.2.11 Flow cytometry of permeabilised cell lines

In order to examine "total" antigen expression, similar studies were performed on cells
which had been deliberately permeabilised prior to the addition of primary antibody.
The levels of uPA and PAI-2 detected are termed total because results from these
experiments were a combination of cell surface and intracellular expression. Initially
cell lines and PBL were fixed in 4% (w/v) paraformaldehyde in PBS for 30min at 4°C.
All subsequent incubations and washes were conducted in freshly prepared
PBS+0.1% (w/v) BSA+0.1% (w/v) saponin. Staining for uPA and PAI-2 were carried
out as described above (section 2.2.10). These experiments were repeated three times.
Human PBL were stained in the same way with the exception that 5xl05cells were
stained and a total of 50,000 events were acquired.

2.2.12 Calculations

For all flow cytometry experiments relative fluorescence was determined by dividing
the mean fluorescence obtained for the test antibody by the mean fluorescence of the
corresponding isotype control. To perform statistics, the mean fluorescence was log
transformed and statistical significance was determined using an unpaired Student's t-
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test with P<0.05 taken as significant. For PAI-2 expression, the relative fluorescence

of cells were compared to the relative fluorescence of the Jurkat cell line which

defined as negative. For cell surface uPA expression, the relative fluorescence o
were compared to the relative fluorescence of the lymphocytes which are negative

cell surface uPA. For the total uPA in permeabilised cells, none of the cells used

could be considered as a negative control cell line, so comparisons were made wit
isotype controls. In this case, cells were considered positive if the relative
fluorescence was more than 3 times that of the isotype control. Results from the
cytometry experiments were expressed as meantstandard deviation from three
experiments.

2.3 RESULTS

2.3.1 Purification of IgG from hybridoma supernatant

When examining the trace from the protein G FPLC purification, two peaks were

observed (Fig. 2). The first larger peak resulted from the wash of all unbound pr
The second smaller peak was the elution of bound IgG from the column. This was
confirmed when looking at the fractions analysed by non-reducing SDS-PAGE (Fig.

3). The unpurified IgG (lane 1) and a sample from the wash (lane 2) consisted of a
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Figure 2. Purification of IgG using a protein G F P L C column. The horizontal axis
is the distance of the trace in m m and the vertical axis is the absorbance at 280nm
(arbitrary scale). Arrow A indicates the start of the wash of unbound protein using
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Figure 3. Analysis of IgG purified by protein G F P L C by non-reducing 7.5% S D S P A G E . Molecular weight markers are indicated on the left in kDa. Lane 1 is
unpurified IgG, lane 2 is a sample of the wash, lanes 3-15 correspond tofractions213 collected after the start of the elution.

mixture of proteins. The majority of purified IgG appeared infractions5-7 (lanes 6-8)
as a major band of 150kDa. The lower bands were believed to be degradation
products of the IgG. In all other fractions collected no purified IgG was observed
(lanes 3-5 and 9-14).

2.3.2 Biotinylation of antibodies

Confirmation of biotinylation of antibodies was achieved by reaction with avidin-POD
on nitrocellulose (Fig. 4). A major band with a molecular weight of >98kDa was

observed for biotinylated OKT8 and IgG2a isotype control (Fig. 4a) on the ligand blot,
under non-reducing conditions. #3750 was found to be still active after biotinylation
because it was able to recognise PAI-2 under either non-reducing or reducing
conditions (Fig. 4b, lanes 3, 4 and 8). With 5 and 2.5ug of PAI-2 three bands of
47kDa, 98kDa and >98kDa were detected with biotinylated #3750. These
corresponded to monomeric, dimeric and polymeric forms of PAI-2. The detection
limit of the Western blot under non-reducing conditions was 2.5p.g of PAI-2 (Fig. 4b,
lanes 5-7). The most intensely staining bands under non-reducing conditions were the
98kDa and >98kDa bands. In contrast, the only band visible under reducing
conditions was the 47kDa band.

a)
kDa

b)
kDa

Figure 4. Biotinylation of antibodies examined by Western blotting. Molecular
weight markers are indicated on the left in kDa. a) Lane 1 is lug of biotinylated
O K T 8 and lane 2 is lu.g of biotinylated IgG2a isotype control. Detection was
with avidin-POD. b) Lane 1 is unlabelled #3750, lane 2 is biotinylated #3750,
lanes 3 is 5ug of PAI-2, lane 4 is 2.5ug of PAI-2, lane 5 is 1.25u\g of PAI-2, lane
6 is 0.625u.g of PAI-2, lane 7 is 0.313u.g of PAI-2 and lane 8 is 5ug of PAI-2
under reducing conditions. Detection was with 5ug/ml biotinylated #3750
followed by avidin-POD.

2.3.3

Single color cell surface staining of lymphocytes

After lysis of erythrocytes, three different populations of leukocytes observed in
human peripheral blood were clearly discriminated on the FACSort by size and
granularity (Fig. 5). The lymphocytes are the smallest and least granular of the three
groups. The monocytes are a little bigger but more granular, while the granulocytes
have an intermediate size and a broad range of granularity compared to the
lymphocytes and monocytes.

To determine the optimal concentration of specific antibodies for the detection of
CD2, CD3, CD4, CD8 and PAI-2 antigen on lymphocytes from human peripheral
blood, concentration courses of antibody were carried out (Fig. 6). With increasing
concentrations of antibody to CD2 the mean fluorescence increased rapidly followed
by a gradual increase to eventually reach a plateau at the highest concentration used
(lOug/ml) (Fig. 6a). Similar curves were obtained for antibodies to CD3 (Fig. 6b) and
CD8 (Fig. 6d). A linear curve was obtained for the antibody to CD4 (Fig. 6c) and did
not reach a plateau with the highest concentration of antibody (lug/ml). No increase
in mean fluorescence was observed with increasing concentrations of antibody to PAI2 (Fig. 6e). Thus for all concentrations of antibody to PAI-2 used, the lymphocytes
were negative for PAI-2 expression. In all cases no increase in mean fluorescence was
observed with increasing isotype control antibody concentration (Fig. 6a-e). For the
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Figure 5. The three populations of leukocytes observed in human peripheral blood
discerned by flow cytometry. The size (forward scatter) of the cell is plot
against the granularity (side scatter) of the cell. Lymphocyte, monocyte and
granulocyte populations are labelled.
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Figure 6. Antibody concentration curves staining for C D 2 , C D 3 , C D 4 , C D 8 and
PAI-2 antigen on the surface of lymphocytes from human peripheral blood. Results
for the isotype control antibody (-•- ) and the test antibody (-»-) are plotted. For
all graphs, the vertical axis represents the m e a n fluorescence and the horizontal axis
represents the concentration of antibody (|ig/ml). The graphs are the result of using
thefoilowing antibodies: a) O K T 1 1 , b) O K T 3 , c) 13B8.2-PE, d) biotinylated
O K T 8 and e) biotinylated #3750. The error bars represent the standard deviation,
n=2.

antibodies to C D 2 , C D 3 and C D 8 an optimal concentration of lOug/ml was used in
subsequent experiments. For the antibody to CD4 a concentration of 1 fig/ml was
used.

Using optimal concentrations of antibodies to the various antigens, positive staini

the cells for CD2, CD3, CD4 and CD8 were observed as very strong shifts to the righ

on the histogram plots when a gate was set on the lymphocytes (Fig. 7). Lymphocytes
that did not stain for CD2 or CD3 (Fig. 7a and b) were a mixture of B-lymphocytes
and natural killer cells. Lymphocytes which did not stain for CD4 (Fig. 7c) were a
mixture of CD4- T-lymphocytes, B-lymphocytes and natural killer cells. Lymphocytes
which did not stain for CD8 (Fig. 7d) were a mixture of CD8- T-lymphocytes, Blymphocytes and natural killer cells. At the highest concentration of antibody
(lOug/ml), the lymphocytes were negative for PAI-2 expression when stained with
biotinylated #3750 (Fig. 7e). The results shown were obtained from blood samples
from one volunteer. Experiments were carried out using PBL from 2 different
volunteers. Similar results were obtained from blood samples from both volunteers.

2.3.4 Dual color cell surface staining of lymphocytes

From the above result, cell surface PAI-2 was not detectable by single color staini
When both dual color staining protocols were implemented, the human lymphocytes
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Figure 7. Detection of C D 2 , C D 3 , C D 4 , C D 8 and PAI-2 antigen on lymphocytes
from human peripheral blood. Shown are histogram plots with cell number on the
vertical axis and the antigen expression (fluorescence intensity) on the horizontal
axis. The isotype controls are represented by the dotted line and the test antibodies
are represented by the solid line, a) C D 2 , b) C D 3 , c) C D 4 , d) C D 8 and e) PAI-2.

were found to be positive for cell surface PAI-2. However with protocol I (section

2.2.6) the results obtained had very high background and were hard to reproduce (Fi
8). The background was such that it appeared that human lymphocytes were positive

for an antigen that they could not synthesise, eg. chicken TNP (Fig. 8a). Adjustmen
of the compensation settings on the F AC Sort had no effects on reducing the
background. When protocol II (section 2.2.7) was used the very high background was

eliminated and an improvement in reproducibility of results was achieved (Fig. 8b).

In order to validate the protocol, lymphocytes were stained with anti-CD4 and antiCD8 both of which are clearly definable and mutually exclusive (Fig. 9). Human

lymphocytes stained with antibodies to CD4+ and CD8+ (Fig. 9a, right plot) displaye
a strong shift with respect to the isotype control (Fig. 9a, left plot). The CD4+
lymphocytes were a well defined population and the CD8+ lymphocytes a more
widely distributed population. Staining lymphocytes with antibody to CD3 followed
by #3750 resulted in positive expression of cell surface PAI-2 on CD3+ lymphocytes

(Fig. 9b, right plot) compared to cells stained with the isotype control (Fig. 9b,
plot).

2.3.5 Stimulation of CD3+lymphocytes

The fluorescence of #3750 positive cells were approximately 2-fold higher than the
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Figure 9. Dual color staining of lymphocytes from human peripheral blood for
C D 3 and PAI-2 expression. The left hand graphs are the control stains, a) The left
graph represents lymphocytes stained with a P E labelled IgGl isotype control
followed by biotinylated IgG2a isotype control. The right graph represents
lymphocytes stained with 13B8.2-PE followed by biotinylated O K T 8 . C D 4
expression is plotted against C D 8 expression, b) The left graph represents
lymphocytes stained with O K T 3 followed by biotinylated IgG2a isotype control.
The right graph represents lymphocytes stained with O K T 3 followed by
biotinylated #3750. PAI-2 expression is plotted against C D 3 expression.

isotype control (Fig. 10a). T o determine if the #3750 epitope that appeared on the
surface of CD3+ T-lymphocytes was due to stimulation of the T-cell receptor by the
OKT3 antibody several other T-cell stimulants were tried. The first was to incubate
the PBL with OKT3 in the absence of FITC labelled anti-mouse immunoglobulin,
followed by the biotinylated #3750 and avidin-PE as usual. In the absence of the
secondary antibody there was no difference when compared to the isotype control
(Fig. 10b). This indicates that the appearance of a #3750 epitope on the surface of
CD3+ T-lymphocytes is dependent upon the secondary antibody.

To investigate the possibility that this meant that the T-cell receptor required cros
linking to put the #3750 epitope on the CD3+ T-lymphocyte cell surface the following
reagents were tried: ConA alone, OKT3 followed by protein G and OKT3 followed by
a different secondary antibody, sheep anti-mouse IgG conjugated to POD. The results
showed that stimulating the lymphocytes using ConA alone, or OKT3 followed by
protein G elicited no #3750 reactivity (Fig. 11a and lib). When the cells were first
stained with OKT3 followed by a peroxidase conjugated sheep anti-mouse IgG
secondary antibody, the #3750 epitope reappeared (Fig. 1 lc).

2.3.6 ELISA mimicry

To determine if the #3750 epitope was due to the cross-reaction with components of
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Figure 11. Effect of stimulation of human lymphocytes with other cross-linking
agents on cell surface PAI-2. Dot plots are shown representing #3750 reactivity
after the C D 3 + lymphocytes are stimulated or stained by: a) ConcanavalinA, b)
O K T 3 followed by protein G and c) O K T 3 followed by a sheep anti-mouse IgG
conjugated to P O D (SAM-POD). Dot plots shown on the left are lymphocytes
stained with biotinylated IgG2a isotype control. Dot plots on the right are
lymphocytes stained with biotinylated #3750.

the assay system an E L I S A was developed. The E L I S A model based on the dual color
staining procedure reveals that there was a difference in the binding of #3750 when
compared to the IgG2a isotype control antibody (Fig. 12). At all of the different
concentrations of FITC labelled anti-mouse immunoglobulin tested, biotinylated
#3750 binding was twice as reactive compared to biotinylated IgG2a isotype control
antibody. This indicated that #3750 was recognising an epitope on the FITC labelled
secondary antibody. Since #3750 was twice as reactive for the FITC labelled anti-

mouse IgG by ELISA, this accounted for the two fold increase in signal from the dual
color flow cytometry assay.

2.3.7 Cell surface staining of various viable cell lines and PBL

In order to determine if PAI-2 could be detected on the cell surface of PAI-2
expressing cell lines, flow cytometry was performed on intact viable cells. Viable

cells were determined by exclusion of PI (located in the lower two quadrants, Fig. 1
and b). The viability of the non-adherent cells ranged from 62-97%. The HaCaT cell
line showed the lowest viability ranging from 33-77%) indicating substantial cell
injury, most likely due to the rigorous method required to prepare these cells as a
single cell suspension for flow cytometric analysis. Positive expression of antigen
observed as a shift to the right (Fig. 13b and c).
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Figure 12. Analysis of binding of #3750 to FITC labelled anti-mouse
immunoglobulin by ELISA. The binding of biotinylated #3750 ( —•— ) was
compared to the binding by biotinylated IgG2a isotype control ( —•— ). The
absorbance at 490nm on the vertical axis is plotted against the reciprocal of the
dilution of the FITC labelled anti-mouse immunoglobulin on the horizontal axis.
The error bars represent the standard deviation, n=2.
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W h e n compared to h u m a n lymphocytes, only viable Jurkat cells were found to be
negative for cell surface uPA (relative fluorescence=2.3+1.0, Fig. 14a). The HaCaT
and K562 cell lines were found to be positive for cell surface uPA (relative
fluorescence=2.8±0.7 and 3.3+1.6 respectively). The other myeloid lines, MM6, U937
and THP-1 were found to be increasingly positive for cell surface uPA (relative
fluorescence=16.5±3.9, 29.1+7.1, and 35.1+17.8 respectively). In human PBL
preparations, only the monocytes and granulocytes were positive for cell surface uPA
(relative fluorescence=5.0+1.1 and 5.9+1.0 respectively).

All of the cell lines tested were negative for cell surface PAI-2, when compared to the
Jurkat cell line (Fig. 14b). Of the cells in the PBL preparations, only the viable
monocytes were found to be weakly positive, for cell surface PAI-2 expression
(relative fluorescence^ 1.4+0.1, Fig. 14b and Fig. 15). No correlation was found
between uPA (or PAI-2) expressed on the cell surface and variations in the

differentiation status of cells along the monocyte/macrophage differentiation pathway.

2.3.8 Staining of permeabilised cell lines and PBL

In order to confirm those cells which express PAI-2 with an intracellular topology, an
that the antibody employed could recognise PAI-2, the total (cell surface and
intracellular) expression of uPA and PAI-2 was determined. The distribution of uPA
in permeabilised cells was fairly uniform. All cell lines examined were positive for
total uPA. The relative fluorescence of permeabilised Jurkat, K562 and THP-1 cells
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were 10.6+3.1, 11.6+1.0 and 24.3+6.7, respectively (Fig. 16a).

The relative

fluorescence of permeabilised HaCaT, MM6 and U937 cells were 17.5+5.1, 17.8+7.3
and 18.4+5.6, respectively. Permeabilised lymphocytes, monocytes and granulocytes

were also positive for total uPA (relative fluorescence=4.7±0.7, 6.0+1.4 and 6.3+2.
respectively).

The distribution of expression of intracellular PAI-2 within populations was found t
be bimodal, containing one strongly positive population and one weakly
positive/negative subpopulation in the PAI-2 expressing cells. The results for total
PAI-2 were derived from the strongly positive peak. In comparison to the Jurkat cell
line, permeabilised MM6, U937 and HaCaT cell lines were positive for PAI-2 (relative
fluorescence=25.4±ll.l, 40.1+11.7 and 69+22.5, respectively, Fig. 16b). The only
group of human PBL positive for total PAI-2 were monocytes (relative
fluorescence=8.5±2.7, Fig. 17). Again, no correlation could be drawn between total

uPA and PAI-2 expression, or between the differentiation status of the cells with to
expression of either uPA or PAI-2 antigen.
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2.4

DISCUSSION

W h e n lymphocytes were dual labelled using O K T 3 and #3750, there appeared to be
CD3+/PAI-2+ lymphocytes. Further experiments showed that: a) stimulation with
ConA or OKT3 alone did not yield a #3750 epitope, b) if another different secondary
antibody was used in the flow cytometry assay system the #3750 epitope appeared and
c) by ELISA #3750 binds two fold better than the IgG2a isotype control to FITC
labelled anti-mouse immunoglobulin/OKT3 complexes. All these results indicate that
the CD3+/PAI-2+ lymphocytes are due to a "false positive" and that CD3+
lymphocytes are actually negative for cell surface PAI-2.

When PAI-2 expressing cell lines were screened for cell surface PAI-2 using #3750
standardised against the IgG2a isotype control, none of the cell lines were positive.
The reason for this result contradicting the observation by Baker et al, (1993) is
probably due to one main reason. In this study the PAI-2 specific monoclonal

antibody is an IgG2a isotype. It is known that some of the monocytic cell lines are Fc
receptor positive, therefore using IgG2a isotype antibodies can lead to relatively
high isotype control mean fluorescence when compared to autofluorescence.
Therefore the controls used are very important and depending on what is defined as a

negative control, there can either be no cell surface PAI-2 or a very strong signal f
cell surface PAI-2.
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The H a C a T cell line was originally used in this study to confirm the presence of cell
surface PAI-2 as a positive control since it has been reported previously to express
cell surface PAI-2 detectable by flow cytometry (Reinartz et al, 1996). In contrast,

this study found that using a gate set strictly on the viable HaCaT cells no PAI-2 was
detectable on the cell surface. There are two possibilities that could explain this

difference. If PAI-2 is on the cell surface it is possible that the epitope recognise
#3750 was masked because a different monoclonal antibody was used in the study by
Reinartz et al, (1996). In this study a gate was set on viable intact cells, while in
study carried out by Reinartz et al, (1996) no gates were set.

The use of #3750 is validated for flow cytometry studies in fixed permeabilised cells
because only cell lines which have been reported to express PAI-2 were found to be
positive in the flow cytometry assay used in this study. The reason for the bimodal
distribution of PAI-2 is not known, but the weakly expressing PAI-2 population may
have been due to a loss of PAI-2 in either dead or apoptotic cells. It has also been

reported previously that the Jurkat cell line expresses PAI-2 (Reiter et al, 1997). In
contrast this study found the Jurkat cell line was negative when compared to the cell
lines which do express PAI-2.

Finally, the results from this chapter indicate that there was no PAI-2 detectable on
cell surface of CD3+ lymphocytes by flow cytometry. Other cell types that express
PAI-2 examined by flow cytometry were also negative for cell surface PAI-2. In the
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next chapter the localisation of PAI-2 to the plasma membrane will be examined in
cell lines using biochemical techniques.

3.

EXAMINATION OF EXPRESSION OF PAI-2 AT THE

PLASMA MEMBRANE

3.1 INTRODUCTION

PAI-2 is predominantly an intracellular protein. However, there is evidence in the

literature (refer to chapter 1) indicating that active plasminogen activator inhibito

can associate with or at least be in close proximity to the plasma membranes of cells
uPA, the primary target of PAI-2, is expressed on the surface of cells. Cell surface
uPA can facilitate the movement of cells by activating plasminogen into plasmin
which can then degrade the ECM. Kirchheimer and Remold (1989b) demonstrated
that invasion of amnion tissue by monocytes stimulated with IFN-y was dependent
on receptor bound uPA. Cell surface bound uPA was also observed to aid the

infiltration of granulocytes into a fibrin matrix (Herijgers et al, 1995). If active P

were localised to the plasma membrane like uPA, this potentially could lead to a very
efficient interaction of activator with inhibitor allowing for precise regulation of
proteolytic activity.

PAI-2 and uPA expression does occur together in certain normal and malignant cell
types. Monocytes express cell surface uPA and are also known to synthesise PAI-2
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(Golder and Stephens, 1983). The h u m a n monocytic cell lines U 9 3 7 and M M 6 , and
the human keratinocyte cell line HaCaT have been shown in this study and by others,
to express cell surface uPA and synthesise PAI-2 (Kruithof et al, 1986b; Reinartz et
al., 1996; Liew et al, 2000 In press).

Results from the previous chapter indicated that there was no PAI-2 detectable on the
cell surface of cells by flow cytometry. The aim of this chapter was to determine if
PAI-2 could be detected associated with the isolated plasma membranes of PAI-2
expressing cell lines, independent of flow cytometry. To study the localisation of
PAI-2 to the plasma membrane of cells, a polyclonal PAI-2 capture ELISA and a
direct PAI-2 Western blot were developed, validated and implemented. These two
assays were then used to determine the presence and molecular weight of any plasma
membrane associated PAI-2 from various cell lines.

3.2 MATERIALS AND METHODS

3.2.1 Reagents

POD conjugated affinity isolated anti-sheep/goat immunoglobulin was obtained from
Silenus, Hawthorn, VIC, Australia. Goat polyclonal (IgG fraction) anti-human PAI-2
(GAH-PAI-2) and recombinant human PAI-2 expressed in either E. coli or
Saccharomyces cerevisae (S. cerevisiae) were obtained from Biotech Australia,
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Sydney, N S W , Australia. H u m a n u P A (a mixture of 33kDa and 55kDa) was from

Serono Australia Pty. Ltd., Frenchs Forest, NSW, Australia. Phenylmethylsulfony
fluoride (PMSF), deoxycholic acid, bovine serum albumin (BSA) and purified POD
were from Sigma Chemical Co., St Louis, MO, USA. Polyscreen polyvinylidene
difluoride (PVDF) membrane was from Dupont (Australia) Ltd., Sydney, NSW,
Australia. Biotinylated broad range SDS-PAGE standards were from Bio-Rad
Laboratories, North Ryde, NSW, Australia. SeeBlue pre-stained SDS-PAGE

standards were from No vex Australia Pty. Ltd., Terrey Hills, NSW, Australia. Th
enhanced chemiluminescence (ECL) kit and high performance autoradiography film
(Hyperfilm) was from Amersham Ltd., Buckinghamshire, UK. CNBr activated
Sepharose 4B and fast performance liquid chromatography (FPLC) Superdex 75
column were from Amrad Pharmacia Biotech, Boronia, VIC, Australia. Microsep

centrifugal concentrators were from Filtron Technology Corp., Northborough, MA,

USA. The Immunopure Plus Activated Peroxidase kit was from Pierce, Rockford, IL,
USA. Avidin-POD was from Calbiochem-Novabiochem Corp., Alexandria, NSW,
Australia. RPMI and Dulbecco's modified Eagles media (DMEM) were from Trace

Bioscientific, Ryde, NSW, Australia. Fetal calf serum (FCS) was from CSL limited

VIC, Australia. The p-nitrophenyl phosphate (PNPP) and alkaline phosphatase (AP
conjugated anti-digoxigenin (DIG) antibody raised in goats was from Boehringer
Mannheim Australia Pty. Ltd., Castle Hill, NSW, Australia.

3.2.2

Generation of a PAI-2 antigen column

Recombinant human PAI-2 was immobilised on CNBr activated Sepharose 4B

according to the manufacturer's instructions. PAI-2 (5mg) was dialysed against thr
changes of 0.1M NaHC03, 0.5M NaCl, pH 8.3 (coupling buffer), overnight at 4°C
followed by concentration to 2ml using a centrifugal concentrator. The CNBr
activated Sepharose 4B was prepared by allowing it to swell in ImM HC1 and washing
it with a further 100ml of ImM HC1. lg of CNBr activated Sepharose 4B makes
about 5ml of gel volume. 1ml of CNBr activated Sepharose 4B was added
immediately to the 2ml of PAI-2. PAI-2 was coupled to the CNBr activated
Sepharose 4B either for lhr at room temperature or overnight at 4°C with rocking.

Following coupling, the Sepharose was placed in a small Bio-Rad plastic column and
washed with 5 bed volumes of coupling buffer at room temperature. Any remaining
active groups on the Sepharose were blocked by washing the column with 5 bed
volumes of 0.1 M Tris-HCl buffer, pH8.0 (blocking buffer). The column was then

filled with blocking buffer and left for either lhr at room temperature or overnig
4°C.

A series of low and high pH washes were employed to remove any PAI-2 not bound

covalently. The column was first washed with 2 gel volumes of 0.1 M sodium acetate,
0.5M NaCl, pH 4.0 (low pH buffer) followed by 2 gel volumes of 0.1 M Tris-HCl,
0.5M NaCl, pH8.0 (high pH buffer). These washes were repeated another 2 times. To
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determine the coupling efficiency of PAI-2 to the C N B r activated Sepharose 4 B a 2ml

sample was taken after each step of generating the PAI-2 column and concentrated t

50ul using centrifugal concentrators. These concentrated samples were assayed wit
the DC protein assay kit, using BSA (0 to 1.5mg/ml) dissolved in PBS (Appendix D)
as standards. If not used immediately the column was stored in PBS+0.02% (w/v)
NaN3 at 4°C.

3.2.3 Immunopurification of GAH-PAI-2

GAH-PAI-2 was purified by affinity chromatography on a PAI-2 antigen column and
absorbance at 280nm monitored using a Bio-Rad ultra-violet (UV) light monitor and
chart recorder. See Appendix E for machine settings. Initially the column was

washed with 10 bed volumes of the following buffers in the following order, 1) lOm
Tris, pH7.5, 2) lOOmM glycine, pH2.5, 3) lOmM Tris, pH8.8 and 4) lOmM Tris,

pH7.5, to ensure that none of the PAI-2 would be eluted from the column during the
immunopurification procedure. A volume of 1ml of the washes was concentrated to
50ul using centrifugal concentrators and assayed for protein content using the DC
protein assay kit. GAH-PAI-2 was loaded onto the PAI-2 antigen column by batch
loading for 60min with rocking at room temperature. The Sepharose was placed back
into the column and then washed with lOmM Tris, pH7.5 until a stable baseline was
achieved. Bound antibody was eluted with lOOmM glycine, pH2.5 into 1 bed volume
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of 1 M Tris, pH9.0. Collected antibody was dialysed against three changes of P B S and
concentrated using centrifugal microconcentrators to approximately 6mg/ml and
stored at -20°C in 100(il aliquots until further use.

3.2.4 POD labelling of immunopurified GAH-PAI-2

Immunopurified GAH-PAI-2 was POD labelled using the Pierce Immunopure Plus

Activated Peroxidase kit according to the manufacturer's instructions. Briefly, prior
the labelling reaction Img of concentrated immunopurified GAH-PAI-2 was dialysed
against 3 changes of 21mM Na2C03, 180mM NaHC03, pH9.4. This is because the
activated POD can be conjugated at a high pH or at a more neutral pH, the higher pH
giving a higher incorporation of peroxidase which is better for use in ELISA and

Western blotting. After dialysis the antibody was added directly to lmg of lyophilis

activated peroxidase and 1 Oul of a reductant solution added. This was then incubate

either overnight at 4°C or for lhr at room temperature. The reaction was then stopped
with 20ul of quenching buffer for 15min at room temperature.

GAH-PAI-2-POD conjugate was further purified on a FPLC Superdex 75 column to
remove unincorporated POD. See Appendix F for machine settings. Filtered
(0.22um) and degassed PBS was used as the loading buffer. The Superdex-75 column
was calibrated with molecular weight markers before loading the GAH-PAI-2-POD.
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For better separation of G A H - P A I - 2 - P O D from free peroxidase, 200ul of G A H - P A I 2-POD reaction mixture was loaded onto the column. Fractions of 0.5ml were
collected every minute. The purity of the GAH-PAI-2-POD was examined by
visualisation on a 10% SDS-PAGE gel under non-reducing conditions. See Appendix
G for SDS-PAGE buffers. The protein concentration was determined, BSA added at a
concentration of lOmg/ml as a stabiliser and the GAH-PAI-2-POD was stored in
100(0.1 aliquots at -20°C until required.

3.2.5 PAI-2 ELISA

The optimised PAI-2 ELISA protocol is as follows. Polystyrene 96 well microtitre
trays were coated with lOOul/well unpurified GAH-PAI-2 (5ug/ml) in coating buffer
overnight at 4°C. All buffers and incubation conditions are the same as in section

2.2.9 unless otherwise stated. The plates were then washed and the plates were then
blocked using PBS-SMT. Following washing, PAI-2 standards and samples

(100fil/well) were applied to the plate diluted in PBS-SMT and incubated overnigh
4°C. Plates were then washed and GAH-PAI-2-POD (100ul/well) added at a final

dilution of 1/100 (4|aig/ml) for 2hr at room temperature. After the final wash, the
substrate was added and absorbance determined at 490nm.

Wells containing only substrate were used as blanks for the experiment. Wells with
no capture antibody but with sample added were analysed to determine non-specific
background. Samples and standards were analysed in duplicate throughout and all
samples were tested twice at different times.

To validate the PAI-2 ELISA, four experiments were carried out. They were:

a) Determination of optimal dilution of GAH-PAI-2-POD to use in the PAI-2 ELISA.
GAH-PAI-2-POD was titrated out in serial doubling dilutions starting from 1/25 and
finishing at 1/819200. For this particular experiment purified GAH-PAI-2 was used to
coat the plates (5(j.g/ml) and PAI-2 was added to the plate at a concentration of
lOOng/ml.

b) Determination of optimal coating concentration of GAH-PAI-2 to use in the PAI-2
ELISA. The concentrations of purified GAH-PAI-2 used to coat the plates were 0.5,
1.0, 2.5, 10 and 20u-g/ml. At each concentration GAH-PAI-2-POD was titrated out in
serial doubling dilutions from 1/10 to 1/640. PAI-2 was added to the plates at a
concentration of lOOng/ml.

c) Determination of limit of sensitivity of PAI-2 ELISA. To examine the sensitivity
of the PAI-2 ELISA, PAI-2 was titrated out in serial doubling dilutions from lOOng/ml
to O.lpg/ml. Immunopurified GAH-PAI-2 was used at a concentration of 5(ig/ml to
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coat the plates with and G A H - P A I - 2 - P O D was used at a dilution of 1/100 (4ug/ml).

d) A comparison between using immunopurified and unpurified GAH-PAI-2 for

coating of the microtitre plates. Plates were coated with 5p.g/ml purified or unpu
GAH-PAI-2 and the PAI-2 titrated from 25ng/ml in serial doubling dilutions down to
0.3ng/ml. GAH-PAI-2-POD was used at a dilution of 1/100 (4u.g/ml).

3.2.6 PAI-2 direct Western blot

The optimised PAI-2 direct Western blotting procedure is as follows. Standards and
samples were separated on a 12% SDS-PAGE and transferred onto a PVDF membrane
at 30V overnight at 4°C. After transfer the membrane was blocked for 2hr at room
temperature using PBS containing 5% (w/v) powdered skim milk and 0.05% (v/v)
Tween 20. The membrane was next incubated in GAH-PAI-2-POD (2|ig/ml) diluted
in blocking solution overnight at 4°C with shaking. This was followed by 4 x lOmin
washes with PBS-T and 2 x 5min washes in PBS prior to development by ECL.
SeeBlue markers were used to ensure adequate transfer of protein to the membrane

and biotinylated markers were used to obtain an accurate assessment of the molecul
weight. Biotinylated markers were detected using avidin-POD diluted 1/1000 in
PBS+0.05% (v/v) Tween 20+0.1% (w/v) BSA. Western blots were repeated twice.
To determine the sensitivity of the Western blot PAI-2 was titrated out in serial
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doubling dilutions from lOOOng to 3.9ng per well.

3.2.7 Cell culture

The Jurkat, THP-1, U937, MM6 and HaCaT cell lines were cultured as described in
section 2.2.2.

3.2.8 Plasma membrane isolation

Prior to cell harvesting a two phase polyethylene glycol(PEG)/dextran system was
prepared. A 5.5% (w/v) dextran (MW 200-300kDa)/4.2% (w/v) PEG (MW 15-20kDa)
solution was prepared in 0.1M sodium phosphate buffer, pH6.4. The mixture was
placed in a separating funnel and allowed to separate overnight at 4°C. The dextran
and PEG were collected in separate bottles and stored at 4°C until required.

Plasma membranes were isolated as previously reported (Brunette, et al. 1971; Rana
and Majumder 1987). Approximately 8xl08 cells were washed 3 times with PBS and
pelleted (500g for 5min at 4°C). The cell pellet was resuspended in 5mM Tris, pH7.4
containing freshly added ImM PMSF and allowed to swell for lOmin at 4°C. The
cells were then homogenised using a Dounce homogeniser and the extent of cell
breakage visualised by light microscopy. Homogenisation was judged completed
when >80% of the cells were lysed.
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The homogenate was centrifuged at 4100g for lOmin at 4°C.

The supernatant

(cytosolic enriched fraction) was stored at -20°C until required. The pellet was t
resuspended in 10ml of PEG. Then 10ml of dextran was added, mixed thoroughly and
centrifuged at 5900g for lOmin at 4°C. The plasma membrane (PM) enriched fraction
which remains at the interphase between the 2 phases of dextran and PEG, was

aspirated into another clean tube. This was then resuspended in another 10ml of PEG
and 10ml of dextran and centrifuged again at 5900g for lOmin at 4°C. The PM

enriched preparation was then transferred into another clean tube and diluted with
volumes of cold distilled water.

This sample was then centrifuged as before at 5900g for lOmin at 4°C. The
supernatant was discarded and the PM preparations were washed by adding 10ml of

cold distilled water and centrifuging at 5900g for lOmin at 4°C. The supernatant wa
discarded and the wash step repeated another time. The pellet was then resuspended
a small volume of cold distilled water and transferred into an Eppendorf tube.

The protein concentration was determined by the DC protein assay kit using BSA as a
standard. The preparation was then centrifuged at 14000rpm for lOmin at 4°C. PM
preparations were resuspended at a concentration of lOmg/ml in lOmM Tris-HCl,
pH7.4, 1% (v/v) Triton-X 100 and 1% (w/v) deoxycholic acid and stored at -20°C
until required. Approximately 1% of the protein recovered was in the PM enriched
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fraction for the suspension cells. For H a C a T cells, an adherent cell line, the percent of
protein recovered in the PM fraction was approximately 20%.

3.2.9 Analysis of plasma membranes

3.2.9.1 PAI-2 antigen content

3.2.9.1.1 PAI-2 ELISA

To determine if there was any PAI-2 in the preparations, all samples were assayed
using the PAI-2 ELISA (section 3.2.5). Cytosolic and PM enriched preparations and
standards had deoxycholic acid added to the PBS-SMT to a final concentration of
ImM to aid solubilisation. All cytosolic and PM enriched preparations were assayed
in volumes of lOOul. Amounts of cytosolic and plasma membrane enriched
preparation assayed ranged between 0.5jLig/well to 100(j.g/well.

3.2.9.1.2 PAI-2 direct Western blot

The PAI-2 direct Western blot (section 3.2.6) was used to examine the size of the PAI2 observed in the cytosolic and PM enriched preparations. The preparations from the
U937 and MM6 cell lines were analysed because they had the highest levels of PAI-2
detected. The preparations from the Jurkat and THP-1 cell lines were analysed as a
negative control. As standards, PAI-2 and PAI-2 complexed with uPA were also
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analysed. This was to determine if the PAI-2 detected was a free protein or complexed
with uPA.

PAI-2 direct Western blots were performed either under reducing or non-reducing
conditions. 100|ig of protein from the cytosolic and PM enriched preparations from
the Jurkat, U937 and MM6 cell lines were assayed under reducing conditions. 200|j.g
of protein from the cytosolic and PM enriched preparations from the THP-1, U937 and
MM6 cell lines were assayed under non-reducing conditions. For standards, ljjig of
PAI-2 and ljug of pre-formed uPA/PAI-2 (0.5^ig/0.5(j.g) complex were used.

The sensitivity of the PAI-2 direct Western blot was increased by using a POD
conjugated anti-sheep/goat immunoglobulin secondary antibody. Following the GAHPAI-2-POD incubation the membrane was washed 4 times with PBS-T for lOmin each
at room temperature. The membrane was then incubated in POD conjugated antisheep/goat immunoglobulin diluted 1/2000 in blocking solution. The membrane was
then washed as before and developed by ECL.

3.2.9.2 Peroxidase (POD) activity

To assay for POD activity, a standard curve of 0.023-0.9mU of POD activity/well was
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used. The substrate used was 0.2M N a 2 H P 0 4 , pH5.0 with citric acid containing
400fig/ml OPD and 0.012% (v/v) H202. To 150(11 of substrate 15ul of standard or
sample was added. To determine background levels of POD activity, samples were
added to buffer not containing OPD. POD activity was allowed to proceed at room
temperature for 45min and the absorbance read at 490nm.

3.2.9.3 Alkaline phosphatase (AP) activity

To assay for AP activity, a standard curve of 0.006-0.75mU of AP activity/well was
used. The substrate used was 1 mg/ml of PNPP dissolved in lOOmM Tris, lOOmM
NaCl and 50mM MgCl2, pH9.5. To 140ul of substrate lOul of standard or sample was
added. To determine background levels of AP activity, samples were added to buffer
not containing PNPP. AP activity was allowed to proceed at room temperature for
60min and the absorbance read at 405nm.

3.3 RESULTS

3.3.1 Generation of a PAI-2 antigen column

Protein assays of the concentrates of each step of the generation of the PAI-2 anti

column revealed a negligible loss of protein after the coupling of PAI-2 to the CNB
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activated Sepharose 4 B (Table 1). From calculating the amount of PAI-2 lost in all of
the steps, the coupling efficiency of PAI-2 to CNBr activated Sepharose 4B was
>99%, indicating approximately 100% of the PAI-2 added was coupled to the
Sepharose beads.

3.3.2 Immunopurification of GAH-PAI-2

No protein was detected in the 4 washes used prior to the immunopurification (Table
1), indicating that the PAI-2 was not washed off the column during the
immunopurification procedure. After the polyclonal IgG had been batch loaded onto

the column, polyclonal IgG not specific for PAI-2 washed off the column (Fig. 1, f

peak). Once the baseline had stabilised PAI-2 specific polyclonal IgG (Fig. 1, seco
peak) was eluted with lOOmM glycine, pH2.5. Examination of the immunopurified
GAH-PAI-2 by reducing 10% SDS-PAGE revealed bands of 51 kDa and 28kDa, which

corresponds to the molecular weights of the heavy and light chains of IgG molecules
(Fig. 2, lane 2). The recovered immunopurified GAH-PAI-2 is identical to the

unpurified polyclonal (Fig. 2, lane 1) in molecular weight, and there is no eviden
PAI-2 leaching off the column into the immunopurified GAH-PAI-2 preparation.

Sample
Before blocking
After blocking
1st (0.1M sodium acetate, 0.5M NaCl, p H 4.0) wash
1st (0.1M Tris-HCl, 0.5M NaCl, pH8.0) wash
2nd (0.1M sodium acetate, 0.5M NaCl, p H 4.0) wash
2nd (0.1M Tris-HCl, 0.5M NaCl, pH8.0) wash
3rd (0.1M sodium acetate, 0.5M NaCl, p H 4.0) wash
3rd (0.1M Tris-HCl, 0.5M NaCl, pH8.0) wash
l O m M Tris, pH7.5
l O O m M Glycine, pH2.5
10mMTris,pH8.8
10mMTris,pH7.5
Total

Protein (jig)
0
1.4
0
0
0
7.5
2.8
1.9
0
0
0
0
13.6

Table 1. Mass of protein detected during each step of the generation of the PAI-2
antigen column. Samples assayed are indicated in the left column. The right
column is the mass of protein (fig) detected in the concentrated sample.
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Figure 1. Analysis of affinity purification of GAH-PAI-2. The absorbance at
280nm is plotted on the vertical axis versus the distance ( m m ) of the trace. Arrow
A indicates the start of the wash with l O m M Tris, pH7.4, and arrow B indicates the
start of the elution with l O O m M glycine, pH2.5. In this particular case, the
absorbance units full scale ( A U F S ) were changed for the elution, from 0.5 to 2.0.
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Figure 2. Analysis of immunopurified GAH-PAI-2 by reducing 1 0 % SDS-PAGE.
Molecular weight markers are indicated on the left in kDa. Lane 1 is unpurified
GAH-PAI-2 and lane 2 is purified GAH-PAI-2.

3.3.3

P O D labelling of immunopurified G A H - P A I - 2

The FPLC profile of the separation of free POD from GAH-PAI-2-POD revealed a

very small peak at the start of the trace and two overlapping peaks (Fig. 3). The fi
small peak was due to an air bubble, generated by the start of the FPLC procedure.
The molecular weight of the two overlapping peaks were >200kDa and 49kDa
respectively. Analysis of the FPLC fractions by non-reducing 10% SDS-PAGE (Fig.
4.) indicated that the first peak corresponded to a mixture of conjugated and
unconjugated GAH-PAI-2, while the second was unincorporated POD. Conjugated
GAH-PAI-2 was visualised as bands of >200kDa molecular weight (Fig. 4, lanes 1,
10-12), larger than the molecular weight of the unconjugated GAH-PAI-2 (Fig. 4, lane
2). The presence of more than one conjugate band was probably due to conjugates
with different ratios of POD incorporation. The band of 49kDa corresponds to free
POD (Fig. 4, lanes 1, 13-16). There was also a band of 72kDa that is thought to be
either a component of the activated peroxidase, a breakdown product of the
conjugation reaction or an unidentified contaminant. Only fractions containing GAHPAI-2-POD were pooled and used for the PAI-2 ELISA and Western blotting.

3.3.4 PAI-2 ELISA

The GAH-PAI-2-POD concentration course was carried out using 2 different batches
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Figure 3. Analysis of gelfiltrationof GAH-PAI-2-POD. The absorbance at 2 8 0 n m
is plotted on the vertical axis versus thefractionnumber collected on the horizontal
axis. Molecular weight markers in k D a are indicated just above the trace.
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Figure 4. Examination of purity of GAH-PAI-2-POD after gelfiltrationby nonreducing 1 0 % S D S - P A G E . Fractions collected from the F P L C Superdex-75
column were analysed by non-reducing 1 0 % S D S - P A G E . Molecular weight
markers are indicated on the left in kDa. Lane 1 is unpurified GAH-PAI-2-POD,
lane 2 is immunopurified GAH-PAI-2, lane 3 isfraction1, lane 4 isfraction5,
lane 5 is fraction 10 and lanes 6-22 arefractions12-28.

of conjugate (Fig. 5). Both batches are on a plateau at a 1/25 dilution of conjugate,
and titrated out below the detection limit of the ELISA at 1/25600 for batch 1 and
1/204800 for batch 2. The GAH-PAI-2-POD was used at a working dilution of 1/100
because it gave a strong signal without being wasteful of antibody.

The optimisation of coating concentrations for the PAI-2 ELISA (Fig. 6) shows that
using coating concentrations of 1, 2.5, 10 and 20fig/ml gave the strongest signal
without much difference between the concentrations. There was a larger difference if
the coating concentration was lowered to 0.5fig/ml, probably because there were still
unoccupied binding sites on the plate for the coating antibody. 5jj.g/ml was chosen as
the optimal coating antibody concentration.

When comparing coating the microtitre plates with either unpurified or purified GAHPAI-2, a difference was observed in the standard curves (Fig.7). The standard curve
using the unpurified and purified GAH-PAI-2 was linear from 0.3-3.lng/ml and 0.325ng/ml, respectively (Fig. 7a). This difference was probably because with the
unpurified GAH-PAI-2 there were other non-specific antibodies present to bind to the
plate, leading to a lower level of saturation of PAI-2 specific antibodies. When
examining the linear portions of the standard curves no striking difference could be

visualised between the standard curves, although the two curves were not parallel (Fig.
7b). Examining the limit of sensitivity of the PAI-2 standard curve, the limit of
detection was 0.3ng/ml using either unpurified or purified GAH-PAI-2. Overall this
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Figure 5. Optimisation of G A H - P A I - 2 - P O D dilution for PAI-2 ELISA. O n the
vertical axis is the absorbance measured at 4 9 0 n m and on the horizontal axis is the
serial doubling dilutions of G A H - P A I - 2 - P O D on a logarithmic scale. The two
different curves represent different batches of GAH-PAI-2-POD. The error bars
are the standard deviations of duplicate dilutions.
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Figure 6. Optimisation of coating concentration of GAH-PAI-2 for the PAI-2
ELISA. The vertical axis is the absorbance at 490nm and the horizontal axis is
the concentration of G A H - P A I - 2 - P O D used to detect lOOng/ml of PAI-2. The
different curves represent 0.5|ig/ml (-•—), 1.0|ig/ml (-•—), 2.5ug/ml ( - A - ) ,
lOjig/ml ( -*- ) and 20fxg/ml ( - » - ) coating concentrations of GAH-PAI-2
respectively. The error bars are the standard deviations of duplicate dilutions.
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Figure 7. A comparison of using either purified or unpurified GAH-PAI-2 as
the coating antibody in the PAI-2 ELISA. a) Standard curves using either
purified (-•-) or unpurified (-•- ) GAH-PAI-2. The absorbance at 490nm is
graphed against the concentration of PAI-2 (ng/ml). b) The same graph but
examining the linear parts of the standard curves by linear regression. The
equation and R 2 value for the linear regressions are written near each of the
respective curves. The error bars represent the standard deviation, n=3.

means that coating with unpurified GAH-PAI-2 does not change the sensitivity

dramatically because the linear portions of the standard curves are very similar. For
all ELISAs performed beyond this section unpurified GAH-PAI-2 was used to coat the
plates to conserve immunopurified antibody for POD labelling.

3.3.5 PAI-2 Western blot

Using the GAH-PAI-2-POD at a dilution of 1/400 it was seen that the Western blot
had a detection limit of 15.6ng (Fig. 8). The recombinant PAI-2 standard gave rise to
3 distinct bands of 47, 113 and 166kDa under non-reducing conditions. The 47kDa
band represented monomeric recombinant PAI-2 while the 110 and 137kDa bands
were thought to represent multimeric SERPIN. The 47 and 1 lOkDa bands stained the
strongest compared to the 137kDa band.

3.3.6 Analysis of plasma membrane preparations

3.3.6.1 PAI-2 antigen

By ELISA, both the Jurkat and THP-1 subclone employed in this study were negative

for PAI-2 in both the cytosolic enriched fraction and the PM enriched fraction (Table
2a). The very weak reactivity for Jurkat cells may have been due to non-specific
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Figure 8. Analysis of limit of sensitivity of PAI-2 direct Western blot. Molecular
weight markers are indicated on the left in kDa, while the amounts of PAI-2 loaded
per lane are indicated along the top of the blot.
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CELL
LINE

CYTOSOLIC ENRICHED
FRACTION
[PAI-21 (ng/mg)

PLASMA M E M B R A N E
ENRICHED FRACTION
[PAI-21 (ng/mg)

Jurkat
THP-1
HaCaT

<0.3
<0.3
41
65
290

<0.3
<0.3
3
9
17

CELL
LINE

CYTOSOLIC ENRICHED
FRACTION
POD activity (mU/mg)

PLASMA M E M B R A N E
ENRICHED FRACTION
POD activity (mU/mg)

Jurkat
THP-1
HaCaT

N.D.
<0.02
<0.02
<0.02
<0.02

N.D.
0.3
<0.02
0.1
<0.02

CELL
LINE

CYTOSOLIC ENRICHED
FRACTION
AP activity (mU/mg)

PLASMA M E M B R A N E
ENRICHED FRACTION
AP activity (mU/mg)

Jurkat
THP-1
HaCaT

N.D.
<0.01
20
0.03
0.1

N.D.
<0.01
17
<0.01
0.2

MM6
U937

MM6
U937

MM6
U937

Table 2. Analysis of cytosolic and P M enriched preparations for PAI-2 antigen
content, P O D activity and A P activity, a) PAI-2 antigen content. Units are
expressed as ng of PAI-2/mg of protein in the cytosolic or P M enriched
preparations (n=2). b) P O D activity. Units are expressed as m U of P O D
activity/mg of protein in the cytosolic or P M enriched preparations respectively
(n=l). c) A P activity. Units are expressed as m U of A P activity/mg of protein in
the cytosolic or P M enriched preparations respectively (n=l).
N.D.=Not
Determined.

binding. In contrast, H a C a T , U 9 3 7 and M M 6 cells were found to be positive for PAI2 antigen in both cytosolic and PM enriched fractions. The majority of PAI-2 was
found in the cytosolic enriched fraction of all 3 cell lines. Increasing levels of
were observed in the following rank order: HaCaT, MM6, and U937 cell lines.

3.3.6.2 POD activity

Both cytosolic and PM preparations were assayed for enzymatic activities of known
markers to compare how PAI-2 distributed compared to other proteins in the PM
enriched preparations. The enzymes chosen to be markers were POD which is a
marker for secretory granules, and AP which is a marker for PM in certain cell

systems. The POD activity was below the detection limit of the assay in the cytosol
enriched fractions of all cell lines tested (Table 2b). The THP-1 and MM6 were the
only cell lines with detectable POD activity in the PM enriched fractions.

3.3.6.3 AP activity

The AP activity detected in either cytosolic or PM enriched fractions (Table 2c) w

contrast to the PAI-2 content. The cell line with the most AP activity was the HaCa
cell line, followed by the U937 and MM6 cell lines. The THP-1 cell line had no

detectable AP activity with the assay used. There was no difference observed betwe
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the cytosolic or plasma membrane enriched fractions when comparing A P activity in
the HaCaT and THP-1 cell lines. In the MM6 cell line, there was only detectable
activity in the cytosolic enriched fraction. The U937 cell line showed a 1.7 fold
enrichment of AP activity in the PM enriched fraction.

3.3.7 Western blotting of PM enriched preparations

In an attempt to determine the relative sizes of the PAI-2 found in each of the two
subcellular fractions, Western blotting experiments were performed (Fig. 9). Under
non-reducing or reducing conditions the PAI-2 detected had several bands. The
recombinant PAI-2 standard (Fig.9, lane 1) showed four distinct bands of 38, 47, 110
and 137kDa molecular weight under reducing conditions. As seen in section 3.3.5, the
47kDa band was monomeric recombinant PAI-2 while the 110 and 137kDa bands
were thought to represent multimeric SERPIN. There was also evidence of a
degradation product in the PAI-2 preparation as visualised by the 38kDa band under
reducing conditions. Under non-reducing conditions only PAI-2 bands of 47 and
11 OkDa were visible.

Since a polyclonal sera was used as the detecting antibody, detection of uPA/PAI-2
complexes was possible. Complexes between uPA and PAI-2 (Fig. 9, lane 2) can be
visualised as three distinct bands of 73, 98 and 177kDa molecular weight. The
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Figure 9. Western blot analysis of cytosolic enriched and P M enriched
preparations of U 9 3 7 and M M 6 cells, a) Reducing Western blot, b) Nonreducing Western blot. Molecular weight markers are indicated on therightin
kDa. Lanes are as follows: 1) lug recombinant human PAI-2, 2) complex of
human recombinant PAI-2(lug) and human uPA(l|ig), 3) negative control (non
PAI-2 expressing) cell line cytosol, 4) negative control cell line P M , 5) U 9 3 7
cytosol, 6) U937 P M , 7) M M 6 cytosol and 8) M M 6 P M . The PAI-2 and
uPA/PAI-2 standards under non-reducing conditions were from a shorter
exposure from the same blot. The arrows on the left of the blots indicate the
molecular weights of the uPA/PAI-2 complexes of 73, 98 and 177kDa.

remaining bands observed corresponded to uncomplexed PAI-2. The 73kDa band
represents a complex between 47kDa PAI-2 and 33kDa uPA, the 98kDa band a
complex between 47kDa PAI-2 and 55kDa uPA and the 177kDa band a complex
between 137kDa PAI-2 and 33kDa uPA. There was no difference in the molecular
weights of the bands either under reducing or non-reducing conditions.

Under reducing conditions (Fig. 9a), the preparations from the Jurkat cell line were

used as negative controls. In agreement with the ELISA results, the preparations fro
the Jurkat cells (lanes 3 and 4) were completely negative for PAI-2. In contrast, a
47kDa band was detected in both the cytosolic (lane 5) and PM (lane 6) enriched
preparations of U937 cells under reducing conditions. A 47kDa band could be seen in
the cytosolic enriched fraction from the MM6 cell line (lane 7), but no band was
observed in the PM enriched fraction (lane 8). This may be because it was below the
detection limit of the Western blot. The 47kDa band corresponded to the molecular
weight of the non-glycosylated recombinant 47kDa PAI-2 standard (lane 1). No bands
co-migrating with uPA/PAI-2 complexes were evident in any of the preparations when
compared to the uPA/PAI-2 complexes standard (lane 2).

Under non-reducing conditions (Fig. 9b), the preparations from THP-1 cells used as
negative controls were negative for PAI-2 (lanes 3 and 4). The 47kDa PAI-2 band was
still evident in the cytosolic enriched preparations of both U937 (lane 5) and MM6
cells (lane 7). In the U937 PM enriched preparation under non-reducing conditions,
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the 47kDa PAI-2 band was replaced by a high molecular weight band around 180kDa
(lane 6). This same band was also weakly present in the U937 cytosolic enriched
preparation (lane 5). The 180kDa band may correspond to multimers of PAI-2, or
may represent an interaction of PAI-2 with other proteins that was sensitive to
reduction. There were no bands detectable in the MM6 PM enriched preparation (lane
8). As was also observed under reducing conditions, no bands co-migrating with the
uPA/PAI-2 complexes standard (lane 2) were evident in any of the preparations under
non-reducing conditions.

3.4 DISCUSSION

The results in this chapter demonstrate that despite a predominantly intracellular
expression, PAI-2 was detected, albeit at low levels, associated with the plasma
membrane of PAI-2 expressing cells. The molecular weight of PAI-2 was determined
in only the plasma membrane preparations from the U937 cell line, with a molecular
weight (47kDa) which was identical to that of the intracellular form of PAI-2. The

distribution of the PAI-2, POD and AP activities in the preparations was very differ
in the cell lines tested. POD antigen has been used as a marker of POD positive

granules in monocytic cells (Mane et al, 1989). AP antigen has been used as a marker
for secretory vesicles and plasma membranes in subcellular fractions of
polymorphonuclear cells (Detmers et al, 1995) and AP activity was used as a marker
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for microvillous membranes (Jensen, P.H. et al, 1989). From the P O D activity, the
results indicate that there were secretory granules detectable in the plasma membrane
enriched fractions of the THP-1 and MM6 cell lines. In addition, the AP results
indicate a poor enrichment for plasma membranes. However, the distribution of the
PAI-2 does indicate that little to none of the total PAI-2 within a cell was associated
with the plasma membrane. Therefore, even though thorough washes were carried out
during purification of plasma membrane, it can not be ruled out that PAI-2 detected in
the plasma membrane preparations may have been a contamination from the cytosol.

The evidence of a thiol-dependent association of PAI-2 in the plasma membrane
enriched fractions obtained from U937 cells poses interesting possibilities. It may
indicate that the small amounts of PAI-2 detected were actively binding to other
plasma membrane proteins or with itself. This could be an important step in PAI-2
secretion or an interaction to protect membrane components against intracellular
proteases. Two variants of the PAI-2 gene has been described; variant A consists of
Asn120, Asn404 and Ser413 (Antalis et al, 1988), variant B has an extra cysteine at
position 413 (Asp120, Lys404 and Cys413) (Ye et al, 1987). The presence of the extra
cysteine on PAI-2 variant B presents a free sulphydryl group for the formation of an
intermolecular disulphide bond. Both isoforms of PAI-2 have been identified in U937
cells (Ye et al, 1989).

The PAI-2 detected associated with the plasma membrane could be in the process of
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being secreted. PAI-2 lacks a signal peptide and undergoes facultative translocation to
be secreted (Belin et al, 1989; Belin, 1993). It is not hydrophobic enough to be
membrane-bound nor does it possess sequences consistent with a membrane-spanning
domain. It can be speculated that perhaps when associated with another protein PAI-2
is then able to pass through the membrane to be secreted. Von Heijne et al, (1991)
has demonstrated that increasing the hydrophobicity of PAI-2 by making point
mutations in the H1-H2 domain increases the efficiency with which it is secreted.
Hence it is possible that PAI-2 observed associated with the plasma membrane is in a
stage prior to being exocytosed.

In conclusion, PAI-2 was detected associated with the plasma membranes of PAI-2
producing cell lines. However, the majority of PAI-2 was confirmed to be localised
within the cytosol of cells. The function of membrane associated PAI-2 is unknown.

It may have a role in an intracellular function (such as protection against inapprop

proteolysis of important cytoskeletal elements during differentiation, eg. desmosome
or it may be in the process of being endocytosed or exocytosed. Taking the
observation that there is 47kDa PAI-2 associating with the plasma membrane of cells
that express PAI-2, but that the PAI-2 can not be detected on the cell surface, this
means that the PAI-2 must be on the inner face of the membrane. The next chapter
will determine if PAI-2 mRNA is synthesised by Jurkat cells using in situ
hybridisation.
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4.

EXAMINATION OF EXPRESSION OF PAI-2 mRNA BY

JURKAT CELLS

4.1 INTRODUCTION

As has been reviewed in chapter 1, PAI-2 has been detected in several different tiss
and cell types. PAI-2 mRNA synthesis can be stimulated by different mediators in
different cells or tissues. PMA and LPS are strong inducers of PAI-2 mRNA
expression in cells of a myelomonocytic lineage (Genton et al, 1987; Schleuning et
al, 1987). In macrophages PAI-2 mRNA expression can be increased by TNF-oc
(Medcalf 1992; Gyetko et al, 1992) and down regulated by dexamethasone (Medcalf
etal, 1988; Wohlwend et al, 1987b). In keratinocytes PAI-2 mRNA expression can
be upregulated by TNF-a (Wang and Jensen, 1998).

As described in chapter 2, using flow cytometry PAI-2 was not detected either

intracellularly or on the cell surface of CD3+ lymphocytes or the T-lymphoblastic ce
line, Jurkat. In addition, in chapter 3, no PAI-2 could be detected by ELISA in

preparations from the Jurkat cell line. However, Reiter et al, (1997) could detect P

2 antigen by ELISA in the Jurkat cell line, as well as other T-lymphoblastic cell li
In contrast, PAI-2 mRNA was not detected by in situ hybridisation in lymphocytes
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stimulated with linomide from human peripheral blood (Billstrom et al, 1997). In the
same study, PAI-2 mRNA expression was found to be upregulated in monocytes.

One possible explanation for the discrepancies in the above observations may be th
the PAI-2 gene is expressed only in T-lymphoblastic cell lines and not in normal
human lymphocytes, and that the expression is dependent upon stimulation.
Furthermore, the reason that the Jurkat cells used in this study were found not to
express PAI-2 protein was because they express a truncated form of PAI-2 mRNA
which does not get translated. In support of this was an observation by Gross and
Sitrin, (1990) that THP-1 cells express a truncated PAI-2 mRNA which did not

translate into PAI-2 protein. To test the hypothesis that T-lymphoblastic cell lin
only express PAI-2 mRNA upon stimulation, the PAI-2 mRNA expression by Jurkat
cells in the presence of the tumor promoting agent, PMA, was examined. The aim of

this chapter was to determine if the Jurkat cell line was capable of expressing PAI
mRNA after stimulation with PMA. In order to do this an in situ hybridisation
protocol was developed and Jurkat cells were assayed for PAI-2 mRNA with anti-

sense RNA probes. Once established, the in situ hybridisation protocol could then b
implemented to assay a mixed population of human PBL to determine if human Tlymphocytes could synthesise PAI-2 mRNA.

Ill

4.2

MATERIALS A N D M E T H O D S

4.2.1 Reagents

The PAI-2 cDNA (1884bp) was a kind gift from Professor E.K.O. Kruithof, Geneva
Medical School. The plasmid pGEM-3Z (2743bp), JM109 E. coli, nitroblue
tetrazolium salt (NBT), and 5-bromo-4-chloro-3-indoyl phosphate (BCIP) toluidinium
salt were obtained from Promega Corp., Sydney, NSW, Australia. The restriction
enzymes EcoRI, Hindlll, and Pstl, the nylon membranes, the AP conjugated anti-

digoxigenin (DIG) goat antibodies, and the DIG RNA labelling kit were obtained from
Boehringer Mannheim Australia Pty. Ltd., Castle Hill, NSW, Australia. The
polyvinylpyrrolidine (PVP), diethyl pyrocarbonate (DEPC), and molecular biology
grade chemicals: Ficoll, yeast tRNA, ribonuclease A, and proteinase K, were from
Sigma Chemical Co., St Louis, MO, USA. Bacterial alkaline phosphatase (BAP) and
T4 DNA ligase was obtained from Gibco-BRL, NSW, Australia. The plasmid midipreparation kit was obtained from Qiagen, NSW, Australia. Tryptone, yeast extract
and agar were obtained from Unipath Ltd., Hampshire, UK. Phorbol myristate acetate
(PMA) was from Calbiochem-Novabiochem Pty. Ltd., Alexandria, NSW, Australia.

4.2.2 Cell culture

Jurkat and U937 cells were cultured as described previously in chapter 2, section
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2.2.2.1. Cells were treated with 20ng/ml P M A , at a density of IO6 cells/ml in R M P I

media. Incubations were carried out in 25cm2 tissue culture flasks at 37°C for 24
As controls, cells were also grown overnight in only RMPI media.

4.2.3 Characterisation of Jurkat cells

Jurkat cells were analysed for cell surface expression of CD2, CD3, CD4 and CD8 by
flow cytometry according to section 2.2.10.

4.2.4 Generation of pGEM-3Z/PAI-2 plasmid

4.2.4.1 Dephosphorylation of the pGEM-3Z plasmid

A schematic diagram of the preparation of the plasmid template for DIG RNA probe

synthesis is shown in Fig. 1. The PAI-2 cDNA was ligated into the expression vecto
pGEM-3Z. Following ligation the pGEM-3Z/PAI-2 plasmid was digested with Pstl to
excise a 1.6kb fragment of the PAI-2 cDNA. The PAI-2 DIG labelled anti-sense RNA
was transcribed from the 372bp of PAI-2 cDNA remaining in the plasmid.

The first step was to linearise 5|ng of pGEM-3Z plasmid by digestion with 15U EcoR
overnight at 37°C in 20ul. The linearised pGEM-3Z was dephosphorylated using
BAP for 30min at 65°C. To remove BAP, a phenol/chloroform extraction was
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Figure 1. Schematic diagram of generation of PAI-2 c D N A template for synthesis
of DIG labelled PAI-2 R N A probes.

performed. This consisted of adding an equal volume of phenol/chloroform to the
dephosphorylated pGEM-3Z plasmid and mixing thoroughly. Centrifugation at
14000rpm in a microfuge was carried out for lmin at room temperature to obtain two
phases. All following centrifugations at 14000rpm were also performed in a
microfuge. The phenol/chloroform (lower) phase was discarded and the extraction
repeated twice more. An equal volume of chloroform was then added to the aqueous
phase and mixed thoroughly prior to centrifugation at 14000rpm for lmin at room
temperature. The chloroform phase was discarded and an ethanol precipitation
procedure performed.

One volume of 3M sodium acetate was added to 9 volumes of sample (linearised
dephosphorylated pGEM-3Z). To this mixture 2.5 volumes of ice cold absolute

ethanol was added and allowed to precipitate overnight at -20°C. The precipitate was
pelleted by centrifugation at 14000rpm for 15min at 4°C and the supernatant

discarded. The pellet was then washed by resuspending in ice cold 70% (v/v) ethanol.
This was then centrifuged at 14000rpm for 15min at 4°C and the supernatant

discarded. The pellet was then dried by draining excess fluid away using a tissue an
resuspended in 20ul of distilled water.

114

4.2.4.2 Ligation of the PAI-2 cDNA

into the pGEM-3Z

plasmid

Approximately 20ng of linearised pGEM-3Z plasmid and 200ng of PAI-2 cDNA were
mixed and heated at 45°C for 5min. The purpose of this was to melt any re-annealed
DNA. The mixture was immediately left on ice for 5min. To ligate the pGEM-3Z
plasmid and PAI-2 cDNA together, 10U T4 DNA ligase was added and held overnight
at room temperature. A control ligation was also performed which involved the
ligation of linearised pGEM-3Z alone. Ligated DNA was stored at -20°C until
transformation of competent JM109 E. coli cells.

4.2.5 Generation of JM109 E. coli which express the pGEM-3Z/PAI-2 plasmid

4.2.5.1 Competent JM109 E.coli formation

Bacterial growth was commenced by incubating 500ul of JM109 E. coli in 100ml of
LB broth (Appendix H), at 37°C in a shaking incubator. The JM109 E. coli were

grown until they reached the stationary phase of growth as determined by absorbanc
at 560nm (A560nm). JM109 E. coli were then centrifuged at 5000rpm for lOmin at 4°C

and the supernatant discarded. The pellet was left on ice for lOmin, then resuspen
in 50ml of lOOmM MgCl2 and centrifuged at 5000rpm for lOmin at 4°C. The pellet
was resuspended in 5ml of lOOmM CaCl2 and glycerol added at a ratio of 1 part
glycerol to 7 parts bacteria. The mixture was divided into 1ml aliquots and snap
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frozen in liquid nitrogen and stored at -70°C until use.

4.2.5.2 Transformation of competent JM109 E. coli with the pGEM-3Z/PAI-2
plasmid

pGEM-3Z/PAI-2 plasmid (lul) was added to lOOul of competent JM109 E. coli and
left on ice for 30min. The bacteria were then heated at 42°C for 45sec followed by
immediate chilling on ice for 2min. SOC media (900ul, Appendix I) was added and

left to incubate at 37°C with shaking for 60min. In order to select for transforman
ampicillin was included in the growth media, since the pGEM-3Z plasmid confers
ampicillin resistance. Three different volumes of bacteria: lOfil,

IOOJJ.1

and 890ul,

were plated out on three separate Z agar plates (Appendix J) containing 200p.g/ml
ampicillin and incubated at 37°C overnight. Colonies that grew close to the middle

the dish were harvested using a sterile toothpick into McCartney bottles containing
3ml LB broth+200ug/ml ampicillin and these cultures were incubated with shaking at
37°C overnight.

4.2.5.3 Mini-preps of plasmid from transformed JM109 E. coli

A 1.5ml sample was taken from each of the overnight cultures of JM109 E. coli and
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centrifuged at 14000rpm for lmin at room temperature.

The supernatant was

discarded and the pellets placed at -20°C for 60min. The pellet was resuspended in
lOOul of solution I (Appendix K) containing 5-10mg/ml of lysozyme and incubated at
37°C for 20min. Solution II (200ul, Appendix L) was added and gently mixed to
prevent shearing of genomic DNA. The mixture was then left on ice for lOmin.
Solution III (150ul, Appendix M) was added, gently mixed as before and left on ice
for lOmin. The mixture was then centrifuged at 14000rpm in a microfuge for 2min at
room temperature. About 90% of the supernatant was then aspirated into a clean
eppendorf tube. A volume of 270ul of isopropanol was added to precipitate plasmid
present in the supernatant. The solution was then mixed thoroughly and left at room
temperature for 5min. The resulting precipitate was pelleted with centrifugation at
14000rpm for 2min at room temperature and the supernatant discarded. The pellet
was dried by draining away the excess fluid with a tissue. The dried pellet was then
resuspended in 20ul of distilled water and stored at -20°C until use.

To determine if the JM109 E. coli transformants chosen did contain PAI-2 cDNA
inserts and to examine the orientation of the PAI-2 cDNA insert in the plasmid, the
mini-preparations of plasmid were examined by agarose gel electrophoresis. To
determine if PAI-2 cDNA inserts were present,

2JLL1

of plasmid was digested with 10U

EcoRI for 3hr at 37°C. To determine the orientation of the PAI-2 cDNA insert, lug of
plasmid was digested with 10U Pstl for 3hr at 37°C. Digested plasmids were then
analysed by electrophoresis on a 1.2% Tris-borate (TBE) (Appendix N) agarose gel.
117

Samples were prepared for electrophoresis by mixing digested plasmid with D N A
sample buffer (Appendix 0). Electrophoresis was conducted at 100V using 0.5xTBE

as the electrophoresis buffer. Electrophoresis was stopped when the dye front near

reached the end of the gel. After electrophoresis, the gels were placed in lOug/lOO
ethidium bromide for 60min at room temperature to stain any DNA present. Stained
DNA bands were visualised using the Novex Gel Documentation System.

4.2.5.4 Midi-preps of pGEM-3Z/PAI-2 from transformed JM109 E. coli

A transformant which was found to have a PAI-2 cDNA insert in the 5'->3'
orientation relative to the T7 RNA polymerase promoter was grown in 30ml of LB
broth+200fj.g/ml ampicillin and placed at 37°C overnight in a shaking incubator.
Plasmid purification was performed using the Qiagen Plasmid Midi-Preparation Kit
according to manufacturer's instructions.

In detail, bacteria were pelleted and buffer PI added. Buffer P2 that had been prewarmed to dissolve the SDS was added and the mixture left for 5min at room
temperature. This was followed by the addition of chilled buffer P3 and gentle

mixing. The mixture was then left on ice for 15min. The resultant solution was then
applied to the supplied columns, followed by 2x1 Oml QC washes. The plasmids were

then eluted with 5ml of the supplied elution buffer. The eluate was divided into s
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700ul aliquots and 490ul of isopropanol added to each one. The resultant solution
was mixed thoroughly and centrifuged at 14000rpm for 30min at 4°C. The pellets
were dried and resuspended in 20ul of distilled water.

The seven samples were then pooled and the volume made up to 200ul with distilled
water. The purity of the plasmid preparation was determined using the ratio of
A

260nm/A280nm- Samples of the purified plasmid were then digested using 10U Pstl for

3hr at 37°C and analysed by electrophoresis on a 1.2% TBE agarose gel. DNA in the
gel was stained using ethidium bromide, and visualised using the Novex Gel
Documentation System.

4.2.6 Generation of a pGEM-3Z plasmid containing a 372bp PAI-2 fragment

The pGEM-3Z/PAI-2 plasmid (5u-g ) was digested with 15U Pstl at 37°C overnight
and DNA sample buffer was then added. The sample was loaded into two separate
wells of a 1.2% TBE agarose gel and conducted at 100V. On completion of

electrophoresis the gel was then placed in lOug/lOOml ethidium bromide for 60min at
room temperature to stain the DNA. Stained DNA bands were visualised with an UV
lamp. The band corresponding to the pGEM-3Z plasmid containing the 372bp
fragment of the PAI-2 cDNA (pGEM-3Z/372bpPAI-2) was excised from the gel with

a razor blade. The excised gel was placed in a piece of dialysis tubing with 400ul o
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0.5xTBE and sealed with dialysis clips. The D N A was then electro-eluted from the

gel by placing the excised gel in an agarose gel tank containing 0.5xTBE, and runn
at 80V. DNA migration out of the gel was monitored using an UV lamp.

Once the DNA had migrated out of the gel, buffer in the dialysis tubing was aspira
and placed in an eppendorf tube. An equal volume of butanol was added and the
solution mixed thoroughly. The resultant solution was centrifuged at 14000rpm for

lmin at room temperature and the butanol (upper) phase discarded. Butanol extractio
was performed 3 times. Butanol extraction reduces the volume of sample as well as

removing ethidium bromide. This was followed by the addition of an equal volume of
phenol/chloroform and thorough mixing. The resultant solution was centrifuged at
14000rpm for lmin at room temperature and the phenol/chloroform phase discarded.
This was followed by the addition of an equal volume of chloroform and thorough
mixing. The resultant solution was centrifuged at 14000rpm for lmin at room
temperature and the chloroform phase discarded. The plasmid was then ethanol
precipitated as described in section 4.2.2.1. The resultant pellet was resuspended

20ul of distilled water and the concentration determined by measuring the absorbanc
at 260nm.

The isolated pGEM-3Z/372bpPAI-2 plasmid was re-ligated and used to transform
more competent JM109 E. coli. To ensure that the transformed JM109 E. coli. did
contain the pGEM-3Z/372bpPAI-2 plasmid, transformants were harvested and mini120

preps isolated. Samples (2ul) of the mini-preps of plasmid were digested with 10U
EcoRI, as well as a digest with 10U EcoRI and 10U Pstl simultaneously at 37°C for
3hr. Digested plasmids were separated using a 1.2% TBE agarose gel. The gel was
then stained with ethidium bromide. Once it had been confirmed that the pGEM-3Z
plasmid and 372bp PAI-2 cDNA insert were the correct sizes midi-preps of the
pGEM-3Z/372bpPAI-2 plasmid were prepared as in section 4.2.5.4. The isolated
pGEM-3Z/372bpPAI-2 plasmid was then stored at -20°C until use.

4.2.7 DIG labelling of anti-sense and sense PAI-2 RNA probes

4.2.7.1 Template preparation

Prior to synthesis of the DIG labelled RNA probe, 5ug of pGEM-3Z/372bpPAI-2
plasmid was digested with 15U EcoRI and 5p.g of pGEM-3Z/372bpPAI-2 was
digested with 15U Hindlll. The EcoRI digest was designated as the template for the

anti-sense probe, and the Hindlll digest designated as the template for the sense pr
(Refer to Fig. 1). The digested plasmids were separated by electrophoresis using a
1.2% TBE agarose gel. The gel was then stained with ethidium bromide. When it was
confirmed that the pGEM-3Z/372bpPAI-2 plasmid was the correct size a
phenol/chloroform extraction and ethanol precipitation were performed as in section
5.2.2.1. The purity of the digests were examined measuring the ratio of A260nm/A2g0nrn.
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4.2.7.2 DIG labelled RNA synthesis

All aqueous buffers used in the synthesis of the R N A probes were treated using D E P C

to inactivate any RNases. DEPC was added at a final concentration of 1% (v/v) and
left overnight at 37°C. The solutions were then autoclaved. The DIG labelled RNA
probe was synthesised using the DIG RNA labelling kit (Boehringer Mannheim)
according to the manufacturer's instructions. The EcoRI digested pGEM3Z/372bpPAI-2 (lug) was mixed with 2ul of transcription buffer, 2ul of NTP
labelling mixture, lul of RNase inhibitor, 2ul of SP6 RNA polymerase and milliQ
water up to 20ul. The Hindlll digested pGEM-3Z/372bpPAI-2 (lug) was mixed with

2ul of transcription buffer, 2ul of NTP labelling mixture, lul of RNase inhibitor
of T7 RNA polymerase and milliQ water up to 20ul. These were then incubated at

37°C for 2hr. DNase I was then added, and the mixture incubated at 37°C for 15min
to digest the DNA. Then 2ul of 200mM EDTA, pH8.0, 2.5ul of 4M LiCl and 75ul of
pre-chilled absolute ethanol was added, and mixed thoroughly.

The resultant solution was allowed to precipitate at -20°C overnight. The precipi
RNA was pelleted by centrifugation at 12000rpm for 20min at 4°C. The pellet was
washed by the addition of 70% (v/v) ethanol and mixed thoroughly. This was then

centrifuged at 12000rpm for 20min at 4°C as before. The supernatant was discarded

and the pellet of RNA resuspended in lOOul of distilled water. RNase inhibitor (l
supplied in the kit was also added to the RNA.
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4.2.8

Confirmation of D I G labelling of R N A probes by dot blot

A 2ul volume of a 1/100 and 1/1000 dilution of DIG labelled RNA in distilled water
was placed onto a positively charged nylon membrane. The spots were allowed to air
dry and the RNA cross-linked to the membrane using UV radiation. This was
performed in a Stratalinker (Stratagene) according to manufacturer's instructions.
membrane was then placed in blocking buffer (PBS + 1% (w/v) PVP + 0.1% (v/v)
Tween20) and left for 30min at room temperature with shaking. The membrane was

then transferred into blocking buffer containing a 1/5000 dilution of AP conjugate
anti-DIG antibody and left for 60min at room temperature with shaking.

The membrane was then washed by placing in PBS + 0.1% (v/v) Tween20 for 15min
at room temperature with shaking. This wash step was repeated again. The membrane
was then rinsed by placing in AP substrate buffer (lOOmM Tris, lOOmM NaCl and
50mM MgCl2, pH9.5) for 2min at room temperature with shaking. Finally, the blot
was developed by placing the membrane in 10ml of AP substrate buffer containing
49.5ug/ml of NBT and 16.5ug/ml of BCIP. The membrane was then allowed to sit in
the substrate solution in complete darkness at room temperature with shaking. The
membrane was examined every few minutes and the reaction stopped with PBS +
20mM EDTA when dots of sufficient darkness appeared.

4.2.9

Confirmation of D I G labelling of R N A probes by electrophoresis and

immunoblotting

4.2.9.1 Electrophoresis of DIG labelled RNA

This was to ensure that the DIG labelled RNA probe was the correct size. A 1.2%
formaldehyde agarose gel (Appendix P and Q) was prepared. Prior to loading and

electrophoresis of the RNA samples, the empty gel was conducted at 100V for 5min.
The RNA samples were prepared by the addition of formamide, 37.5% formaldehyde
and RNA sample buffer (Appendix R and S). Samples were then heated at 65°C for

lOmin and the samples loaded into the wells of the gel. The gel was then conduc
100V using lxMOPS as electrophoresis buffer.

The gel was then washed by placing in distilled water for lOmin at room temperat

to remove the formaldehyde. The wash was then repeated. The gel was then placed i
50mM NaOH for 30min at room temperature. The NaOH was neutralised by placing
the gel in 200mM Tris, pH7.4 for 15min at room temperature. The gel was then
placed in 200mM Tris, pH7.4 containing lOug/lOOml ethidium bromide for 20min at
room temperature to stain any RNA present. To remove excess stain, the gel was

placed in 200mM Tris, pH7.4 for 30min at room temperature. Stained RNA in the gel
was visualised using the Novex Gel Documentation System.

4.2.9.2 Immunoblotting of DIG labelled RNA

The R N A in the gel was then transferred onto a positively charged nylon membrane by

capillary action. The transfer apparatus was set up in a large clean dish, see Fig. 2.
An upturned gel casting stand was placed on the bottom. Then items were placed on
top of each other in the following order:
1) Two pieces of Whatman paper that would cover the top of the stand as well as
cover part of the bottom of the glass dish were placed on top of the stand. The
Whatman paper in the bottom of the glass dish acted as a wick.

2) The gel.
3) Four small pieces of parafilm arranged around the edges of the gel. Enough
parafilm was used to cover the entire edge of the gel. The parafilm prevented the top
pieces of tissue dipping into the buffer and short-circuiting the transfer.
4) A piece of nylon membrane that only covered the gel.
5) A few pieces of Whatman paper that only covered the gel.
6) A thick wad of tissue.
7) A thick glass plate, or something flat and hard.
8) A weight (eg. glass Schott bottle).

Then enough 5xSSC was added to the glass dish to cover the wicks, but not the stand.
The transfer was carried out overnight at room temperature.
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Figure 2. Schematic diagram of the apparatus used to transfer R N A separated on
formaldehyde gel to a nylon membrane.

Following transfer the gel and membrane were removed from the apparatus. The gel

was then stained again as described in section 4.2.9.1 to determine if complete trans
of RNA onto the membrane was achieved. The membrane was allowed to air-dry and
transferred RNA was cross-linked to the membrane using UV radiation. The
membrane was then blocked, probed with AP conjugated DIG antibody and bands
developed with substrate. Refer to section 4.2.8.

4.2.10 In situ hybridisation of the DIG labelled PAI-2 RNA probes

4.2.10.1 Pre-hybridisation treatment of U937 and Jurkat cells

The in situ hybridisation protocol used here follows that detailed by Wilkinson (1992)

U937 and Jurkat cells were harvested into polypropylene centrifuge tubes and pelleted
with centrifugation at 200g for 5min at room temperature. The supernatant was
discarded and the cells washed in PBS followed by centrifugation at 200g for 5min at
room temperature. Washes were performed three times. Cells (105) were then
centrifuged (lOOOrpm for 6min at room temperature) onto round 12mm glass

coverslips using a cytospin. Coverslips were placed with the cells on the upper surfa
into separate wells of a polystyrene 24 well plate. Cells were fixed by the addition
500ul of cold PBS+4% (w/v) paraformaldehyde and left on ice for lOmin. The 4%
(w/v) paraformaldehyde was discarded and methanol added to the cells. The cells
were then stored at -20°C until required.
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Coverslips were re-hydrated by a series of graded methanol washes. Thefirstwash
was performed by the addition of 75% (v/v) methanol in PBS to the cells. This was

left for 5-10min at room temperature. The 75% (v/v) methanol was then discarded an
the following washes performed in the same way:
1) 50% (v/v) methanol in PBS.
2) 25% (v/v) methanol in PBS.
3) PBS wash.

Cells were then permeabilised by the addition of 20mM Tris-HCl, pH7.5, 2mM CaCl2
containing lug/ml proteinase K and incubated at 37°C for 15min. Cells were washed
using PBS and then fixed again by the addition of PBS+4% (w/v) paraformaldehyde
for 5min on ice. The PBS+4% (w/v) paraformaldehyde was then discarded. The cells
were then rinsed with distilled water followed by dehydration through a series of
graded ethanol washes: 70%, 95% and 100% (v/v) ethanol at room temperature for
5min. Finally, the coverslips were allowed to air-dry at 37°C for 30min.

4.2.10.2 Hybridisation and post-hybridisation treatments

All reagents used in the hybridisation were treated with DEPC as described in sec

4.2.7.2. Glass slides were also treated by soaking in ethanol and autoclaving. Se
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and anti-sense D I G labelled R N A probes were diluted 1/1000 in the hybridisation mix
(Appendix T) and heated at 65°C for 2min. The sterile glass slides were placed on a
tissue paper soaked in 4xSSC (Appendix U) containing 50% (v/v) formamide to
reduce evaporation. A volume of 7.5ul of probe was placed on a glass slide. The
coverslips were then taken out of the 24 well plate and placed upside down so that
cells were in contact with the probe. Cells were hybridised with the DIG labelled
RNA probes by incubation at 50°C overnight.

Coverslips were soaked off the glass slide by immersion in 5xSSC for 5mins, and the
placed back into separate wells of a 24 well plate followed by washes. 5xSSC was
added to wells containing coverslips and left to incubate at 42°C for 30min. The
5xSSC was discarded and the coverslips washed with 2xSSC containing 50% (v/v)
formamide for 20min at 60°C. This was followed by 2 x lOmin (lOOmM Tris-HCl,
pH7.5, 400mM NaCl, 50mM EDTA) washes at 37°C. To digest any unhybridised
DIG labelled RNA probe the cells were then incubated in RNase buffer containing
lOOug/ml RNaseA at 37°C for 30min. The RNaseA was then washed off with
RNase A buffer as before. Coverslips were then washed with increasing stringency.
The first wash was performed by the addition of 2xSSC at 37°C for 15min. The
second wash was performed by the addition of O.lxSSC at 37°C for 15min.
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4.2.10.3

Detection of hybridised DIG labelled PAI-2

RNA

Coverslips were blocked with Tris buffered saline (TBS) (Appendix V ) containing
10% (v/v) normal goat serum, 0.1% (v/v) Triton-X 100 and 0.1% (v/v) Tween20 for
60min at room temperature with constant shaking. Following blocking cells were
incubated in TBS containing 1% (v/v) normal goat serum, 0.1 % (v/v) Triton-X 100,
0.1 % (v/v) Tween20 and a 1/1000 dilution of AP conjugated anti-DIG antibody

overnight at 4°C with constant shaking. The antibody solution was discarded and the
coverslips washed using TBS containing 0.1% (v/v) Tween20 for lOmin at room
temperature with constant shaking. The wash was repeated another three times. The

coverslips were equilibrated in AP substrate buffer for 2min at room temperature w

constant shaking. Color was developed by the addition of 10ml of AP substrate buffe
containing 49.5ug/ml of NBT and 16.5ug/ml of BCIP. Color development was
allowed to occur from a few hours to overnight at room temperature in the dark. To
stop the development of color the cells were washed with PBS+0.5% (w/v) EDTA for
lOmin at room temperature. The solution was then discarded and the coverslips
mounted with cells facing down onto clean glass slides.

4.2.10.4 Modifications to the in situ hybridisation protocol

Results obtained from the protocol used above had high background. Therefore, in
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order to determine if the protocol used could be improved, certain steps were
modified. The modifications tested are listed below.

1) Increasing the temperature of RNA hybridisation from 50°C to 64°C.
2) Increasing the temperature of all washes following hybridisation to 75°C prior
to detection of the DIG labelled RNA. The only incubation temperature not increased
was the RNaseA step.
3) Increasing the concentration of DIG labelled probe (from 1/1000 to a 1/100
dilution) in the hybridisations.
4) Limited alkaline hydrolysis of the DIG labelled RNA probe from 372 bases to
150 bases in length. This was achieved by adding 30ul of 0.2M Na2C03 and 20ul of
0.2M NaHC03 to 50ul of DIG labelled RNA probe. The mixture was incubated at
60°C for 37min and 18sec.

The length of time required for limited alkaline hydrolysis was calculated using the
following equation (Wilkinson 1992):

time (min) = (starting length, kb)-(desired length, kb)
(0.1 l)(starting length, kb)(desired length, kb)

The hydrolysis was stopped by the addition of 3ul of 3M sodium acetate, pH6.0 and
5ul of 10%) (v/v) acetic acid. A volume of lOul of lOmg/ml yeast tRNA was then
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added. The hydrolysed probe was precipitated by the addition of 2.5 volumes of ice
cold ethanol and left at -70°C for 60min. The precipitated RNA was pelleted with
centrifugation at 14000rpm in a microfuge for lOmin at 4°C. The supernatant was
discarded and the pellet resuspended in 25 ul of DEPC treated distilled water.

In addition, to determine if the PAI-2 RNA probes were binding to the cells nonspecifically, cells were treated with RNaseA. Following permeabilisation with
proteinase K during the pre-hybridisation, cells were treated with lOOug/ml RNaseA at
37°C for 30min. The RNaseA was then aspirated and the protocol continued as
described after the proteinase K step.

4.2.10.5 Controls for in situ hybridisation

In addition to the sense probe control another control was employed for the in situ
hybridisation experiments. The control included was hybridisation of cells in the
absence of either PAI-2 sense or anti-sense RNA probe.
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4.3

RESULTS

4.3.1

Analysis of expression of C D 2 , C D 3 , C D 4 and C D 8 on the surface of

Jurkat cells

Viable Jurkat cells were positive for cell surface CD2 and CD4 (Fig. 3, a and c).

a sub-population of the Jurkat cells were positive for CD3 (Fig. 3, b). The Jurkat
were negative for cell surface CD8 (Fig. 3, d).

4.3.2 Examination of the pGEM-3Z/PAI-2 plasmid

Screening of transformants for the PAI-2 cDNA insert (Fig. 4) indicated that 7 out
the 9 transformants selected contained the insert (lanes 1-4 and 6-8). The band at
2.7kB corresponds to the linearised pGEM-3Z plasmid and the band at 1.9kB
corresponds to the PAI-2 cDNA.

Examining the orientation of the insert using Pstl revealed that there were
transformants with the PAI-2 cDNA inserted in both forward (5'->3') and reverse
(3'-»5') orientation (Fig. 5). The PAI-2 cDNA insert reading from 5'->3' from the
promoter was defined as the forward orientation, and would yield 2 bands when
digested with Pstl. The PAI-2 cDNA insert reading from 3'-»5' from the T7 promoter
was defined as the reverse orientation, and would yield 1 band when digested with
132

a)

h
£
|
f
«
U

b)

900800700600500i
400300200100-

o10°

i
i

t

io1
C D 2 expression

IO4 10°
C D 3 expression
d)

10 2
103
C D 4 expression

IO4 10°
C D 8 expression

Figure 3. Analysis of C D 2 , CD3, C D 4 and C D 8 cell surface expression on viable
Jurkat cells by flow cytometry. Histogram plots are shown with cell number on
the vertical axis and the antigen expression on the horizontal axis. The isotype
controls are represented by the dashed line and the test antibodies are represented
by the solid line, a) C D 2 , b) CD3, c)CD4 and d) CD8.
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Figure 4. A 1.2% T B E agarose gel examining insertion of the PAI-2 c D N A into
the p G E M - 3 Z plasmid. O n the left are markers in kilobases. Lanes 1-9 are minipreps from JM109 transformants 1-4, 6-9 and 12. Plasmids were digested with
EcoRI for 3hr at 37°C.
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Figure 5. A 1.2% T B E agarose gel analysis of digestion of pGEM-3Z/PAI-2
plasmid to determine the orientation of PAI-2 c D N A . O n the left are markers in
kilobases. Lanes 1-7 are mini-preps from transformants 1-4 and 7-9, respectively.
Plasmids were digested with Pstl for 3hr at 37°C.

Pstl.

Transformants expressing the PAI-2 c D N A in the reverse orientation yielded a 4.3kB
band when digested with Pstl (Fig. 5, lanes 2 and 6). Transformants expressing the
PAI-2 in the forward orientation yielded 2 bands, a 3.1kB band and a 1.5kB band

(lanes 1, 3-5 and 7). In addition a third band of 1.9kB was evident in transformant
and 9 (lanes 4 and 7). This was possibly an extra insert of PAI-2 cDNA. The
transformants expressing the 3 bands were eliminated from further selection.

4.3.3 Examination of the pGEM-3Z/372bpPAI-2 plasmid

Digestion of the pGEM-3Z/PAI-2 plasmid with Pstl leads to the generation of bands
of 3.1 kB and 1.5kB (Fig. 6, lane 2). The band of 3.1kB corresponds to pGEM-3Z
containing 0.37kB of the PAI-2 cDNA. The 1.5kB band corresponds to the remainder
of the PAI-2 cDNA. Digestion of the pGEM-3Z plasmid with Pstl resulted in a 2.7kB
band (lane 1).

Examination of the competent JM109 E.coli transformed with pGEM-3Z/372bpPAI-2
revealed all of the transformants chosen expressed plasmids of 3.1kB when digested

with EcoRI (Fig. 7). To ensure that the plasmids did contain the 0.37kB insert, one

the transformants was selected and the plasmid double digested using EcoRI and Pstl

133

Figure 6. A 1.2% T B E agarose gel analysis of the plasmids p G E M - 3 Z and
pGEM-3Z/PAI-2 digested with Pstl. O n the left are markers in kilobases. Lane 1
is p G E M - 3 Z and lane 2 is pGEM-3Z/PAI-2. Plasmids were digested with Pstl for
3hr at 37°C.
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Figure 7. A 1.2% T B E agarose gel analysis of plasmid isolated from p G E M 3Z/372bpPAI-2 transformants digested with EcoRI. O n the left are the markers in
kilobases. Lanes 1-10 are transformants 1-10 respectively. Plasmids were digested
with EcoRI for 3hr at 37°C.

(Fig. 8). Digesting the plasmid yielded 2 bands (Fig. 8, lane 3), the 2.7kB band
corresponding to pGEM-3Z and the faint 0.37kB band corresponding to the truncated
PAI-2 cDNA insert. As a comparison, undigested pGEM-3Z/372bpPAI-2 (Fig. 8, lane
1) and pGEM-3Z/372bpPAI-2 digested with EcoRI (Fig. 8, lane2) were analysed in
the same gel.

4.3.4 Examination of DIG labelled sense and anti-sense PAI-2 RNA probes

The PAI-2 RNA probes were DIG-labelled as demonstrated by a dot blot (Fig. 9).
Judging by the intensity of the dots at both dilutions of probe tested, the sense

had a higher incorporation of DIG than the anti-sense probe. The size of the gener

probes indicated that the sizes of both the anti-sense and sense probes were the s

and smaller than that of the pre-labelled lkB control probe provided in the kit (Fi

10). As observed in the dot blot, the sense probe had a higher incorporation of DIG

than the anti-sense probe as judged by the intensity of the bands. At 1/100 the sen

RNA probe was darker than the anti-sense probe. At dilutions of 1/1000 neither prob
had discernible bands. DNA markers were used in order to obtain an estimate of the
size of the RNA, however the markers were not observed on the ethidium bromide
stained gel so no markers were shown in this figure.
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Figure 8. A 1.2% T B E agarose gel analysis of pGEM-3Z/372bpPAI-2 digested
with EcoRI and Pstl. O n the left are markers in kilobases. Lane 1 is undigested
pGEM-3Z/372bpPAI-2, lane 2 is pGEM-3Z/372bpPAI-2 digested with EcoRI and
lane 3 is pGEM-3Z/372bpPAI-2 digested with EcoRI and Pstl. Plasmids were
digested for 3hr at 37°C. The arrow on the right indicates the 372bp PAI-2 c D N A .
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Figure 9. Detection of D I G labelled R N A spots on a nylon membrane by
detection with an A P labelled D I G antibody. The probe used as a positive
control was a lkb D I G labelled R N A probe provided with the kit and the probes
tested were the sense and anti-sense PAI-2 R N A probes.
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Figure 10. Detection of D I G labelled R N A bands on a nylon membrane after
transfer from a 1.2% formaldehyde agarose gel. Bands were detected with an
A P labelled D I G antibody. The probe used as a positive control was a lkb D I G
labelled R N A probe used at 1/100 and 1/1000 dilutions. The probes tested were
the sense and anti-sense PAI-2 R N A probes also at dilutions of 1/100 and
1/1000.

4.3.5

In situ hybridisation of a PAI-2 anti-sense R N A probe with m R N A in

U937 and Jurkat cells

In U937 cells hybridised in the absence of RNA probe, there was very little staining

the cells (Fig. 11a and b). Cells stained with the RNA probes lead to a uniform stain

throughout the cytoplasm (Fig. llc-f). Cells that were not stimulated in culture with
PMA were slightly darker when hybridised with the anti-sense probe compared to the
sense probe (Fig. lie and e). In PMA stimulated U937 cells, the results were similar
to the unstimulated cells (Fig. 1 Id and f).

As with the U937 cells, the Jurkat cells hybridised in the absence of RNA probe
showed little staining of the cells (Fig. 12a and b). In unstimulated Jurkat cells,

staining with the sense probe (Fig. 12c) was homogenous, while staining with the anti
sense probe (Fig. 12e) was more heterogeneous. But, no significant difference in
staining intensity between the two was observed. Similar results were obtained with

PMA stimulated cells (Fig. 12d and f). These results suggests that Jurkat cells do no
synthesise PAI-2 mRNA.

The in situ hybridisation protocol used, led to relatively high backgrounds which we

very difficult to remove. The modifications to the protocol: increasing the temperat
of RNA hybridisation to 64°C; increasing the temperature of all washes following
hybridisation to 75°C; increasing the dilution of DIG labelled probe from 1/1000 to
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Figure \\. In situ hybridisation of D I G labelled sense and anti-sense PAI-2 R N A
probes with U 9 3 7 cells. Panels on the left are control unstimulated U 9 3 7 cells and
panels on the right are P M A stimulated U 9 3 7 cells. Panels a) and b) are U 9 3 7
cells hybridised in the absence of any R N A probes. Panels c) and d) are cells
hybridised with the PAI-2 R N A sense probe and panels e) and f) are U 9 3 7 cells
hybridised with the PAI-2 anti-sense R N A probe. 40x magnification.
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Figure 12. In situ hybridisation of D I G labelled sense and anti-sense PAI-2 R N A
probes with Jurkat cells. Panels on the left are unstimulated Jurkat cells and panels
on the right are P M A stimulated Jurkat cells. Panels a) and b) are Jurkat cells
hybridised in the absence of any R N A probes. Panels c) and d) are cells hybridised
with the PAI-2 R N A sense probe and panels e) and f) are Jurkat cells hybridised
with the PAI-2 anti-sense R N A probe. 40x magnification.

1/100 in the hybridisations and limited alkaline hydrolysis of the D I G labelled R N A
probe from 372 bases to 150 bases in length did little to reduce the background. The
background was not due to the DIG labelled RNA probes binding non-specifically to
the cells because when incubations were carried out after a pre-incubation with
RNaseA, there was no staining.

4.4 DISCUSSION

Overall, the results show that U937 cells were synthesising PAI-2 mRNA. However
there was little to no difference in PAI-2 mRNA expression between PMA stimulated

and unstimulated U937 cells using the in situ hybridisation method stated above. This

is in contrast to the reported findings by others (Kruithof et al, 1986b; Genton et al
1987; Wohlwend et al, 1987a; Wohlwend et al, 1987b; Schleuning et al, 1987;
Alving et al, 1988; Arndt et al, 1989; Oliver et al, 1989; Antalis and Dickinson,
1992; Dickinson et al, 1993; Niiya et al, 1994). The reasons for this may be due to
the cells used or the detection method. The majority of studies examining PAI-2
mRNA expression have implemented Northern blot analysis and not in situ
hybridisation. In contrast to this work, the studies that have analysed PAI-2
expression by in situ hybridisation have used radiolabeled RNA probes for mRNA
detection (Lyons-Giordano et al, 1994; Billstrom et al, 1996). Using in situ

hybridisation also results in higher sensitivity, so detection is better however, the
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background poses more of a problem.

Flow cytometric analysis of Jurkat cells (chapter 2), indicated that these cells do not
express PAI-2 protein. The findings from chapter 2 and this chapter using both flow
cytometry and in situ hybridisation indicate that Jurkat cells do not express PAI-2
protein or mRNA. Therefore the hypothesis that the Jurkat cells may be expressing a
truncated form of PAI-2 mRNA is incorrect.

The major problem experienced with the in situ hybridisation protocol employed in
this chapter was the high background obtained in the negative controls. The most
likely source of the background in this assay was thought to be from the probe used,

because other researchers using a similar probe have also experienced relatively high
background (Billstrom et al., 1996). To improve the assay better strategies might be
to: synthesise different length PAI-2 RNA probes, use DNA or oligonucleotide probes

and to ensure that there is equivalent labelling on both sense and anti-sense probes
addition, other techniques could have been implemented to examine the expression of
PAI-2 mRNA. These include reverse transcriptase-polymerase chain reaction (RTPCR) or Northern blotting. These further experiments were not implemented because
the results from flow cytometry and ELISA (chapter 2 and 3) indicated that Jurkat
cells did not express any PAI-2 antigen. Human PBL were not tested because the
assay was judged to be not good enough to implement in further experiments.
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T o date not m u c h work has been carried out to examine the expression of PAI-2 by Tlymphocytes and T-lymphoblastic cells. The results from this thesis so far indicate
that unstimulated T-lymphocytes and T-lymphoblastic cells do not express PAI-2.
The final chapter will deal with providing an alternative site for the localisation of
PAI-2. Rather than PAI-2 being localised to the cell surface to inhibit uPA, it is
proposed that PAI-2 localises to the ECM.
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5.

PAI-2

AND

THE

EXTRACELLULAR

MATRIX:

INCORPORATION INTO FIBRIN CLOTS

5.1 INTRODUCTION

Transglutaminases occur in a variety of tissues, cell types and extracellular fluids
(Greenburg et al, 1991). The most well known is the plasma transglutaminase, factor

Xllla that is formed at sites of blood coagulation to stabilise fibrin clots. Fibrino
cleaved by thrombin to give rise to fibrin monomers. The fibrin monomers are then
cross-linked together by factor Xllla. Factor Xllla occurs as a tetramer composed of
two A chains and two B chains with a total molecular weight of approximately
360kDa (Greenburg et al, 1991). Factor Xllla occurs as a pro-enzyme and requires
•in "3Q

cleavage by thrombin at Arg -Gly

in the A chains to become active (Lorand, 1986).

The cross-linked bond is formed between primary amines and the y-carboxamide
group of glutamine residues. Therefore, either e-(y-glutamyl)lysine or (yglutamyl)polyamine bonds are formed between proteins (Folk and Finlayson, 1977)

PAI-2 has three glutamine residues identified as potential substrates for
transglutaminase activity: Gin83, Gin84 and Gin86 (Jensen, P.H. et al, 1994). PAI-2

can be cross-linked by transglutaminase activity to syncytiotrophoblast microvillous
membranes, cytotrophoblast membranes and Matrigel (Jensen, P.H. et al, 1989;
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Jensen, P.H. et al, 1993; Jensen, P.H. et al, 1994). In keratinocytes PAI-2 was

observed to be a part of the cornified envelope, a very stable structure found just und
the plasma membrane of keratinocytes that is stabilised by keratinocyte
transglutaminase activity (Jensen, P.J. et al, 1995). In addition peptides
corresponding to PAI-2 have been obtained from CNBr digests of cornified envelopes
(Robinson et al, 1997). If PAI-2 is cross-linked to the ECM this could provide a stop
signal for migrating cells as well as a mechanism to protect the ECM from uPA
mediated proteolysis. The cross-linking phenomenon is not limited to PAI-2, but also
applies to the specific inhibitor of plasmin, a2-antiplasmin. In a study by Sakata and
Aoki (1980), a2-antiplasmin was found to be cross-linked to fibrin in the presence of
factor Xllla and calcium ions.

Physiologically, an area where transglutaminase activity could lead to the crosslinking of PAI-2 to the ECM is during blood coagulation. Fibrin clots ideally only
occur at a wound site, and PAI-2 synthesis is enhanced in macrophages under such
conditions. It is known that PAI-2 synthesis is stimulated by inflammatory mediators
like TNFa (Gyetko et al, 1992; Zoellner et al, 1993). PAI-2 has also been observed

in the fibrin rich matrix of healing human skin wounds, though associated with cellular
infiltrate (Schaefer et al, 1996b). Most recently, Ritchie et al, (1999) observed that
PAI-2 secreted from monocytes was cross-linked to fibrin and could inhibit uPA

mediated fibrinolysis. Therefore it appears that PAI-2 can be incorporated into a fibri
matrix formed at a wound site.
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The results obtained thus far (refer to chapter 2 and 3) indicates that there is no cell
surface PAI-2. As an alternative hypothesis to PAI-2 being on the cell surface, it
proposed in chapter 1 that PAI-2 can localise to elements of the ECM by
transglutaminase activity. The aim of this final chapter was to characterise the
interaction of PAI-2 with an in vitro fibrin clot model using SDS-PAGE and
autoradiography.

5.2 MATERIALS & METHODS

5.2.1 Reagents

Recombinant human PAI-2 (rPAI-2) purified from yeast, and a PAI-2 purified (sPAI-

2) from Chinese Hamster Ovary (CHO) cells were the kind gift of Biotech Australia,
Roseville, NSW, Australia. Human urokinase (a mixture of 33kDa and 55kDa) was
from Serono Australia Pty. Ltd., Frenchs Forest, NSW, Australia. Hank's balanced
salt solution (HBSS) without calcium or magnesium was obtained from Trace
Bioscientific, Ryde, NSW, Australia. Bovine fibrinogen (fraction 1) was from BDH
(Merck Pty. Limited), Kilsyth, VIC, Australia. Bovine thrombin (plasminogen free)
and Glu-Gly-Arg chloromethyl ketone (EGR-CMK) were obtained from CalbiochemNovabiochem Pty. Ltd., Alexandria, NSW, Australia.
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Iodine (125I) and high

performance autoradiography film (Hyperfilm) were from Amersham Ltd., UK.
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Iodoacetamide (IAA) was obtained from Sigma Chemical Co., St Louis, M O , U S A .
Iodo-beads and NAP-10 columns were from Pierce, Rockford, IL, USA. Mark 12
unstained molecular weight markers were obtained from Novex Australia Pty. Ltd.,
Terrey Hills, NSW, Australia. Pre-stained broad range molecular weight markers were
from Bio-Rad Laboratories, North Ryde, NSW, Australia. Polystyrene tissue culture
plates (24 well) were from Corning, USA.

5.2.2 Iodination and characterisation of rPAI-2, sPAI-2 and uPA

5.2.2.1 Iodination

175

Proteins were radiolabeled with Na-

I using the iodo-bead method (Markwell,

1982). Three iodo-beads were washed with iodination buffer (lOOmM sodium
phosphate buffer, pH7.2) and allowed to dry on lint free tissue. The NAP-10 column
195

used to separate labelled protein from free

I was equilibrated with elution buffer

(50mM sodium phosphate buffer, pH7.2 containing 0.1%) (w/v) BSA) by passing 3
bed volumes of buffer through the column. Iodination buffer containing 0.5mCi of
I25

I was then added to the dried beads in an eppendorf tube and incubated for 5min at

room temperature. After 5min, 80ug of proteins (rPAI-2, sPAI-2 or uPA) dissolved in
PBS was added to the

125

I mixture and left for 15min at room temperature. The total

reaction volume was 500ul.
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T o stop the iodination process the supernatant was removed from the beads. The
beads were rinsed with another 500ul of iodination buffer and pooled with the
supernatant. The iodination mixture was added to the NAP-10 column and 0.5ml
fractions were collected. A sample from each fraction was counted using an AutoGammaR 5,000 (Packard Instrument Co.) gamma counter. The fractions containing

iodinated proteins were pooled and stored at 4°C. All protein preparations were use
within two weeks of iodination.

5.2.2.2 Characterisation of iodinated proteins

Prior to use in any experiment the

125

I-labelled proteins were characterised to ensu

that their activities were not altered as a consequence of the iodination. Either 5
of

125

I-sPAI-2 or 500ng

temperature for 45min.

125

I-rPAI-2 were added to 500ng uPA and left at room

125

I-uPA (500ng) was added to 500ng rPAI-2 and also left at

room temperature for 45min. Incubations were in a volume of 30ul PBS. In addition,
125

I-uPA or unlabelled-uPA was inhibited using ImM EGR-CMK for 20min at room

temperature prior to the addition of PAI-2. To stop the reaction reducing sample
buffer was added to all samples. Unlabelled rPAI-2, sPAI-2 and uPA were
characterised in the same way.
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Samples were then boiled for 4min and loaded into the wells of a 1 2 % S D S - P A G E
gel. Following electrophoresis, the gel was then fixed by placing in 50% (v/v)
methanol and 10% (v/v) acetic acid for 30min at room temperature. The gel was then
rehydrated in distilled water for lOmin at room temperature and then dried between a
piece of cellophane and Whatman filter paper in a gel dryer (Bio-Rad) for 1 -2hrs. The
dried gel was then exposed to a piece of Hyperfilm or a phosphor-imaging screen for
autoradiography. Phosphor-imaging screens were analysed using the Storm system
(Molecular Devices).

5.2.3 Bovine fibrin clots

5.2.3.1 Formation

The bovine fibrin clots were formed by incubating 200ug of fibrinogen and 2.5U of
thrombin in HBSS containing ImM CaCl2 and 0.1% (w/v) BSA. No exogenous factor
Xllla was required because the fibrinogen used contained traces of transglutaminase
activity. Reactions were carried out in 500ul volumes for 5.5hr at 37°C, in 24 well
polystyrene tissue culture plates. After 5.5hr the clots formed were harvested. This
involved separating the clot from the sides of the well with a toothpick, then
transferring both the clot and the supernatant into eppendorf tubes. The clots were
then pelleted by centrifugation at 14,000rpm for 5min at room temperature. The
supernatant was discarded, being careful not to dislodge the pellet. The pellets were
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then washed three times with P B S . Washes involved resuspending the pellet in P B S
and centrifuging at 14,000rpm for 5min at room temperature. The supernatant was
discarded and the wash step performed another two times.

After the final wash the pellets were resuspended in lOOul of reducing sample buffer
The sample was then boiled for lOmin before being separated using 10% SDS-PAGE.
All fibrin clots formed in subsequent experiments were treated as described above.
The gels were stained in 0.2% (w/v) Coomassie Blue R250, 50% (v/v) methanol and
10% (v/v) acetic acid for a few hours at room temperature. To remove the stain the
gels were placed in destaining solution (50% (v/v) methanol and 10% (v/v) acetic
acid) for a few hours at room temperature. The gels were then re-hydrated and dried
as described in section 5.2.2.2.

5.2.3.2 Fibrin clot characterisation

In order to characterise the fibrin clot formed, the transglutaminase activity was

inhibited by one of three ways: 1) omitting calcium from the reaction; 2) the additi

of ImM IAA which inhibits transglutaminase activity by alkylating the cysteine found
at the active site; 3) using lOmM EDTA to chelate all of the calcium ions in the
reaction mix. All three conditions listed above were used from the beginning of the
reaction. Any clots formed were harvested and analysed by SDS-PAGE as described
above (section 5.2.3.1).
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5.2.4

125

Interaction between

I-rPAI-2 and thrombin and fibrinogen

I-rPAI-2 was incubated separately with either 2.5U thrombin or 200ug fibrinogen,

as well as with thrombin and fibrinogen together. Incubations were in a volume of
30ul PBS, for 5.5hr at 37°C. To stop the reactions reducing sample buffer was added.
The samples were then boiled for 4min and diluted 1/10 with more reducing sample
buffer. A volume of lOul of sample was then loaded into the wells of a 10% SDSPAGE gel. The gel was then conducted, fixed and dried followed by autoradiography
as described above in section 5.2.2.2.

5.2.5 Incorporation of

125

I-rPAI-2 and

125

I-sPAI-2 into bovine fibrin clots

The clots were formed the same way as described above (section 5.2.3.1) with the
addition of lug of either

125

I-rPAI-2 or

125

incubation period at 37°C. The clot with

I-sPAI-2 from the beginning of the 5.5hr

125

I-rPAI-2 or

125

I-sPAI-2 were also formed

in the presence of transglutaminase inhibitors as described above (section 5.2.3.2).
Any clots formed were harvested, washed, boiled and then separated using 10% SDSPAGE as described above (section 5.2.3.1). The gels were then either stained or fixed
straight away, dried and exposed to Hyperfilm or a phosphor-imaging screen for
autoradiography. Lengths of exposure varied from a few days to several weeks
depending on signal strength. As standards
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125

I-rPAI-2/uPA and

125

I-sPAI-2/uPA

complexes were formed as described above in section 5.2.2.2.

5.2.6 Incorporation of

125

I-rPAI-2 and

125

I-sPAI-2 into human fibrin clots

Human fibrin clots were formed using plasma from volunteers. The human plasma
was obtained as a by-product of lymphocyte isolation procedures. This involved
dilution of human unseparated blood by the addition of two volumes of HBSS without
calcium or magnesium. Two volumes of the blood/HBSS mixture was layered over
one volume of Ficoll-paque in a polypropylene centrifuge tube. The blood mixture
was centrifuged at 200g for 30min at room temperature. This resulted in plasma
diluted 1 in 3 being found on the top phase of the mixture. The plasma was then
transferred into a new tube and stored at -20°C until used in clotting experiments.

The human fibrin clot was formed by the addition of CaCl2 (to a final concentration o
ImM) to the diluted human plasma. Immediately after lug of
125

125

I-rPAI-2 or lug of

I-sPAI-2 was added, reactions were incubated at 37°C for 5.5hr as above. Plasma

from 2 different volunteers were tested. These samples were treated as above (sectio
5.2.3.1) and the resulting autoradiograph analysed.
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5.2.7

Analysis of rPAI-2/bovine fibrin clots by Western blotting

Bovine fibrin clots were formed overnight in the presence of20ug of rPAI-2 or sPAI2. The clots were harvested, washed and separated using reducing 10% SDS-PAGE as
described in section 5.3.2.1. Separated proteins were then transferred to a PVDF
membrane for Western blotting as described in section 3.2.6.

5.2.8 Determination if PAI-2 incorporated into bovine fibrin clots was active

Bovine fibrin clots were formed overnight in the presence of 20ug of rPAI-2 or sPAI2. Prior to the addition of

125

I-uPA, EDTA was added to the clots to give a final

concentration of ImM to inhibit transglutaminase activity. The clots were separated

from the sides of the well only on one side so that it could contract allowing removal
of the supernatant using a pipette. The purpose of this was to remove as much free
PAI-2 still found in solution as possible. An amount of 500ng I125-uPA in HBSS
containing 5mM EDTA were added to the clots and left for 60min at room
temperature. The clots and supernatant were then transferred into eppendorf tubes. As
before three washes were carried out with PBS. The pellets were then resuspended in
reducing SDS-PAGE sample buffer and analysed using 10% SDS-PAGE and
autoradiography.
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In addition, separate reactions were set up with

I-uPA alone (500ng),

ImM EGR-CMK or I-uPA and 1U aprotinin. As a comparison,

I-uPA and

125

I-uPA was added

to bovine fibrin clots formed in the presence of rPAI-2 and sPAI-2. Any clots for
were harvested, washed, boiled and separated as above and analysed by 10% SDSPAGE and autoradiography.

5.2.9 Analysis

All experiments were carried out at twice, but only representative gels from
experiments are shown.

5.3 RESULTS

5.3.1 Iodination of rPAI-2, sPAI-2 and uPA

On average the activity of iodinated proteins ranged from 2-3uCi/ug protein. As
be seen from the autoradiograph (Fig. 1) the
and

125

125

I-rPAI-2 (lane 1),

125

I-sPAI-2 (lan

I-uPA (lane 7) have molecular weights of 38kDa, 47kDa and 33kDa,

respectively. All of the molecular weights of the iodinated proteins were in

accordance with those obtained for the unlabelled proteins (Fig. 2). Under reduc
SDS-PAGE conditions the
149
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I-labelled uPA (Fig. 1, lane 7) and unlabelled uPA (Fig
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Figure 1. Analysis of 125
^T-rPAI-2,
T-sPAI-2 and ^T-uPA
by autoradiography of
a 12%) reducing SDS-PAGE gel. Molecular weight markers are shown on the left
125T
in kDa. Lane 1 is ^T-rPAI-2, lane 2 is 125r
^T-rPAI-2+uPA, lane 3 is "T-rPAI2+uPA+EGR-CMK, lane 4 is 125I-sPAI-2, lane 5 is 125I-sPAI-2+uPA, lane 6 is 125IsPAI-2+uPA+EGR-CMK, lane 7 is 125I-uPA, lane 8 is 125I-uPA+rPAI-2 and lane 9
is125I-uPA+rPAI-2+EGR-CMK.
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Figure 2. Analysis of uPA, rPAI-2 and sPAI-2 by 1 0 % reducing SDS-PAGE.
Molecular weight markers are shown on the left in kDa. Lane 1 is uPA, lane 2
is rPAI-2, lane 3 is rPAI-2+uPA, lane 4 is rPAI-2+uPA+EGR-CMK, lane 5 is
sPAI-2, lane 6 is sPAI-2+uPA and lane 7 is sPAI-2+uPA+EGR-CMK.

2, lane 1) were 33kDa. However there were discrepencies between the published

molecular weight of PAI-2 which is 47kDa and that of the protein used in this study.
It appears that the rPAI-2 has been proteolytically degraded during storage.

A 63kDa band was observed in all lanes of the autoradiograph (Fig. 1) and not presen
in the Coomassie stained gel (Fig. 2). This is thought to be iodinated BSA. The

reason why BSA was iodinated was not known, since it was only present in the elution
buffer. This band slightly masked the

125

I-rPAI-2/uPA (Fig. 1, lane 2) and rPAI-2/125I-

uPA (Fig. 1, lane 8) complex band seen at 62kDa. Further evidence of complex
175

formation was a reduction in intensity of the

I-PAI-2 band of 38kD (lane 2) and the

125

I-uPA band at 33kDa (lane 8). There was also evidence of further degradation of
125

I-rPAI-2 after incubation with u P A indicated by the presence of the band at 35kDa
125

(Fig. 1, lane 2). The formation of

I-sPAI-2/uPA complexes were evident at 71 k D a

i nc

(Fig. 1, lane 5) and was accompanied by a reduction in the

I-sPAI-2 band. The

molecular weight of the uPA/PAI-2 complexes formed with the iodinated proteins was

the same as the unlabelled proteins (Fig. 2, lane 3 and 6). However, when unlabelled
uPA and rPAI-2 were complexed there was a band at 45kDa which was present in the

Coomassie stained gel (Fig. 2, lane 3), but not the autoradiograph (Fig. 1, lane 2 a
lane 8) which was probably a further degradation product of the rPAI-2/uPA complex
that is not labelled with

125

I.

All complex formation was inhibited in the presence of E G R - C M K , a specific peptidyl

inhibitor of uPA activity (Lijnen et al, 1984b), that can be seen by autoradiography

(Fig. 1, lanes 3, 6 and 9) and in the Coomassie blue stained SDS-PAGE (Fig. 2, lanes
4 and 7). Therefore I was successfully incorporated into the proteins and the
iodinated proteins still retain their activity, even the truncated rPAI-2 molecule.

5.3.2 Bovine fibrin clot formation

After 5.5h, formation of the bovine fibrin clots were assessed visually by examining

the solution in the wells. If the solution became gelatinous it indicated that the f
clot had formed. Clot formation was then confirmed using SDS-PAGE. Analysis of
bovine fibrinogen indicated that the protein consisted of three subunits, a, (3 and
63kDa, 56kDa and 48.5kDa, respectively (Fig. 3, lane 1). When bovine fibrinogen
alone was incubated at 37°C in either the absence or presence of calcium, no fibrin
was formed (ie. no visible pellet). This was confirmed by the lack of any recovered
protein (Fig. 3, lanes 2 and 3).

Fibrin clot formation was achieved with the addition of calcium and thrombin. This

resulted in marked changes in the patterns and intensity of the protein bands. Dimer
of the y subunit were seen as a 92kDa band (lane 5). This was also confirmed by the
loss of the y monomer band. The y dimer has been observed in other studies and is a
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Figure 3. Bovine fibrin clot formation analysed by a Coomassie Blue stained
10%) reducing S D S - P A G E gel. Molecular weight markers are indicated on the
left in kDa. Lane 1 is bovinefibrinogen,lane 2 isfibrinogen-CaCl2,lane 3 is
fibrinogen+CaCl2, lane 4 is fibrinogen-CaCl2+thrombin, lane 5 is
fibrinogen+CaCl2+thrombin. Lanes 6-10 are the same reaction conditions as
lane 5 except in the presence of the transglutaminase inhibitors. Lane 6 is
O.lmM IAA, lane 7 is l O m M IAA, lane 8 is I m M E D T A , lane 9 is 5 m M E D T A
and lane 10 is 5 0 m M E D T A .

result of transglutaminase activity (Hetassch et al, 1997; Lorand et al, 1998;
Brummel et al, 1999; Elssner et al, 1999). There was also a 195kDa band and other
weaker staining bands above it. These are the polymers of the a subunit. There was
also a decrease in intensity of the a monomer band (lane 5), while no changes were
observed in the (3 subunit.

When the reaction was carried out in the presence of varying concentrations of IAA
(lane 6 & 7) and EDTA (lanes 8-10) or in the complete absence of calcium (lane 4),
the contents of the wells appeared gelatinous. This indicated that the fibrin clot
formed. But, examination by SDS-PAGE revealed no evidence of transglutaminase

activity because there were no a polymers or y dimers (lanes 4 and 6-10), indicating

that the fibrin clot formed had not been stabilised by transglutaminase cross-links

all the concentrations of IAA and EDTA used, transglutaminase activity was inhibite

5.3.3 Interaction between

125

I-rPAI-2, bovine thrombin and bovine fibrinogen

When uPA was incubated with the

125

I-rPAI-2 at room temperature for 45min there

was evidence of a degradation product at 35kDa, as well as a slight reduction in the
intensity of the 38kDa

125

I-rPAI-2 band (Fig. 4, lane 2), compared to the

125

I-rPAI-2

standard (lanel). The uPA/PAI-2 complex band was masked by the band of 63kDa
already present in the preparation. There was a weak band at 45kDa that could be a

152

Figure 4. Analysis of the interaction of T-rPAI-2 with thrombin and bovine
fibrinogen by autoradiography of a 1 0 % reducing S D S - P A G E gel. Molecular
weight markers are shown on the left in kDa. Lane 1 is 125I-rPAI-2 , lane 2 is
125
I-rPAI-2 + u P A (45min at room temperature), lane 3 is 125I-rPAI-2+uPA (5.5hr
at 37°C), lane 4 is 125I-rPAI-2+thrombin, lane 5 is 125I-rPAI-2+fibrinogen and
lane 6 is125I-rPAI-2+thrombin+fibrinogen.

further degradation product of the uPA/PAI-2 complex as seen in Fig. 2, lane 3. At
37°C the loss of the 38kDa PAI-2 band was more pronounced which was accompanied
by an increased amount of degradation product at 35kDa (lane 3). The band at 45kDa
was also more pronounced at 37°C.

i 9c

There was no interaction of the

I-rPAI-2 with thrombin (Fig. 4, lane 4) when

175

compared to the interaction between

I-rPAI-2 and u P A for the same incubation

period (lane 3). When examining the interaction between fibrinogen and I-rPAI-2,
125

there was evidence of some degradation of

I-PAI-2, with the appearance of a 32kDa

125

band below the monomeric

I-rPAI-2 band (lane 5). This 32kDa band was believed

175

to be a degradation product of

I-PAI-2 due to trace amounts of protease in the

fibrinogen preparation. Apart from this interaction, it appears that fibrinogen doe
interact with

125

I-PAI-2. Likewise, the

125

I-rPAI-2 did not interact with a combinatio

of thrombin and fibrinogen either (lane 6), since the bands formed were the same as
with fibrinogen alone.

5.3.4 Incorporation of

Inclusion of

125

I-PAI-2 into bovine fibrin clots

125

I-rPAI-2 in the incubation mix from the beginning of the reaction to

form a bovine fibrin clot, resulted in the formation of four bands (Fig. 5, lane 4)
There was a 38kDa monomeric
153
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I-rPAI-2 band, which indicated that all the
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Figure 5. 125I- rPAI-2 incorporation into a bovine fibrin clot analysed by
autoradiography of a 1 0 % reducing S D S - P A G E gel. Molecular weight markers
are shown on the left in kDa. Lane 1 is 125I-rPAI-2 standard, lane 2 is 125I-rPAI-2
+ fibrinogen, lane 3 is125I-rPAI-2 + thrombin + fibrinogen, lane 4 is125I-rPAI-2 +
CaCl 2 + thrombin + fibrinogen, lane 5 is 125I-rPAI-2 + CaCl 2 + thrombin +
fibrinogen + I A A and lane 6 is 125I-rPAI-2+CaCl2 + thrombin + fibrinogen +
E D T A . Arrows on therightof the autoradiograph indicate the bands of <31kDa,
38, 78 and >200kDa respectively.

rPAI-2 could not be removed from the clot. There was protein of >200kDa that only

just migrated into the separating gel. In addition to that, there was also radiolabel

protein that remained in the wells of the gel. There was also evidence of degradation
125

of the

I-rPAI-2 as determined by the presence of a band <31kDa and increased

radioactivity at the dye front. These three bands were evident in all of the bovine
fibrin clots formed, even when transglutaminase activity was inhibited either by the
absence of calcium (lane 3) or the presence of IAA (lane 5) or EDTA (lane 6). There
was also a band at 78kDa that disappeared when transglutaminase activity was
inhibited (lanes 3, 5 & 6). This indicates that the 78kDa band was a complex between
125

one of the fibrinogen subunits and

I-rPAI-2 that had been cross-linked together by

transglutaminase activity. In the presence of bovine fibrinogen alone no visible clot
was formed and subsequently resulted in only a weak band of 38kDa I-rPAI-2 (lane

2) indicating that some of the radiolabelled rPAI-2 binds non-specifically to the si
the tube.

5.3.5 Incorporation of

125

I-PAI-2 into human fibrin clots

To determine if the same results could be achieved using an in vitro human system,
human fibrin clots were formed in the presence of I-rPAI-2 or I-sPAI-2 (Fig. 6).
Formation of human clots resulted in protein banding patterns that were very similar
to that of bovine fibrin clots formed in the presence of I -rPAI-2. As seen in the
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Figure 6. Analysis of I-rPAI-2 and I-sPAI-2 incorporation into human
fibrin clots by autoradiography of a 1 0 % reducing S D S - P A G E . Molecular
weight markers are indicated on the left in kDa. Lanes 2-6 are clots formed in
175

the presence of I-rPAI-2, while lanes 8-12 are clots formed in the presence of
125
I-sPAI-2. Lane 1 is125I-rPAI-2 standard and lane 7 is 125I-sPAI-2 standard.
The clots were formed under different conditions as follows. Lanes 2 and 8 are
bovine fibrinogen+CaCl2, lane 3 and 9 arefibrinogen+thrombin,lanes 4 and 10
are bovine fibrinogen+thrombin+CaCl2, lanes 5 and 11 are clotted plasma from
one volunteer and lanes 6 and 12 are clotted plasma from another volunteer.
Arrows on the right of the autoradiograph indicate the bands of 78 and 84kDa
respectively.

previous figure (Fig. 5, lane 2), in the presence of only bovine fibrinogen no visible
clot was formed and subsequently resulted in only a band of 38kDa

125

I-rPAI-2 (Fig.

lane 2). In the presence of bovine fibrinogen and thrombin, a <31kDa band, a 38kDa
125

I-rPAI-2 band and a >200kDa band were present (lane 3). A s before, only in the

presence of bovine fibrinogen, thrombin and calcium did a third major band of 78kD
appear (lane 4). The same 3 bands of 38kDa, 78kDa and >200kDa were present in the
two human fibrin clots formed from human plasma (lanes 5 and 6). However, in
contrast to the bovine clots, there is less degradation of the I125-rPAI-2 as seen
weaker <3 lkDa band.

175

The pattern of bands were almost identical if
fibrin clots instead of

125

I-sPAI-2 was incorporated into the

I-rPAI-2 (lanes 7-12). Both the

125

I-rPAI-2 and

125

I-sPAI-2

125

controls were similar. The presence of bovine fibrinogen alone resulted in a

I-sPAI-

2 band at 47kDa (lane 8). Bovine fibrinogen together with thrombin resulted in ban
at <31kDa, 38kDa, 47kDa and >200kDa (lane 9). The bands at <31kDa and 38kDa
indicate degradation of the

125

I-sPAI-2 (lanes 9 and 10). When bovine fibrinogen,

thrombin and calcium were incubated together, a transglutaminase dependent band at
125

84kDa (lane 10) also appeared. W h e n the human fibrin clots were formed with I sPAI-2, there were four bands, 38kDa, 47kDa, 84kDa and >200kDa (lanes 11&12).

155

5.3.6

Western blotting of PAI-2/bovine fibrin clots

Western blotting was employed in order to confirm that it was PAI-2 incorporated into
the bovine fibrin clots. The rPAI-2 standard can be seen as four bands of 47, 38, 35
and <31kDa (Fig. 7, lane 1). The 47kDa band represents intact rPAI-2, while the
bands at 38, 35 and <31kDa represent degraded rPAI-2. There is weak reactivity with

the a subunit of fibrinogen at 63kDa (lane 2) but no reactivity with control fibrin cl
formed in vitro (lanes 3-5). There were 3 bands of >200, 38 and 35kDa detected in
rPAI-2/bovine fibrin clots (lane 6). The >200 and 38kDa are consistent with the bands
seen by autoradiography in section 5.3.4 when

125

I-rPAI-2 was incorporated into

bovine fibrin clots.

5.3.7 Determination if PAI-2/bovine fibrin clots were active

To determine if the PAI-2 that was incorporated into the bovine fibrin clots was activ
195

I-uPA was incubated with PAI-2/fibrin clots (Fig. 8). W h e n a rPAI-2/bovine fibrin
clot was incubated with

125

I-uPA a strong band of 62kDa and a relatively weak 33kDa

band were detected in association with the clot (lane 6). These bands corresponded to
the

125

I-uPA/rPAI-2 complex standard (lane 4) and

Incubation of

125

I-uPA standard (lane 3).

125

I-uPA with the sPAI-2/bovine fibrin clot resulted in the appearance of

a 71 kDa band and a very weak 33kDa band (lane 7). The 71kDa band corresponded to
156
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Figure 7. PAI-2 incorporation into a bovine fibrin clot analysed by Western
blotting. Molecular weight markers are shown on the left in kDa. Lane 1 is
rPAI-2 standard, lane 2 is fibrinogen standard, lane 3 is fibrinogen + CaCl 2 , lane
4 isfibrinogen+ thrombin, lane 5 isfibrinogen+ thrombin + CaCl 2 and lane 6 is
fibrinogen + thrombin + C a C l 2 + rPAI-2.
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Figure 8. Autoradiography of a 1 0 % reducing S D S - P A G E gel of I-uPA
binding to a PAI-2/bovinefibrinclot. Molecular weight markers are indicated
125
on the left in kDa. Lane 1 is 12 T- rPAI-2 standard, lane 2 is 1Z T-T sPAI-2
standard, lane 3 is 125I- u P A standard, lane 4 is 125I-uPA/rPAI-2 standard, lane 5
is a clot+125I-uPA, lane 6 is rPAI-2/clot+125I-uPA, lane 7 is sPAI-2/clot+125IuPA, lane 8 is rPAI-2/clot+EDTA+125I-uPA and lane 9 is sPAI2/clot+EDTA+125I-uPA. Arrows on the right of the autoradiograph indicate the
position of uPA/rPAI-2 and uPA/sPAI-2 complexes respectively.

I-uPA/sPAI-2 complexes, while the 33kDa band corresponded to free

125

I-uPA.

Formation of the rPAI-2 or sPAI-2/bovine fibrin clots in the presence of EDTA had
effect on the appearance of the

125

I-uPA complexed with rPAI-2 or sPAI-2 bands

(lanes 8 and 9). If a clot without PAI-2 was incubated with

I25

I-uPA, the clot was

degraded by the end of the 60min incubation at room temperature (lane 5) resulting
no visible bands. In contrast, the clots formed in the presence of PAI-2 were not
degraded. In addition there was a band of lOOkDa in the uPA/rPAI-2 standard (lane
which must be a contamination.

To examine this observation further other protease inhibitors were included in the
uPA binding experiment (Fig. 9). In the Coomassie Blue stained gel, there were no
bands visible in the lanes of the

125

I-uPA,

I25

I-uPA/rPAI-2 complex or

125

I-uPA/sPAI-

2 complex standards because the amount of protein loaded was below the detection

limit of the stain (Fig. 9a, lanes 1, 2 and 10). In the other lanes of the Coomass
175

stained gel were the remains of thefibrinclots after the

I-uPA binding experiment.

In the absence of calcium there could be seen the 3 subunits of fibrinogen a (63kD

(3 (56kDa) and y (48.5kDa) (Fig. 9a, lanes 3, 4 and 7). In the presence of calcium

a and (3 subunits were still there, but now the cross-linked y dimer and a polymer
appeared at 92kDa (Fig. 9a, lanes 5, 6, 8, 9 and 11).

125

W h e n clots without any E G R - C M K were incubated with

I-uPA, the clots were
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Figure 9. Examination offibrinclot degradation and 125I-uPA binding to PAI-2 in
a bovinefibrinclot by a Coomassie Blue stained 1 0 % reducing S D S - P A G E gel
and autoradiography. Molecular weight markers are indicated on the left in kDa.
a) Coomassie Blue stained 1 0 % SDS-PAGE, b) Autoradiograph of same SDSP A G E . Lane 1 is 125I-uPA standard, lane 2 is 125I-uPA/rPAI-2 standard, lane 3 is a
125T
clot-CaCl2+ T-uPA, lane 4 is a clot-CaCl 2 +EGR-CMK+ T-uPA,
lane 5 is a
125T
clot+CaCl2+ T-uPA, lane 6 is a clot+CaCl 2 +EGR-CMK+ T-uPA, lane 7 is a
125
clot-CaCl2+aprotinin+ T-uPA, lane 8 is a clot+CaCl2+aprotinin+ T I-uPA, lane 9
iZ T
is a clot+CaCl2+rPAI-2+1 T-uPA, lane 10 is125
T-uPA/sPAI-2 standard and lane 11
125T
is clot+CaClz+sPAI^+^T-uPA

degraded as judged by there being a large reduction in protein harvested (Fig. 9a, lanes
3 and 5). If the binding was performed using

125

I-uPA inactivated beforehand with

EGR-CMK the clot was not degraded (lanes 4 and 6). The same applies if the clots
were incubated with

125

I-uPA in the presence of 1U of aprotinin (a plasmin inhibitor)

(lanes 7 and 8). This would indicate that the clot degradation is being mediated by t

activation of traces of plasminogen into plasmin, rather than uPA directly. The PAI-2

present in the fibrin clot also conferred protection against uPA mediated proteolysi
(lanes 9 and 11).

19^

B y autoradiography as seen previously, the
the

125

I-uPA has a molecular weight of 33kDa,

I-uPA/rPAI-2 complex has a molecular weight of 62kDa and the

125

I-uPA/sPAI-

2 complex has a molecular weight of 71kDa (Fig. 9b, lanes 1, 2 and 10). There was
125

very little

I-uPA binding to the remains of the fibrin clots, as detected by

autoradiography (lanes 3-9 and 11). As seen in figure 8,

125

I-uPA/rPAI-2 complex and

125

I-uPA/sPAI-2 complex could be detected binding to the fibrin clot (lanes 9 and 11).

5.4 DISCUSSION

125

W h e n bovine or h u m a n fibrin clots were formed in the presence of

I-PAI-2, four

different detectable forms of PAI-2 were observed. The first form was cross-linked
into the fibrin clot, probably to the y subunit of fibrinogen, by transglutaminase
158

activity. However, it can not be ruled out that the PAI-2 was cross-linked to another
PAI-2 molecule, since this has been observed previously (Jensen, P.H. et al, 1993;
Ritchie et al, 1999). The cross-linking of PAI-2 has been demonstrated before
(Jensen, P.H. et al, 1993; Jensen, P.H. et al, 1994) and has very recently been
investigated in fibrin clots (Ritchie et al, 1999). This form of PAI-2 was not

detectable by Western blotting probably because it was either below the detection limi
of the assay. However, it is possible that this form may not even contain PAI-2 since
it was not detectable by Western blotting. The cross-linked PAI-2 did not appear to be
125

active, because it was not able to form SDS-stable complexes with

I-uPA.

The second form was a very high molecular weight band that only just migrated into
the separating gel. This band was formed independently of transglutaminase activity
and must be a very stable interaction of PAI-2 with fibrin which was unaffected by the
denaturing conditions. This form of PAI-2 did not appear to be active, because no
I-uPA/PAI-2 complexes greater than 200kDa were observed, in the

125

I-uPA

175

binding experiments. The third form was monomeric

I-PAI-2, which was found

binding to the clots. It is possible that monomeric PAI-2 does bind to the fibrin as ha

been found with the annexins via it's CD interhelical region (Jensen, P.H. et al, 1996)
125

In addition more monomeric

I-PAI-2 was observed to bind to the fibrin clot

125

compared to

I-uPA.

It can not be ruled out that the PAI-2 is binding non-

specifically. This form of I-PAI-2 was found to be forming complexes with I-

159

u P A and contributed to protection against u P A mediated clot lysis. The final form
175

was a degraded

I-PAI-2 with a molecular weight of <31kDa. This was most likely

generated by trace amounts of protease in the fibrinogen preparation.

The rPAI-2 used in this study was found to be degraded, while the sPAI-2 was not.
The difference in molecular weight is probably due to degradation of the rPAI-2 by
traces of a contaminating protease from the purification of the recombinant protein.
However, both rPAI-2 and sPAI-2 were found to be active because of the ability to
complex with uPA, as well as be incorporated into a fibrin clot. The truncated PAI-2

used in this study is the same in size observed by Jensen, P.H. et al, (1994) in huma
promyelocyte leukemia NB4 cells undergoing apoptosis and produced by PL-21 cells
(Takeuchi et al, 1990).

The PAI-2 may protect more against uPA rather than tPA in a fibrin clot model. In the
absence of PAI-2 from the clot, the addition of

l25

I-uPA resulted in degradation of th

clots as visually observed and confirmed by SDS-PAGE. Plasmin is the protease
responsible for the degradation of the fibrin clot in this study as the clot was not
degraded when

125

I-uPA was added in the presence of aprotinin. uPA has

demonstrated fibrinolytic activity via the activation of plasminogen (Zamarron et a
1984). It has been observed using a recombinant and naturally occurring uPA with
human plasma fibrin clots immersed in citrated human plasma. Single-chain uPA can

bind to fibrin (Kasai et al, 1985a; Kasai et al, 1985b), and it has been postulated t
160

upon conversion into twin-chain u P A it can further enhance plasminogen activation,

facilitating further degradation of the fibrin clot (Pannell et al, 1988). In addition tP
bound to fibrin is protected against inhibition by PAI-2 (Leung et al, 1987). This is
also supported by the findings of Ritchie et al, (1999) who observed that the PAI-2
incorporated into fibrin clots were not able to inhibit tPA mediated clot lysis.

The cross-linked PAI-2 observed in this thesis are not identical to those found by
Ritchie et al, (1999). Ritchie et al, (1999) observed a cross-linked PAI-2 dimer of
approximately 85kDa, and several species of PAI-2 cross-linked to fibrin >120kDa.
The differences in the results could be explained if not enough transglutaminase was
added for the cross-linking of PAI-2 to the fibrin in this thesis. However, from the
result in figure 3 all of the y fibrinogen subunit was dimerised by the factor Xllla
activity, so there must be a saturating concentration of factor Xllla.

In contrast to the work done previously, (Jensen, P.H. et al, 1989) uPA could not be
detected binding to the cross-linked PAI-2. This may be because the signal from such
a complex in this system is below the detection limit of autoradiography. This could
also be due to the complexity of the syncytiotrophoblast membranes used in the
previous study because the PAI-2 could be cross-linked to any of a number of possible
proteins. Ritchie et al, (1999) found active PAI-2 in thrombi and fibrin clots formed

in vitro. From their results it can be seen that cross-linking does not affect the activ
of PAI-2. In contrast to the study by Ritchie et al, (1999) this study found the cross161

linked PAI-2 to be inactive. The discrepancy between the two results could be due to
the different methods used to investigate the activity of cross-linked PAI-2. In the
study by Ritchie et al, (1999) the activity of PAI-2 was assessed by observing the

change in absorbance of a fibrin clot. This actually measures the activity of everyth

in the sample, and the relatively low abundance and therefore activity of cross-linke
PAI-2 would have been masked by the monomeric PAI-2. This is supported by the
result in this thesis that the monomeric PAI-2 associated with the fibrin clot was
active. In vivo, PAI-2 incorporation into fibrin clots would add to the protection
conveyed by PAI-1 and a2-antiplasmin, but probably has more of a role with other
components of the ECM, such as fibronectin (Jensen, P.H. et al, 1989).

The results support the findings so far that PAI-2 is a substrate for transglutaminas
In the model used, the binding of uPA by cross-linked PAI-2 could not be detected,
but binding of uPA by monomeric PAI-2 was. PAI-2 may be able to inhibit the
plasminogen cascade by two means. Firstly PAI-2 could associate with fibrin and

protect against uPA mediated lysis. Secondly, independent of its inhibitory activity,
could be cross-linked to fibrin preventing plasminogen binding via the kringle
domains. This would be an indirect way of preventing plasminogen activation since
plasmin is protected from inhibition by a2-antiplasmin when bound to fibrin (Plow et

al, 1986; Gonias et al, 1989; Ellis et al, 1991). This is potentially a site where PA

may localise and could act as an important inhibitor in the protection against in viv
fibrinolysis.
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6. CONCLUSION
The only peripheral blood leukocyte reported in the literature to date that express
PAI-2 has been the monocyte/macrophage (Golder and Stephens, 1983; Vassalli et al,
1984; Chapman and Stone, 1985; Saksela et al, 1985; Kruithof et al, 1986b). It has
been found that T-lymphocytes upon stimulation do express uPAR (Nykjasr et al,
1994; Jardi et al, 1996; Bianchi et al, 1996) and uPA (Gundersen et al, 1997). An
observation was made that T-lymphocytes from human peripheral blood express
PAI-2 on their cell surface (McPhun, unpublished observation). This thesis has
demonstrated that T-lymphocytes from human peripheral blood do not express cell
surface PAI-2. Human T-lymphocytes were also shown to not express PAI-2

intracellularly as determined from flow cytometry of permeabilised cells. In support
of this were the observations by Billstrom et al, (1996) that T-lymphocytes do not
express PAI-2 mRNA. Reiter et al, (1997) previously detected PAI-2 from
homogenates of the Jurkat cell line. In contrast, no PAI-2 could be detected in the

lymphoblastic cell line, Jurkat, either by ELISA or by flow cytometry in this study.
A possible explanation is that like the THP-1 cell line, the Jurkat cell line may
synthesise a truncated form of the PAI-2 mRNA (Gross and Sitrin, 1990).

Differences in the observations found in this study and that by Reiter et al, (1997)
may also be due to the use of different antibodies. Reiter et al, (1997) used a
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monoclonal antibody in their ELISA, while a polyclonal antibody was used in this
study.

There is evidence from the literature to support PAI-2 being on the surface of cells.
PAI-2 has been observed at the cell surface as a complex with uPA on keratinocytes
(Reinartz et al, 1996). In vivo, PAI-2 has been detected associated with isolated
placental microvillous membranes (Jensen, P.H. et al, 1989) and associated with the
periphery of cells located in the suprabasal granular cell layer of normal human

epidermis (Lyons-Giordano et al, 1994). However, in the latter studies it is difficul

to assess how close to the surface of cells the PAI-2 was, or whether it may have bee
deposited in the ECM pericellularly. The data from this thesis indicates that

endogenous PAI-2 is not associated with the cell surface in the cells and cell lines
have been examined. In support of this, PAI-2 could not be found on the surface of
apoptotic HeLa cells (Dickinson et al, 1998).

To provide an alternative site in the ECM where PAI-2 may localise, a fibrin clot was
investigated. As was observed with a2-antiplasmin (Sakata and Aoki, 1980), PAI-2

could be cross-linked by transglutaminase activity to fibrin. Ritchie et al, (1999) a

recently investigated the cross-linking of PAI-2 to fibrin. Their results indicated t
PAI-2 could be cross-linked to fibrin, primarily by Gin83 and Gin86. oc2-Antiplasmin
cross-linked to fibrin was found to inhibit plasmin induced lysis (Sakata and Aoki,
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1980). In addition, Ritchie etal, (1999) found that cross-linking of PAI-2 did not

affect its activity. In contrast, this thesis found that the cross-linked PAI-2 was not
active.

In addition, there was also active monomeric PAI-2 binding to the fibrin clot
independent of transglutaminase activity. Ritchie et al, (1999) also observed that
active monomeric PAI-2 could be extracted from isolated human thrombi that were
formed in vivo. In both cases, the clots were washed prior to analysis so the
monomeric PAI-2 is not from the surrounding media. This seems to indicate that it is
possible that there may exist another mechanism by which PAI-2 can associate with
fibrin and protect it from uPA mediated proteolysis.

There is evidence in the literature that does support the possibility that PAI-2 can
localise to the ECM by transglutaminase activity. PAI-2 has been cross-linked to
basement membrane proteins (Matrigel) and to fibronectin (Jensen, P.H. et al, 1993).

PAI-2 can also be found in the cornified envelope of keratinocytes (Jensen, P.J. et al,
1995; Robinson et al, 1997), a cross-linked structure formed just under the plasma
membrane. The cornified envelope is an important component of the stratum
corneum that protects the epidermis.

The levels of PAI-2 used in thefibrinclot experiment in this thesis, as well as in the
study by Ritchie et al, (1999), are higher than the levels of PAI-2 found
physiologically. PAI-2 was used at a concentration of 2ug/ml and 9ug/ml
respectively in these experiments. Meanwhile, PAI-2 levels have been found to be
below the detection limit (<10ng/ml) in plasma from non-pregnant women (Kruithof
et al, 1987). During pregnancy, at term the levels of PAI-2 in the plasma increase
approximately 25-fold. This would mean that PAI-2 would normally not be likely to
associate with the ECM, but would be more likely to associate with the ECM during
pregnancy. Perhaps the PAI-2 levels increase, leading to an increased association
the ECM to protect the mother from the "invading" fetus.

An important question is whether a PAI-2 /ECM localisation is relevant. It is a

logical place to put PAI-2 as active uPA is on the cell surface. It is envisaged th
PAI-2/ECM interaction may have the most relevance in a wound, in particular at the
skin. If a wound does occur at the skin there is an abundance of PAI-2 in the
epidermis (Hibino et al, 1988; Chen, C. et al, 1993; Gissler et al, 1993; LyonsGiordano etal, 1994; Spiers etal, 1994). Monocytes/macrophages in the area would
also produce PAI-2 under this sort of inflammatory condition (Gyetko et al, 1992;
Zoellner et al, 1993). There would also be elevated fransglutaminase activity to

stabilise fibrin clots formed in the plasma, as well as to stabilise the damaged EC
(Jandl, 1996; Bowness and Tarr, 1997; Bowness et al, 1998). Thus PAI-2 could get
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deposited onto the surrounding E C M to protect against proteolysis so the w o u n d site
could be repaired, making a PAI-2/ECM interaction very relevant. However, it must
be put in perspective, PAI-1 and a2-antiplasmin are far more abundant
extracellularly, so the role of PAI-2 is probably secondary. In addition, it has been
observed that in vivo PAI-2 was primarily associated with the cellular infiltrate in a
healing skin wound (Schaefer et al, 1996b).

There are several future experiments to try. Surface proteins could be biotin labelled
and immunoprecipitated with PAI-2 antibodies to ascertain cell surface localisation or
the association with ECM proteins. Northern blotting and RT-PCR could be used to
more accurately determine whether Jurkat cells produce a splice variant of PAI-2
mRNA. To determine which subunit(s) of fibrinogen the PAI-2 gets cross-linked to,
and how the inhibition of uPA by clot associated PAI-2 compares to free fluid phase
PAI-2. The interaction between other different components of the ECM, like
fibronectin and PAI-2 also requires investigation. Finally, it would be interesting to
test if PAI-2 associated with a fibrin matrix does inhibit movement of uPA expressing
cells in a migration assay.

In conclusion, there are three main results from this thesis. Firstly, results from this
thesis indicate that PAI-2 produced endogenously by a cell does not localise to the
cell surface. Secondly, the results indicate that PAI-2 can bind to fibrin clots and
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protect against u P A mediated lysis. Finally, the results indicate that the PAI-2 not
covalently associated with the fibrin clot is responsible for protection against uPA
mediated lysis. The research thus far has focused on the role of PAI-2 located
intracellularly. A number of studies found in the literature have demonstrated that
inhibitors are located in the ECM to regulate protease activity. Having PAI-2
localised pericellularly in the ECM, would allow for tight regulation of plasmin
activity at the cell surface. The possible localisation of PAI-2 to the ECM and it's
role requires further investigation.
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APPENDICES
Appendix A:
FPLC settings for purification of IgG from hybridoma conditioned media
280nm
Chart speed=lmm/min
AUFS=1.0
Range=1.0V
Zero suppression=0
Flow rate (loading)=0.5ml/min
Flow rate (elution)=0.5ml/min

Appendix B:
Settings for FACSort, single color stain
Detector
Voltage
FSC
E00
SSC __
342
FL1
780
FL2
665
Threshold(FSC): 56

AmpGain
1.30
1.00
1.00
1.00

Mode
Linear
Linear
Log
Log

Appendix C:
Settings for FACSort, dual color stain
Detector
Voltage
FSC
E00
SSC
342
FL1
780
FL2
665
Threshold(FSC): 56
Compensation:
FL1-0.5%FL2
FL2-44.0%FL1

AmpGain
1.30
1.03
1.00
1.00

Mode
Linear
Linear
Log
Log

i

Appendix D:
lOxPBS
80g/l NaCl
2g/l KC1
2.4g/l K H 2 P 0 4
14.4g/l N a 2 H P 0 4

Appendix E:
Instrument settings for Bio-Rad Econosystem UV monitor and chart recorder
U V monitor: 280nm
Absorbance units full scale (AUFS)(loading)=0.5
A U F S (elution)=2.0
Chart recorder:
chart speed=2mm/min
lV=CAL-0 (default settings)

Appendix F:
FPLC settings for purification of GAH-PAI-2-POD
280nm
Chart speed=5mm/min
AUFS=0.1
Range=1.0V
Zero suppression^
Flow rate=0.5ml/min

Appendix G:
SDS-PAGE separating gels

.

Distilled water
1.5M Tris-HCl, pH8.8
1 0 % (w/v) SDS
3 0 % (w/v) Acrylamide/Bis
10%) (w/v) Ammonium persulfate (APS)
N,H,N',N' Tetramethylethylenediamine (TEMED)

PERCENTAGE GEL
12%
10%
7.5%
3.35ml 4.05ml 4.85ml
2.5ml
2.5ml
2.5ml
lOOul
lOOul
lOOul
4.0ml 3.33ml
2.5ml
50|ail
50ul
50ul
5ul
5ul
5ul

S D S - P A G E 4 % stacking gel
6.1ml Distilled water
2.5ml 0.5M Tris-HCl, pH6.8
lOOul 1 0 % (w/v) S D S
1.3ml 3 0 % (w/v) Acrylamide/Bis
50ul 1 0 % (w/v) A P S
lOulTEMED
SDS-PAGE 4x reducing sample buffer
4.0ml Distilled water
1.0ml 0.5M Tris-HCl, pH6.8
0.8ml Glycerol
1.6ml 1 0 % (w/v) S D S
0.4ml 2-P-Mercaptoethanol
0.2ml 0.05% (w/v) Bromophenol blue

For non-reducing sample buffer, replace 2-P-Mercaptoethanol with distilled w
SDS-PAGE lOxTris-glycine running buffer
30g/l Tris base
144g/l Glycine
10g/

Appendix H :
LB broth
10g/l Tryptone
5g/l Yeast extract
lOg/lNaCl

Appendix I:
SOC media
2%(w/v) Tryptone
0.5%(w/v) Yeast extract

lOmMNaCl
2.5mM KC1
20mM MgCl2
10mMMgSO4
20mM Glucose
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Appendix J:
Z agar plates
10g/l Tryptone
5g/l Yeast extract
lOg/lNaCl
0.37g/l CaCl2
15g/l Agar

Appendix K:
Solution I
5 0 m M Glucose

lOmMEDTA
25mM Tris-HCl, pH8.0

Appendix L:
Solution II
5 0 m M Glucose
2 5 m M Tris-HCl, pH8.0
10mMEDTA,pH8.0

Appendix M :
Solution III
60ml 5 M Potassium acetate
11.5ml Glacial acetic acid
28.5ml Distilled water

Appendix N:
5xTBE
54g/l Tris base
27.5g/l Boric acid
20ml 5 0 0 m M E D T A , pH8.0
For 1.2% gel, dissolve 1.2g DNA grade agarose/lOOml 0.5xTBE by melting in
microwave for l-2min followed by pouring into casting stand.

Appendix O:
6 x D N A sample buffer
0.25%) Bromophenol blue
0.25%) Xylene cyanol FF
3 0 % Glycerol in water

Appendix P:
20xMOPS
41.86g/l 3-[N-Morpholino] propanesulfonic acid (MOPS)
6.8g/l Sodium acetate
3.8g/l E D T A
pH7.0
Keep in dark

Appendix Q:
1.2% formaldehyde agarose gel preparation
1.5ml 2 0 x M O P S
5.4ml 37.5% Formaldehyde
23.1ml Distilled water

To prepare gel, melt the agarose in 20xMOPS and distilled water in a microwave
oven. The mixture is then placed in a 55°C water bath for about lOmin and then the
5.4ml of 37.5% formaldehyde added in a fume hood and the mixture poured into the
casting stand and allowed to cool and set.

Appendix R:
lOxRNA sample buffer
25%> (v/v) bromophenol blue xylene cyanol
2 5 % (v/v) DEPC-distilled water
5 0 % (v/v) glycerol
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Appendix S:
RNA preparation for electrophoresis
4.8ul R N A
9ul Formamide
3.2ul 3 7 % Formaldehyde
lu!20xMOPS
2ul of R N A sample buffer

Appendix T:
In situ hybridisation mixture
4 0 m M Tris-HCl, pH7.4
600mMNaCl
l O m M EDTA, pH8.0
2 0 m M NaH 2 P0 4 -2H 2 0, pH8.0
0.04% Ficoll
0.04% P V P
0.04%) acetylated B S A
100ng/ml£.co//tRNA
50%) formamide

Appendix U:
20xSSC
175.3g/lNaCl
88.2g/l Sodium citrate
pH7.0

Appendix V:
TBS
20mM Tris-HCl, pH7.5
137mMNaCl

